A study of chemotherapy resistance in acute myeloid leukemia by Rathe, Susan Kay
 
 
 
 
 
 
A Study of Chemotherapy Resistance in Acute Myeloid Leukemia 
 
 
 
 
A DISSERTATION 
SUBMITTED TO THE FACULTY OF THE GRADUATE SCHOOL 
OF THE UNIVERSITY OF MINNESOTA 
BY 
 
 
 
 
Susan Kay Rathe 
 
 
 
 
 
 
IN PARTIAL FULFILLMENT OF THE REQUIREMENTS 
FOR THE DEGREE OF 
DOCTOR OF PHILOSOPHY 
 
 
 
David A. Largaespada 
 
 
 
 
October, 2013 
 
 
 
 
 
 
  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© Susan Kay Rathe 2013
i 
 
 
Acknowledgements 
 
 
Funding:  The leukemia research was funded by The Leukemia & Lymphoma Society 
(grant 7019-04).   The MMuFLR workflow was funded by The Children's Cancer 
Research Fund.   
 
University of Minnesota Resources:  The BioMedical Genomics Center provided 
services for gene expression microarray, RNA sequencing, oligo preparation, and Sanger 
sequencing.  The Minnesota Supercomputing Institute maintains the Galaxy Software, as 
well as provides data management services and training.  The Masonic Cancer Center 
Bioinformatics Core provided guidance in the analysis of the RNA-seq data.  The FDA 
Drug Screen was performed at the Institute for Therapeutics Discovery and Development. 
 
Colleagues:  First and foremost, I would like to recognize Dr. David Largaespada for his 
mentorship and the opportunity to continue research he started while a postdoc in Dr. 
Neal Copeland’s lab.  I would also like to thank the many members of the Largaespada 
lab who provided direct or indirect assistance to my research.  Dr. Bin Yin continued Dr. 
Largaespada’s work on the BXH-2 AML cell lines by making drug resistant derivatives 
and provided training in cell culture and drug assay techniques.  Dr. Won-Il Kim 
developed the TNM mouse model and provided training in mouse related experimental 
techniques.  Miechaleen Diers did all of the tail vein injections for the AML transplants 
and assisted with necropsies.  Dr. Branden Moriarity designed the Dck knockout 
TALENs, the CRISPR KOs, and DCK overexpression vectors and did the transfections 
ii 
 
with the assistance of Dominic Beckmann.  Dr. Eric Rahrmann did the Western blots.  Dr. 
Timothy Starr provided training in qPCR and various lab protocols.  I would also like to 
acknowledge the assistance I received from my undergraduate volunteers.  Natashay 
Bailey participated in the research for 3 years, Teng Zhang, Alexandra Ellingston, 
Christopher Stoltenberg, Ellen Melrose, and Natalie Aumann for 2 years, Chase Liska 
and Willemijn Veldhuijzen for 1 year, and Natasha Delgado and Nigest Balla for a 
semester.  Their participation is outlined in the following table. 
 
I would also like to thank all of the other members of the Largaespada lab both past and 
present, the members of the MICaB program, my prelim committee members (Dr. 
iii 
 
Timothy Hallstrom, Dr. Jaime Modiano, Dr. Xianzheng Zhou, Dr. Yoji Shimizu and Dr. 
Steve Rice), and my thesis committee (Dr. David Largaespada, Dr. Scott McIvor, Dr. 
Chris Pennell, and Dr. Nikunj Somia).  
iv 
 
Dedication 
 
I dedicate this thesis to my husband, David D. Rathe.  I’m finding it difficult to 
find words to adequately describe the importance of his patience and encouragement 
during this very demanding process.  He took the time to learn and understand many 
aspects of my research, and took sincere interest in its progress.  He provided proof-
reading services, and was a sounding board for problem solving.  He retired and took on 
most of the household duties, so when I did get a break from research, I could devote the 
time to enjoying my family and friends.  His support never wavered even when he was 
called back to work on a critical project for his former company.  During the many 
months he was working over 60 hours a week, he still managed to make me feel my 
research was still what mattered most.  He is an amazing person, and I feel so lucky to 
have him for a husband and best friend. 
v 
 
Abstract 
 
 Acute myeloid leukemia (AML) is the most deadly of the leukemias.  Due to its 
heterogeneous genetic nature it has been difficult to find effective targeted treatments.  
Standard induction chemotherapy, which includes cytarabine (Ara-C) as its primary 
component, will in most cases result in remission, but the remission is short-lived and 
usually results in the presentation of an Ara-C resistant form of AML at relapse.  A 
thorough understanding of how chemotherapy resistance develops in AML would lead to 
the establishment of drug profiles describing the molecular conditions under which a drug 
should be considered or rejected as a treatment option.  With the ultimate goal of 
providing patient specific drug treatment options to restore or preserve chemotherapy 
sensitivity, the research presented here had five objectives:  (1) to develop and/or 
evaluate mouse models of Ara-C resistance in vitro and in vivo and determine their ability 
to mimic the Ara-C resistance found in human disease, (2) to discover cellular 
mechanisms of Ara-C resistance, (3) to find effective drug partners for Ara-C in treating 
de novo AML, (4) to find drugs for treating chemotherapy refractory AML, and (5) to 
predict drug response based on the molecular profile (gene expression patterns and 
specific mutations) for each AML patient.  Although these objectives are broad and 
aggressive, this research has resulted in some significant strides towards meeting them.  
Using gene expression microarray, transcriptome sequencing, and targeted mutagenesis 
via TAL endonuclease treatment, it was determined mutations in Dck were the primary 
factor in the development of Ara-C resistance in an in vitro model of Ara-C resistance.  
Drug screens were used to determine Ara-C resistant cells became more sensitive to 
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glucocorticoids, and cladribine is an affective partner to Ara-C in treating de novo 
disease.  Also, an in vivo model of Ara-C resistance was developed by passaging AML 
cells through SCID/beige mice and treating the mice with low doses of Ara-C.  
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Chapter 1:  The Challenges of Treating Acute Myeloid Leukemia 
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The development of drug resistance, to the chemotherapy drug cytarabine, is a 
life-threatening complication which occurs in the treatment of most acute myeloid 
leukemia patients.  This introductory chapter will provide a background on characteristics 
of acute myeloid leukemia, the use of cytarabine in induction chemotherapy, the methods 
we are using to study cytarabine resistance, and the primary goals of this research project. 
Acute Myeloid Leukemia Background 
 Hematopoietic stem cells, residing in the bone marrow, give rise to all of the 
various types of blood cells, via a complex cellular program of cell replication and 
differentiation.  There are two primary branches of hematopoietic differentiation, myeloid 
and lymphoid, and both pathways are characterized by a series of differentiation steps.  
Each step of each pathway produces a distinctly different progenitor cell, which is 
capable of further differentiation or self-renewal.  If oncogenic mutations appear in any 
of these progenitors, it can result in leukemia, which is the unfettered proliferation of 
immature cells incapable of undergoing normal differentiation (Passegue et al., 2003). 
The American Cancer Society (ACS) divides leukemias into five groups based 
predominantly on the maturity of the cells (acute or chronic) and the primary 
developmental pathway (myeloid or lymphoid).  In general, the term “acute” refers to 
cells which more closely resemble the hematopoietic stem cells or early progenitors, 
while the term “chronic” refers to cells which are more differentiated.  The main four 
types of leukemias are acute lymphocytic leukemia (ALL), acute myeloid leukemia 
(AML), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML).  
Leukemias not falling into these four categories are grouped into an “other” grouping and 
they include hairy cell leukemia, chronic myelomonocytic leukemia, and juvenile 
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myelomonocytic leukemia. Each year the ACS issues a “Cancer Facts and Figures” 
document describing cancer incidence trends and providing estimates for the current year.  
The “Cancer Facts and Figures 2013” showed leukemia as the 6th leading cause of cancer 
death in the United States for both men and women.  They estimated 48,650 people will 
be diagnosed with leukemia in 2013 and 23,720 will die from the disease (Table 1.1).  
Although acute myeloid leukemia makes up only 30% of the newly diagnosed leukemias, 
it accounts for 43.7% of the leukemia deaths. 
The high mortality rate is reflective of the aggressiveness of AML and its 
heterogeneous nature.  Although AML likely originates in the bone marrow, it rapidly 
expands as blast cells into the peripheral blood, where it outcompetes normal white blood 
cells, red blood cells and platelets, resulting in immunodeficiency-related symptoms, as 
well as anemia and thrombocytopenia.  Blood tests can detect a rise in white blood cell 
count, but bone marrow samples are required to accurately determine the subtype of 
AML.  Currently, prognosis and treatment options are dependent on the AML subtype 
(Estey, 2013).  
Classification of AML 
 The first attempt to define subtypes of AML occurred in 1976, when the French-
American-British (FAB) classification system was introduced (Bennett et al., 1976).  
FAB offered 8 subtypes, M0-M7, and involved the characterization of AML based on 
microscopic examination to determine how closely the AML cells resembled various 
myeloid progenitors (Figure 1.1) (van Doorn-Khosrovani, 2004).   
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 The FAB system also employed cytogenetics to detect specific genetic alterations, 
and attempted to group each major chromosomal abnormality (i.e. translocation) into a 
specific subtype.  However, defining a one-to-one correlation between translocations and 
FAB subtypes was only possible in the case of the t(15:17) translocation PLM-RAR 
found in acute promyelocytic leukemia (APL), which is classified as FAB subtype M3 
(Piazza et al., 2001).  
In 2001, the World Health Organization (WHO) proposed a new method of AML 
classification, based on factors such as genetic alterations, treatment-induced disease, or 
evolution from other diseases, such as myelodysplastic syndrome (MDS) or 
myeloproliferative disease (MPD), as outlined in Table 1.2 (Vardiman et al., 2002).  One 
of the key distinctions in the WHO classification as compared to the FAB system was the 
separation of MDS-derived AML from de novo AML.  MDS, formerly referred to as 
preleukemia, is exemplified by anemia or cytopenia, with few, if any, blast cells in the 
peripheral blood, and small percentages of blast cells in the bone marrow.  The WHO 
classification changed the blast cell percentage in the bone marrow from 30% to 20% for 
establishing the AML threshold.  The WHO classification also added a distinct sub-
classification in the MDS group for 5q-syndrome, a slow growing dysplasia characterized 
by a 5q chromosomal deletion.  
With the advent of gene expression microarray technology, an attempt was made 
to create AML subtypes based on gene expression patterns (Valk et al., 2004).  
Unsupervised clustering of gene expression patterns of 285 AML patient samples 
identified 16 distinct groupings.  Although there was a not a definitive correspondence to 
the FAB or WHO classification systems, within the 16 clusters there was a cluster for 
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AMLs containing CBG-MYH11 fusions, a cluster for PML-RAR fusions, and a cluster 
for AMLs containing AML1-ETO fusions.  FAB subtypes M4 and M5 also fell into a 
single cluster.   
Through the development of mouse models, AML researchers have shown the 
evolution of AML requires two distinct mutations, one to encourage unchecked 
proliferation (Class I mutations), and a second to block normal differentiation and/or 
promote self-renewal (Class II mutations).  When the two class hypothesis was originally 
proposed (Gilliland and Griffin, 2002) the Class I mutations were described as mutations 
in a single gene, while the Class II mutations were shown as fusion events, such as the 
ones listed in Table 1.2.  Examples of Class I mutations were the FLT3 internal tandem 
duplication (ITD), and various point mutations in KIT, KRAS, NRAS, and PTPN11.   
However, nearly half of all human AML samples display a normal karyotype 
(Dohner and Dohner, 2008).  Since the original definition of the two class model, a 
number of point mutations have been identified as Class II events.  These include 
mutations in several transcription factors:  AML1, C/EBP, and MLL.  There are also a 
number of recently identified recurring mutations which have not been fully 
characterized, and so have not yet been assigned to either class, such as DNMT3a and 
NPM1 (Takahashi, 2011). 
If a Class I mutation, such as K-rasG12D, is introduced to a transgenic mouse 
model, the result is often a MPD phenotype (Chan and Gilliland, 2004).  If a Class II 
mutation, such as AML1S291fsX100, is introduced to a transgenic mouse, a MDS phenotype 
is frequently the result (Beachy and Aplan, 2010).  Combining Class I and Class II 
mutations in a transgenic mouse typically result in AML, such as in the mouse model that 
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combined a FLT3-LM mutation with an AML1-ETO fusion (Schessl et al., 2005), and in 
the TNM mouse model that combined a N-ras oncogene with an Mll-AF9 fusion (Kim et 
al., 2009).  Many patient samples display a similar pattern of Class I and Class II 
mutations in AML (Ishikawa et al., 2009), which makes the mouse models particularly 
useful tools for studying cellular changes associated with various mutations, and for 
testing various drugs and drug combinations. 
Because of the abundance of AML samples available for study, the relative 
simplicity of acquiring AML samples from the bone marrow, and the ease at which 
subsets of cells can be characterized by flow cytometry, many of the advances in the 
understanding of the role of translocations in cancer and the theory of cancer stem cells 
has been progressed from the study of acute myeloid leukemia.  It has been theorized 
there is a small population of leukemia initiating cells, commonly referred to as leukemic 
stem cells (LSC), present in each case of AML.  Fractions of human AML cells, 
separated based on surface markers using flow cytometry, where introduced into severe 
combined immunodeficient (SCID) mice.  It was shown the CD34+ CD38- population 
was able to establish disease in the SCID mice, but not the CD34+ CD38+ or CD34- 
populations (Lapidot et al., 1994).  Many attempts have been made to further characterize 
these LSCs, but it has proved as difficult as classifying AMLs into subtypes (Horton and 
Huntly, 2012).  One popular theory maintains specific drugs and drug combinations can 
be developed which will prove toxic to LSCs, but not to normal hematopoietic cells 
(Jordan, 2007; Ravandi and Estrov, 2006).   
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Prognosis of AML 
AML prognosis is dependent upon a number of factors including age, medical 
history, AML subtype, and cytogenetic/molecular features.  In 2010, the European 
LeukemiaNet (ELN) proposed prognostic groups based on cytogenetic and molecular 
abnormalities for AML, excluding APL (Table 1.3) (Dohner et al., 2010). 
In 2011, a German research group used the ELN system to characterize the 
outcome of 1557 patients undergoing standard leukemia treatments between 1996 and 
2005 (Rollig et al., 2011).  In the 847 patients falling into the 18-60 age group, the overall 
survival and probability of survival was distinctly different for each of the ELN 
prognostic groups.  The probability for relapse within 5 years for the adverse group was 
near 80% while the probability of relapse for the favorable group was just below 40%.    
The Intermediate-II group had more favorable outcomes than the Intermediate-I group, 
with probabilities of relapse at approximately 75% and 50%, respectively.  
The Valk et al. study, which identified 16 subtypes of AML based on the 
clustering gene expression, was followed by a plethora of studies with the goal of 
developing prognostic gene expression patterns.  The most recent attempt resulted in the 
identification of a set of 24 genes which can be used in predicting survival (Li et al., 
2013).  Two sets of patients, 277 patients from the Netherlands and 548 patients from 
Germany, were statistically separated into two groups based on the expression levels of 
the 24 genes.  The 5 year survival rate was twice as high in one group versus the other; 
~50% vs. ~20% in the Netherlands group and ~40% vs. ~20% in the Germany group.  
The set of genes were composed of ALS2CR8, ANGEL1, ARL6IP4, BSPRY, C1RL, 
CPT1A, DAPK1, ETFB, FGFR1, HEATR6, LAPTM4B, MAP7, NDFIP1, PBX3, 
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PLA2G4A, PLOD3, PTP4A3, SLC25A12, SLC2A5, TMEM149, TRIM44, TRPS1, and 
VAV3. 
Despite the progress being made in this area, prognostic factors are inexorably 
tied to treatment options.   Introducing treatment options beyond the current standard of 
care and based on the molecular characteristics of an individual’s AML could radically 
alter the gene expression versus prognosis correlations as they are currently defined. 
Induction Chemotherapy with Cytarabine (Ara-C) 
 With the exception of APL (subtype M3), which is treated with retinoic acid, 
clinicians use the ELN risk stratification system to predict patient response and outline an 
appropriate treatment strategy (Estey, 2013).  All patients are initially treated with 
induction chemotherapy  to eliminate blast cells, and the AMLs characterized as 
“favorable” or “intermediate 1” are followed by consolidation therapy to target the 
leukemic stem cells.  FLT3-ITD+ patients are also given a FLT3 inhibitor.  If the patient 
is strong enough, and the patient achieves a complete remission following induction 
therapy, bone marrow transplants are given to the “intermediate 1” group.  Patients 
falling into the “intermediate 2” or “adverse” groups are typically shuttled to clinical 
trials appropriate to the genetic abnormalities of their AML. 
For over 40 years cytarabine, referred to as cytosine arabinoside or Ara-C 
(Arabinosyl Cytosine), has been the primary component of both standard induction 
therapy and consolidation therapy.  High dose Ara-C combined with an anthracycline 
(HiDAC 3+7) is given for induction chemotherapy, while lower doses of Ara-C are given 
for consolidation (Estey, 2013).  Most AML patients will initially respond well to 
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chemotherapy, but then most will relapse with an Ara-C resistant form (Kubal and 
Lancet, 2013).  
Ara-C is a cytidine analog which contains an arabinose sugar in place of the 
normal ribose sugar found in cytidines.  It enters the cell using the same highly conserved 
dNTP Salvage Pathway used by the cell to recover normal cytidines from its 
surroundings (Figure 1.2) (Toy et al., 2010).   
Ara-C is metabolically activated by the addition of three phosphates.  The first 
phosphate is added by deoxycytidine kinase (DCK), which is also the rate limiting 
enzyme in the dNTP Salvage Pathway.  Ara-C is incorporated into the DNA during the S-
phase, and interferes with replication by inhibiting polymerase and topoisomerase 
activity.  As an independent molecule, Ara-C is quickly deaminated into a nontoxic uracil 
derivative and has a half-life of less than an hour, but once incorporated into DNA it can 
still be detected after 24 hours (Grem et al., 1995).  As a result, Ara-C is more toxic to 
fast growing cancer cells than to slow growing cells, and to be an effective treatment for 
AML, it must be given intravenously in a continuous manner over a period of 7 days.  
 Ara-C has been found to be particularly effective when combined with an 
anthracycline.  However, this course of treatment is harsh and is not always a viable 
option for older patients with other medical conditions.  In the hopes of finding 
alternative treatment options, hundreds of clinical trials are underway, using a wide 
variety of new drugs and drug combinations (clinicaltrials.gov).    
Ara-C Resistance Research 
In one of the earliest studies of Ara-C resistance, it was noted the presence of Ara-
C resistance was more prevalent in ALL cells if the patient had been treated with Ara-C 
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prior to the acquisition of the cell sample  (Preisler et al., 1984). The first study finding a 
connection between Ara-C resistance and loss of deoxycytidine kinase (Dck) function 
was published in 1985 (Young et al., 1985).  In 1995, transfection of Dck cDNA into 
Ara-C resistant rat leukemic cells with loss of Dck function, restored Ara-C sensitivity  
(Stegmann et al., 1995).  Mutations in Dck and Slc29a1, both components of the dNTP 
Salvage Pathway, were identified in Ara-C resistant human leukemic cell lines (Cai et al., 
2008).  Interestingly, the loss of Dck function is the only suggested mechanism of Ara-C 
resistance that has appeared in more than one research study, suggesting it may the most 
prominent mechanism of Ara-C resistance.  Despite this emphasis on Dck, there has been 
no published studies describing how cells adapt to Dck loss, what drugs can be used to 
treat AML experiencing functional loss of Dck, or any clinical studies which include an 
evaluation of Dck functionality.  
Models of Ara-C Resistance in AML 
Although there have been a number of publications describing the analysis of 
Ara-C resistant human and mouse AML cell lines (Abe et al., 2006; Cai et al., 2008; Jin 
et al., 2009; Negoro et al., 2011; Veuger et al., 2000; Yin et al., 2006a), there are none 
describing the generation of an in vivo mouse model of Ara-C resistance.  The  Abe et al. 
study established Ara-C resistant K562 human AML cell lines, the Cai et al. study used 
Ara-C resistant human CCRF-CEM cell lines, the Jin et al. study created Ara-C resistant 
HF6 murine AML and K562 human AML cell lines, and the Negoro et al.  study 
established 5 Ara-C resistant human cell lines (from HL-60, K562, CEM, THP1, and 
U937 cells).  The research conducted for this thesis utilizes an in vitro model of Ara-C 
11 
 
resistance utilizing 2 Ara-C resistant murine BXH-2 cell lines established in the Yin et al. 
study, and involves the generation of an in vivo model of Ara-C resistance. 
In vitro model of Ara-C resistance 
In 1969, twelve BXH strains were developed at The Jackson Laboratory by Dr. 
Benjamin Taylor from crosses between C57BL/6J and C3H/HeJ strains.  It was quickly 
discovered that the BXH-2 strain spontaneously developed AML, due to the presence of a 
retrovirus (Bedigian et al., 1981).  AML cells from two BXH-2 mice, B117 and B140, 
were used to create two AML cell lines, B117P and B140P, respectively (Largaespada et 
al., 1995).  Nf1 transcription in the B117P cells was disrupted by proviral insertions in the 
Evi-2 locus.  This mimics human disease in that loss of NF1 has been shown to be a 
driver of human AML in complex karyotypes (Mrozek, 2008).  With the goal of creating 
a model of Ara-C resistant refractory AML, these two cells lines were subjected to 
increasing concentrations of Ara-C until two highly resistant cell lines resulted, B117H 
and B140H, which tolerated Ara-C concentrations 500-1000 times that of the parental 
lines (Yin et al., 2006a).  All four cell lines (B117P, B117H, B140P, and B140H) have 
been characterized by flow cytometry of phenotypic surface markers (unpublished data).  
Interestingly, the B117 cells display phenotypic markers consistent with stem cells or 
early progenitors, such as CD34 and c-kit, while the B140 cells do not.   
In vivo model of Ara-C resistance 
Vav-tTA; TRE-NRASG12V; Mll-AF9 (TNM) transgenic mice were generated to 
study the nature of oncogene addiction (Kim et al., 2009).  This model is representative 
of a combination of a Class I mutation, NRASG12V, and a Class II mutation, Mll-AF9.  A 
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bank of viable cells was made from spleen cells harvested from these mice.  This is a Tet-
off model, in which the oncogenic NRAS can be turned off by presence of doxycycline.  
Doxycycline can be given continuously to the mice by adding it to their drinking water, 
or can be given in pulses by IP injection.  If doxycycline is given as an IP injection with 
subsequent oral delivery in drinking water, transcription of the NRAS oncogene is 
terminated within 6 hours of IP injection, while the NRAS protein persists in the cells for 
about 48 hours (Sachs et al, submitted).  This model has a number of advantages.  It is 
based on the most common MLL fusion found in human AMLs.  It engrafts readily and 
the disease progresses rapidly in SCID/beige mice with full-blown AML (WBC > 150 
K/ml) occurring at approximately 16 days.  Depending on the type of experiment being 
conducted, the NRAS oncogene can be left active, or deactivated by treating the mice with 
doxycycline.  Deactivation of the NRAS oncogene by treatment with doxycycline results 
in a nearly complete remission.  If the doxycycline is subsequently withheld, the NRAS 
oncogene will be expressed again and the AML reestablished. 
Methods for Evaluating Gene Expression 
The turn of the current century brought about the introduction of gene expression 
microarrays to evaluate the levels of expression of RNA in cells.  This provided a 
powerful tool for comparing Ara-C resistant cells to Ara-C sensitive cells.  Prior to the 
introduction of microarrays, RNA expression was evaluated a gene at a time.  
Microarrays are small, thumb-nail size chips with organized sections of embedded 
oligonucleotides, typically 25-mers, whose sequences correspond to a specific RNA 
sequence.  The processing of the microarray involves the isolation of RNA, the 
generation of a cDNA copy of the RNA, fragmentation of the cDNA, addition of 
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fluorescent labels to the cDNA fragments, and exposure of the labeled fragments to the 
microarray chip.  The fragments preferentially bind to complementary sequences on the 
chip, and the intensity of the fluorescence is measured for each section of the chip.  
Software tools are used to normalize the fluorescent signals across each individual chip 
and to normal expression levels between chips.  The final product is a list of genes and 
their relative expression levels for each of the RNA samples being evaluated (Harrington 
et al., 2000). 
Although gene expression microarrays were a significant advancement, they still 
had limitations.  They were only able to evaluate a predefined set of genes, it was not 
possible to design probes to distinguish between genes with similar sequences, and there 
was an inherent level of background signal, which could distort the signal levels, 
especially for genes expressed at low levels. 
The year 2010 brought about the rapid deployment of high-throughput deep-
sequencing devices.  The University of Minnesota ran its first set of RNA-sequencing 
samples in November of 2010.  The RNA-seq processing also starts with the isolation of 
RNA and the generation of a cDNA copy, followed by fragmentation.  The goal of the 
fragmentation process is to create fragments of similar length.  The fragments are run out 
on a gel and the location with highest level of RNA is cut out and isolated from the gel.  
Adaptors are added to one or both ends of the fragments, depending on whether single 
reads or paired-end reads are being performed.  The fragments are then sequenced to a 
predefined length by the deep-sequencing device (Wang et al., 2009).  
Theoretically, RNA-sequencing should provide the opportunity for superior gene 
expression analysis from that of its predecessor, gene expression microarrays, due to its 
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unbiased approach for selecting and evaluating cDNA fragments.  In addition, RNA-
sequencing has the potential to evaluate expression levels at an isoform level, detect rare 
and novel transcripts and splice variants, distinguish between similar variants, and 
identify the existence of various types of mutations and fusions.  However, the analysis of 
the RNA-seq data is only as good as the software tools being used, and the software tools 
are still in their infancy.  As the software tools evolve, the true power of RNA-
sequencing will be realized.  An in-depth comparison of the microarray and RNA-seq 
approaches for gene expression analysis is provided in the Discussion section of Chapter 
3.  A description of the analysis of RNA-sequencing data is included in Appendix D. 
Methods for Knocking Down and Knocking Out Gene Expression 
Finding candidate genes, by either microarray or RNA-seq, is only the first step in 
determining the gene changes involved in drug resistance.  The candidate genes need to 
be tested to confirm their involvement.  Two methods were used in this research:  RNA 
interference to knockdown gene expression, and Transcription Activator-Like Effector 
Nucleases (TALENs) to achieve total knockout of genes.   
Since the initial discovery of the process of RNA interference (RNAi) in C. 
elegans in 1998 (Fire et al., 1998), a plethora of techniques have been developed to take 
advantage of introducing small fragments of RNA designed to interfere with a specific 
gene’s expression.  Unfortunately, the effectiveness of these techniques is typically 
dependent of the quantity of vectors transfected into the cells.  This is a problem for 
difficult-to-transfect cells, such as AML.  Partial knockdown can be accomplished in 
AML cells and may suggest a trend in the change of drug response, but the results may 
not be statistically significant.   
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Techniques, which have the ability to specifically and completely knockout a 
gene by damaging all copies of the gene at the DNA level, such as TALENs, are far 
superior to RNAi, since many drug resistant phenotypes are associated with specific gene 
mutations that completely knockout gene function.  The TAL system was first discovered 
in Xanthomonas bacteria, and consists of the FokI endonuclease and TAL effector 
proteins that guide FokI to a specific DNA sequence, where FokI executes a non-specific 
double-strand break (Cermak et al., 2011).  Double-strand break repair mechanisms 
repair the break, but usually with the loss of one or more nucleotides.  The TAL effector 
proteins contain a tandem repeat sequence.  Toward the middle of each repeat sequence 
there are two amino acids that specificly bind to a single nucleotide.  Researchers take 
advantage of this naturally occurring mechanism by engineering a pair of TAL effector 
proteins targeting two nucleotide (NT) sequences about 15 NTs in length and 
approximately 15 NTs apart, on opposite sides of the DNA strand.   If the TAL effector is 
designed to target the first translated exon of the target gene, there is a high probability it 
will cause a deletions in all DNA copies of the gene, resulting in complete loss of gene 
function. 
Pre-clinical Drug Assays for Testing Anti-Leukemia Drugs and Drug Combinations 
MTS-tetrazolium based assays were optimized for this research to provide a 
consistent method of determining inhibitory concentrations and combination indices.  
Inhibitory concentrations can be established describing the concentration of drug needed 
to negatively influence the expansion of live cells at a specific percentage.  The inhibitory 
concentration at 50% (IC50) is a standard measure of toxicity of a drug in a specific cell 
line.  Although the MTS assay can be used to measure inhibition of cell expansion, it 
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provides no indication of whether the inhibition was due to a drop in proliferation or an 
increase in cell death.   
The combination index (CI), invented by Chou and Talalay in 1984, is used to 
measure the level of synergy or antagonism exhibited by a combination of two or more 
drugs in a specific cell line (Chou and Talalay, 1984).  When combining two drugs at a 
constant ratio, the formula for calculating the CI50 is CIA+B = (DA|A+B/DA) + (DB|A+B/DB), 
where D is the drug concentration at IC50, and A and B represent each of the two drugs.  
The nomenclature of the DA|A+B/DA calculation represents the concentration of drug A in 
the combination assay (A+B) at the IC50 point divided by the IC50 concentration of drug 
A when given alone.  If the drug combination is synergistic the CI will be < 1.0, if 
perfectly additive the CI = 1.0, and if antagonistic the CI is > 1.0. 
The exact protocol for the MTS-tetrazolium assay is provided in the Appendix A:  
Methods and Materials.  It is a highly reproducible colorimetric assay performed in 96-
well plates.  Its sensitivity and specificity has been compared favorably to other 
toxicological techniques for determining IC50 (Malich et al., 1997).   A general layout for 
the plates is provided in Figure 1.3. 
The drug concentrations used in each drug assay are specifically selected to 
optimize the number of data points within the range of 0.05-0.95 for the fraction of cells 
affected.  After performing regression analysis of the data points, the IC50 is determined 
by locating the drug concentration associated with the point where half the cells are 
affected.  A generic example of results from an MTS-Tetrazolium assay is provided in 
Figure 1.4.   
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The drug assays are conducted at least 3 times for each drug and cell line 
combination.  For the results to be deemed acceptable for this research, there must be at 
least 5 data points between 0.05 and 0.95 fraction affected, and the r value for the 
regression analysis must be greater than 0.88. 
Research Objectives 
There have been over 14,000 research papers published on AML 
(www.ncbi.nlm.nih.gov/pubmed/) and there are over 1,600 active or completed clinical 
trials (clinicaltrials.gov).  Despite the significant focus on AML and potential treatment 
options, there remains an incomplete understanding of what molecular factors determine 
how well patients will initially respond to induction chemotherapy, and what causes Ara-
C resistance to develop. 
The research conducted for this thesis had a number of objectives.  The first goal 
was to determine the genetic alterations responsible the Ara-C resistance in the B117H 
and B140H cell lines described above.  This was accomplished using two distinct 
technologies, microarray gene expression analysis (Chapter 2), and RNA-sequencing 
(Chapter 3).  The second goal was to identify drugs which are most appropriate for 
treating Ara-C resistant disease, and to identify drugs synergistic with Ara-C to treat de 
novo AML (Chapter 4).  The third goal was to establish an in vivo model of Ara-C 
resistance in mice, to mimic refractory disease for testing new drug combinations 
(Chapter 5).  A summary of the results, along with conclusions, and subsequent research 
opportunities are also described in Chapter 5. 
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Table 1.1:  Estimated New Cases of Leukemia and Deaths in 2013 (ACS) 
Projections of new leukemia cases and deaths for 2013 from the American Cancer 
Society’s Cancer Facts & Figures 2013. 
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Type of Leukemia Number % of total Number % of total
ALL ‐ Acute lymphocytic  6,070        12.5 1,430        6.0
AML ‐ Acute myeloid 14,590      30.0 10,370      43.7
CLL ‐ Chronic lymphocytic 15,680      32.3 4,580        19.3
CML ‐ Chronic myeloid 5,920        12.2 610           2.6
Other 6,350        13.1 6,730        28.4
Total 48,610      23,720     
New cases Deaths
2013 ‐ Estimated
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Table 1.2:  WHO Classification of Acute Myeloid Leukemia 
The World Health Organization created categories of AML based on genetic alterations 
and therapeutic response (Vardiman et al., 2002). 
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Category     Includes 
de novo AML with translocations    AML1‐ETO, CBF‐MYH11, PML‐RAR, MLL 
fusions 
Multilineage dysplasias    Progression from MDS/MPS, 2+ myeloid lineages 
Therapy related    Alkylating agents, radiation, topoisomerase II 
inhibitors 
AML not categorized above     
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Table 1.3:  ELN Proposed Prognostic Groups for AML 
ELN prognostic groups for AML are based on both cytogenetic and molecular 
abnormalities.  Adapted from Table 4 (Dohner et al., 2010).    
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Prognosis  Includes 
Favorable  AML1‐ETO, CBF‐MYH11, Solo NPM1 or CEBPA mutations 
Intermediate I  Normal karyotypes, mutated NPM1 with FLT3‐ITD 
Intermediate II  MLLT3‐MLL, abnormal karyotypes not in other groups 
Adverse  RPN1‐EV1, DEK‐NUP214, MLL fusions, del(5q), complex 
karyotypes (3 or more chromosomal abnormalities) 
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Figure 1.1:  FAB Classification of Acute Myeloid Leukemia 
FAB subtypes (M0-M7) for AML are determined based on how closely the cancer cells 
resemble various myeloid progenitors. 
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Figure 1.2:  Ara-C Is Metabolized by the dNTP Salvage Pathway 
Ara-C is processed in the same manner as salvaged cytidines.  It enters the cell via the 
ENT1 transporter (Slc29a1), and is triply phosphated before being incorporated into 
DNA where it interferes with DNA replication.  
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Figure 1.3:  Plate Layout for the MTS-Tetrazolium Drug Assay  
Plate layout for the MTS-Tetrazolium drug assay includes each cell sample and drug 
combination being done in quadruplicate, plus 10 separate drug concentrations being 
tested.   
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Figure 1.4:  Determining the IC50 from the MTS-Tetrazolium Assay Results 
Regression analysis is used to determine a trend line.  The IC50 concentration is the 
location on the trend line where 50% of the cells are affected. 
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Chapter 2:  Deoxycytidine Kinase Is Down-regulated in Ara-C Resistant Acute 
Myeloid Leukemia Murine Cell Lines 
 
[Portions of this chapter were published in Leukemia (Rathe and Largaespada, 2010).  
Leukemia does not require a release form for including this material in a thesis by the 
primary author.] 
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Acute myeloid leukemia (AML) is a malignant expansion of immature cells in the 
bone marrow.  Although chemotherapeutic treatments containing cytosine arabinoside 
(Ara-C) typically result in dramatic remissions, resistance to chemotherapy frequently 
occurs.  To achieve a better understanding of how Ara-C resistance develops, two highly 
Ara-C resistant BXH-2 derived AML cell lines (B117H and B140H) were compared to 
their respective parental cell lines (B117P and B140P) using gene expression microarray.  
The microarray identified deoxycytidine kinase (Dck) as the gene with the most 
significant change in expression levels.  PCR identified the presence of an aberrant form 
of Dck in the B117H cells.  Evaluation of several other chemotherapy drugs showed that 
the Ara-C resistant cells were also highly resistant to decitabine.  The results of the drug 
assays are consistent with the microarray results, since both Ara-C and decitabine rely on 
Dck for metabolic activation.    
Introduction 
Patients presenting with Ara-C resistant AML have a reduction in the active 
metabolized form of Ara-C (Ara-CTP), but the mechanisms responsible for this reduction 
are still being investigated (Chou et al., 1977).  In previously published work two AML 
cell lines (B117P and B140P), derived from BXH-2 strain mouse leukemias, were 
subjected to increasing concentrations of Ara-C to create two highly resistant derivatives 
(B117H and B140H) that tolerate Ara-C concentrations ~800 times that of their parental 
lines (Yin et al., 2006a).  In this study, gene expression microarrays were conducted to 
determine the expression changes common to both sets of cell lines.  The results were 
verified by qPCR and the specificity of drug resistance was evaluated. 
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Materials and Methods 
Procedures for performing cell culture, RNA isolation, gene expression 
microarray and analysis, quantitative PCR, and drug assays for determining IC50 are all 
described in Appendix A.  Primers are provided in Supplementary Table A.1. 
Results 
Gene expression microarrays identify genes that may be associated with Ara-C resistance 
Microarray gene expression analysis to compare differences between the parental 
cell lines (B117P and B140P) and their highly resistant derivatives (B117H and B140H) 
was performed on 12 RNA isolations (3 isolations for each cell line from different 
passages) using Affymetrix Mouse Genome 430 2.0 Arrays containing 45,101 murine 
oligonucleotide sequences.  The detection values were processed using Genedata 
Expressionist software (Genedata AG, Basel, Switzerland) using the robust multiarray 
average (RMA) normalization technique.  The raw data are available online at 
http://www.ncbi.nlm.nih.gov/geo/ (accession number GSE18322).  Group t-test analysis 
was used to compare the B117P cells to the B117H cells, and the B140P cells to the 
B140H cells.  Only expression changes greater than 2.0 fold with p-values < 0.01 were 
considered.  One hundred and twenty differentially expressed probe sets representing 104 
genes were obtained when comparing B140H to B140P.  Two hundred and eighty six 
differentially expressed probe sets representing 239 genes were obtained when comparing 
B117H to B117P.  In Table 2.1 those genes with consistent expression changes (>2.0 
fold) upon selection for Ara-C resistance in both cell lines are listed. 
The most significant changes occurred in the expression of Dck.  However, there 
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were three Affymetrix probes designed to detect Dck levels and only two showed 
significant changes.  The average detection levels for each of the Dck probes are 
presented in Table 2.2. 
It is also possible the Ara-C resistance was caused by different mechanistic 
changes to each of the Ara-C resistant cell lines.  The number of genes with greater than 
2-fold of differentially expressed genes, when comparing each Ara-C resistant cell line to 
its parental cell line, is in the hundreds.  Table 2.3 and Table 2.4 list a subset of 
differentially expressed genes with fold changes greater than 10 fold when comparing 
B117H to B117P, and B140H to B140P, respectively. 
Downregulation of Dck is found in both Ara-C resistant cell lines 
According to the microarray gene expression data the deoxycytidine kinase (Dck) 
gene mRNA level was altered to a greater extent than any other single gene.  Starting 
levels of Dck expression were similar in both the B117P and B140P parental cell lines.  
However, the Dck levels in the B117H cells were near zero, while the Dck levels in 
B140H cells were decreased 8.0 fold compared to B140P.  Affymetrix had three probes 
designed to detect Dck.  The probe sets showing a significant decrease in Dck expression 
targeted the 3’-UTR of Dck.  Expression changes for the Dck gene were confirmed by 
quantitative PCR (qPCR).   PCR primers were designed to target both the translated 
portion (primer set 1) and the 3’ end of the Dck transcript (primer set 2).  Rps9, a gene 
that is expressed at moderate and consistent levels across all four cell lines, was used to 
normalize the results.  The qPCR analysis using primer set 2 confirmed the altered 
expression levels found at the 3’ end in the microarray (Figure 2.1).  The qPCR using 
primer set 1 showed an 8 fold decrease in transcript levels in both sets of cells, while the 
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microarray probe 1428838_a_at showed no significant change in expression levels 
between all four cell lines. 
Abnormal Dck transcript found in B117H cells 
 qPCR could find no evidence of expression toward the 3’ end of the Dck 
transcript in the B117H cell line, indicating the presence of an abnormal Dck transcript.   
To determine if the Dck transcript was unusual, four sets of primers were designed to 
detect 800 bp overlapping sections of Dck (Figure 2.2).  The amplified bands were 
sequenced.  In addition to amplifying a segment of Dck, the Q3 primers also amplified a 
700 bp segment of Prpf38b.  Only the Q1 primers amplified a segment of Dck in the 
B117H cells.   
Ara-C resistant cells are also resistant to decitabine 
Drug assays were conducted on all four cell lines to determine if Ara-C resistance 
conferred drug resistance to other chemotherapy drugs (Table 2.4). Resistance to Ara-C 
did not confer resistance to other drugs, expect in the case of decitabine.  There was a 
significant change in the response to decitabine in both sets of cells, with a greater than 
900 fold increase in IC50 values in Ara-C resistant derivatives compared to parental cell 
lines.  
If the cause of the Ara-C resistance is related to downregulation of Dck, it would 
seem probable the Ara-C resistance cells would be more sensitive to CPEC, an inhibitor 
of the de novo pathway for generating cytidines.  However, there is only a slight drop in 
the IC50 for CPEC in the Ara-C resistant cells when compared to the parentals,  
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Phenotypic differences between the B117P and B140P cell lines 
The parental cell lines (B117P and B140P) are markedly different phenotypically 
and yet their response to Ara-C is about the same with similar 50% inhibitory 
concentrations (IC50).  B117P grows 2.3 times faster than B140P (data not shown), and 
they have differences in gene expression patterns, as detected by microarray analysis.  
Although CD34 has not been found to be associated with any particular AML subtype or 
to be prognostically significant, B117P and B117H highly express Cd34, while B140P 
and B140H do not (a 183-fold difference).  Furthermore, the level of myeloperoxidase 
(Mpo) is 34-fold greater in the B117P cells when compared to the B140P cells.  In 
addition, the B117P expressed significantly higher levels of both Gp49a (27.6 fold) and 
Laptm4b (8.7 fold) than the B140P cells.  The presence of Gp49a and Laptm4b are 
indicators of “stem-ness” in hematopoietic cells, while their absence is associated with 
more mature hematopoietic cells (Lee et al., 2010).  Despite these differences, both Ara-
C resistant cell lines showed a significant decrease in the gene expression of Dck upon 
selection for Ara-C resistance.  
Discussion 
The parental cell lines used in this study (B117P and B140P) were markedly 
different in both phenotypic markers and in response to various drugs.  Despite these 
differences, both sets of cells have similar sensitivity to Ara-C, and both were readily 
transformed into Ara-C resistant cell lines (Yin et al., 2006a).  RNA was isolated from all 
four cell lines from three separate passages and the results analyzed by gene expression 
microarray to search for common changes associated with Ara-C resistance. 
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The Affymetrix microarray chip used in this study had three probes designed to 
detect expression levels of Dck.  The 1428838_a_at probe targeted the translated portion 
of the transcript while the other two probes targeted the 3’-UTR.  The microarray 
analysis identified the two most significant expression changes between the Ara-C 
resistant cell lines and their parental lines, which were in the 3’-UTR of Dck.  qPCR 
confirmed the Dck expression level changes in the 3’-UTR, but the qPCR of the area 
targeted by the 1428838_a_at detected 8-fold decreases in that area as well.  The signal 
strength for the 1428838_a_at probe was significantly less than that observed in the other 
two probes, and the signal was comparable across all 4 cell lines, indicating there may be 
other probes attracting the Dck fragments.  This is always a possibility when working 
with microarray technology.  However, the downregulation of Dck in the Ara-C resistant 
cell lines was verified by qPCR and an aberrant form of Dck was detected in the B117H 
cells by RT-PCR. 
Dck encodes deoxycytidine kinase, which phosphorylates deoxyribonucleosides 
including deoxycytidine, deoxyguanosine and deoxyadenosine.  DCK performs the rate-
limiting step in Ara-C metabolic activation, which is monophosphosphorylation after 
import of Ara-C through the SLC29A1 nucleoside transporter (Grant, 1998).  Thus, 
down-regulation of this kinase would be expected to lead to resistance to Ara-C.  Indeed, 
polymorphisms in the human DCK gene have been associated with patient’s response to 
AML chemotherapies containing Ara-C (Shi et al., 2004), and expression of alternatively 
spliced isoforms of DCK are found in some Ara-C resistant AML patients (Veuger et al., 
2000).  A recent paper described alterations in DCK expression in a human AML cell line 
selected for resistance to Ara-C in vitro (Song et al., 2009).  These investigators also 
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noted that primary human AML samples differ in the level of DCK transcript, and that 
these differences may be related to Ara-C sensitivity, at least as measured in an in vitro 
assay. 
Both Ara-C and decitabine are deoxycytidine analogs, and are tri-phosphorylated 
by the same kinases (including Dck).  However, their methods of interfering with cell 
proliferation are entirely different.  Once triphosphorylated, Ara-C is incorporated into 
DNA during replication, blocking polymerase and topoisomerase activity, whereas 
decitabine inhibits DNA methyltransferase activity. Since the change in resistance to both 
Ara-C and decitabine are comparable, this supports the hypothesis that the Ara-C drug 
resistance of the B117H and B140H cells is driven specifically by the down-regulation of 
Dck. 
If the lack of Dck is the primary change associated with the Ara-C resistance, it 
would be logical to assume that in order for the Ara-C resistant cells to survive, the cells 
would become dependent on the de novo pathway of deoxycytidine triphosphate (dCTP) 
generation rather than the savage pathway.  In the de novo pathway, dCTPs are created 
from deoxyuridine triphosphates (dUTPs) by CTP synthetase (CTPS).  CTPS is 
ubiquitously expressed and its role is to keep dUTPs and dCTPs in balance, which is 
accomplished by negative feedback in which dCTP inhibits CTPS (Chang and Carman, 
2008).  The drug cyclopentenyl cytosine (CPEC) inhibits CTPS (Kang et al., 1989), so if 
the Ara-C resistant cells lack the ability to process dCTPs via the dNTP salvage pathway, 
it seems likely the cells are relying on the de novo pathway for dCTPs during replication.  
If so, there should be a dramatic decrease in the IC50 for CPEC in the Ara-C resistant cell 
lines.  However, there was only a slight decrease in the CPEC IC50, which can be 
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interpreted in a number of ways:  1) Dck is not the only kinase capable of 
monophosphorylating deoxyribonucleotides in the dNTP salvage pathway, 2) CPEC is 
not completely effective at blocking CTPS activity, 3) there is another method of 
converting dUTPs to dCTPs other than CTPS, or 4) there is a third unknown method of 
providing dCTPs to the cells other than the dNTP salvage pathway or the de novo 
pathway.  
Regardless, there are other changes taking place in the cells that may play a 
supporting role in the development of drug resistance.  For example, the urea transporter 
Slc14a1 is up-regulated in both sets of Ara-C resistant cells.  This suggests that the Ara-C 
resistant cells are producing more urea than their Ara-C sensitive parental cells.  Down-
regulation of Dck would also interfere with the cells ability to get deoxycytidines via the 
salvage pathway.  So, one possible explanation for this increase in urea is that the Ara-C 
resistant cells are deriving the building blocks for de novo synthesis of cytosine from the 
degradation of thymidine.  Urea is a byproduct of the thymidine degradation process. 
Manipulation of the Wnt pathway may also be involved in Ara-C resistance.  
Dab2, an adaptor protein that stabilizes Axin, and thus blocks Wnt signaling (Jiang et al., 
2008), is down-regulated in both Ara-C resistant cell lines, suggesting an increase of 
Wnt/-catenin signaling may be present in the Ara-C resistant derivatives. 
Another gene of particular interest is Ifitm1, which was significantly down-
regulated in both Ara-C resistant cell lines.  Ifitm1, also called Leu13, is an interferon 
induced antiproliferative transmembrane protein.  Lower levels of IFITM1 expression 
have been shown to correlate with decreased survival in chronic myeloid leukemia 
(Akyerli et al., 2005).  A decrease in IFITM1 expression in esophageal squamous cell 
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carcinoma has been shown to correlate with increased resistance to cis-platinum (Fumoto 
et al., 2008). 
Since the gene expression patterns of B117P and B140P cells are so different, 
analysis of gene expression changes for each cell line upon selection for Ara-C may 
provide clues for identifying additional drug resistance genes (Tables 2.2 and 2.3).  For 
example, in the B140H cells there was a 36-fold down-regulation of Spint2, which has 
been characterized as a tumor suppressor gene in medulloblastoma (Kongkham et al., 
2008).  B117H cells have upregulated the neuregulin-4 (Nrg4) gene transcript 10-fold.  
Nrg4 can bind to and activate epidermal growth factor receptor (EGFR)-family receptors 
and so their activation could contribute to the Ara-C resistant phenotype in this cell line 
perhaps by activation of the Ras/MAPK pathway which has been shown to modulate 
Ara-C responsiveness (Yin et al., 2006b).  S100a10 gene expression is dramatically 
down-regulated in B140H cells and the product of this gene interacts with Annexin-11, 
which has been described as an anti-apopototic protein involved in chemotherapy 
resistance (Chuthapisith et al., 2009). 
Further studies are underway to determine the mechanisms behind the reduction 
in Dck expression and to identify whether the expression changes of other genes 
identified by the microarray analysis are required by the cells to compensate for loss of 
Dck expression or participate in the development of Ara-C resistance by other 
mechanisms.  Drugs targeting the pathways that can cooperate with Dck downregulation 
to allow Ara-C resistance may be useful for preventing the selection of Ara-C resistant 
clones in patients. 
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Table 2.1:  Common gene expression changes between Ara-C resistant cell 
lines and their Ara-C sensitive parental lines (> 2.0 fold). 
Gene expression microarray analysis comparing B117H to B117P and B140H to B140P.  
Genes with greater than 2-fold in both comparisons are listed.  Microarray was done on 
RNA isolated from 3 separate passages of cells. 
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Probe ID Gene ID Description B117H vs. B117P
B140H vs. 
B140P
1439012_a_at Dck deoxycytidine kinase -273.157 -8.264
1449176_a_at Dck deoxycytidine kinase -92.503 -7.488
1415673_at Psph phosphoserine phosphatase -4.571 -2.606
1424254_at Ifitm1 interferon induced transmembrane 
protein 1 -4.456 -2.788
1420498_a_at Dab2 disabled homolog 2 (Drosophila) -4.338 -3.251
1423805_at Dab2 disabled homolog 2 (Drosophila) -3.632 -2.108
1429693_at Dab2 disabled homolog 2 (Drosophila) -3.566 -2.480
1455991_at Ccbl2 cysteine conjugate-beta lyase 2 -2.176 -3.308
1433521_at Ankrd13c ankyrin repeat domain 13C 2.055 2.021
1428114_at Slc14a1 solute carrier family 14 (urea 
transporter), member 1 2.692 2.135
1433939_at Aff3 AF4/FMR2 family, member 3 2.737 2.180
Fold Change
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Table 2.2:  Average probe signal strength for each of the Dck probes. 
Average of the signal strength for each of the Affymetrix probes for Dck in the 4 BXH-2 
cell lines. 
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Affy Probe ID B117P B117H B140P B140H
1428838_a_at 245.8 224.7 206.8 78.9
1439012_a_at 2793.6 10.2 2464.9 298.3
1449176_a_at 1288.1 13.8 1067.9 141.2
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Table 2.3:  10-fold gene expression changes comparing Ara-C resistant 
B117H cells to B117P parental cells. 
Gene expression microarray analysis comparing B117H to B117P.  Genes with greater 
than 10-fold are listed.  Microarray was done on RNA isolated from 3 separate passages 
of cells. 
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Fold Change
Probe ID Gene ID Description B117H vs. B117P
1439012_a_at Dck deoxycytidine kinase -273.157
1426438_at Ddx3y DEAD (Asp-Glu-Ala-Asp) box polypeptide 
3, Y-linked
-112.117
1449176_a_at Dck deoxycytidine kinase -92.503
1452077_at Ddx3y DEAD (Asp-Glu-Ala-Asp) box polypeptide 
3, Y-linked
-30.279
1426598_at Uty Ubiquitously transcribed tetratricopeptide 
repeat gene, Y chromosome
-15.103
1419905_s_at Hpgd hydroxyprostaglandin dehydrogenase 15 
(NAD)
-13.998
1421408_at Igsf6 immunoglobulin superfamily, member 6 -13.870
1421571_a_at LOC100045833, 
Ly6c1, Ly6c2
lymphocyte antigen 6 complex, locus C -13.366
1433930_at Hpse heparanase -11.545
1426439_at Ddx3y DEAD (Asp-Glu-Ala-Asp) box polypeptide 
3, Y-linked
-11.326
1433944_at Hectd2 HECT domain containing 2 10.212
1421681_at Nrg4 neuregulin 4 10.217
1459860_x_at Trim2 tripartite motif-containing 2 12.334
1446594_at Gm4371 eukaryotic translation initiation factor 3, 
subunit I pseudogene
13.897
1439036_a_at Atp1b1 ATPase, Na+/K+ transporting, beta 1 
polypeptide
13.990
1420822_s_at Sgpp1 sphingosine-1-phosphate phosphatase 1 15.374
1420821_at Sgpp1 sphingosine-1-phosphate phosphatase 1 17.392
1424292_at Depdc1a DEP domain containing 1a 31.617
1426236_a_at Glul RIKEN cDNA 5830403L16 gene 43.289
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Table 2.4:  10-fold gene expression changes comparing Ara-C resistant 
B140H cells to B140P parental cells. 
Gene expression microarray analysis comparing B140H to B140P.  Genes with greater 
than 10-fold are listed.  Microarray was done on RNA isolated from 3 separate passages 
of cells. 
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Fold Change
Probe ID Gene ID Description B140H vs. B140P
1456642_x_at S100a10 S100 calcium binding protein A10 
(calpactin)
-95.306
1416762_at S100a10 S100 calcium binding protein A10 
(calpactin)
-44.896
1438968_x_at Spint2 serine protease inhibitor, Kunitz type 2 -36.941
1426980_s_at E130012A19Rik RIKEN cDNA E130012A19 gene -13.315
1422776_at Serpinb8 serine (or cysteine) proteinase inhibitor, 
clade B, member 8
-11.758
1455865_at Insm1 insulinoma-associated 1 -10.926
1434353_at Sfmbt2 Scm-like with four mbt domains 2 -10.866
1426523_a_at Gnpda2 glucosamine-6-phosphate deaminase 2 -10.369
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Figure 2.1:  qPCR Measurement of Dck Expression in Ara-C resistant cell 
lines and their parental lines. 
qPCR was repeated 3 times for each cell line.  Rps9 was used to normalize the data.  
Primers are described in Supplementary Table C.1. 
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Figure 2.2:  B117H cells lack normal transcripts in the area of quartiles 2, 3, 
and 4. 
RT-PCR was performed using primers designed to amplify 800bp overlapping segments 
of the Dck transcript.  Rps9 was used as a loading control. 
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Table 2.5:  IC50 Values for Other Chemotherapy Drugs 
MTS-Tetrozolium Assays (as described in Appendix A) were repeated at least 3 times for 
each drug and cell line.  (Except for the fluoruracil in B117H and nelarabine in B140P, 
which were only repeated twice). 
56 
 
 
   
Fold  Fold 
Drug Tested Average Std. Dev. Average Std. Dev. Change Average Std. Dev. Average Std. Dev. Change
CPEC 0.132 0.026 0.080 0.015 ‐1.651 0.064 0.010 0.027 0.004 ‐2.345
Daunorubicin 0.256 0.043 0.236 0.009 ‐1.085 0.057 0.022 0.074 0.016 1.302
Decitibine 0.318 0.131 301.666 54.875 948.427 0.100 0.016 110.182 18.309 1099.564
Didox 65.499 4.848 47.845 5.826 ‐1.369 48.100 12.407 32.254 32.254 ‐1.491
Etoposide 0.560 0.399 0.526 0.221 ‐1.064 0.245 0.096 0.272 0.059 1.113
Fluorouracil  1.201 0.079 2.266 0.193 1.887 0.847 0.259 0.487 0.054 ‐1.741
MK457 0.950 0.158 1.015 0.088 1.068 0.242 0.013 0.254 0.040 1.050
Nelarabine 16.809 3.303 22.097 5.735 1.315 27.289 0.440 26.401 2.795 ‐1.034
PD‐0325901 0.013 0.004 0.010 0.004 ‐1.312 0.113 0.046 0.032 0.008 ‐3.491
PI‐103 2.262 0.696 1.043 0.295 ‐2.168 0.721 0.271 0.630 0.149 ‐1.143
B117P B117H B140P B140H
50% Inhibitory Concentration (IC50) inM
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Chapter 3: Combining the Power of Transcriptome Sequencing and Transcription 
Activator-Like Effector Nucleases to Identify Mechanisms of Drug Resistance in 
Acute Myeloid Leukemia Murine Cells 
 
[Manuscript is being prepared for submission.] 
 
Susan K. Rathe1,6, Branden S. Moriarity PhD1,2,3, Christopher B. Stoltenberg1, Natalie K. 
Aumann, Eric P. Rahrmann PhD1,2,3, Natashay J. Bailey1, Ellen G. Melrose1, Dominic A. 
Beckmann2,3, Chase R. Liska1,   David A. Largaespada PhD1,2,3,4,5 
 
1Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA; 2Department of Genetics, Cell 
Biology and Development, University of Minnesota, Minneapolis, MN, USA; 3Center for Genome 
Engineering, University of Minnesota, Minneapolis, MN, USA; 4Brain Tumor Program, University of 
Minnesota, Minneapolis, MN, USA; 5Department of Pediatrics, University of Minnesota, Minneapolis, 
MN, USA 
   
58 
 
Contributors 
 
Branden S. Moriarity designed and constructed the TALENs for knocking out Dck and 
the vectors for overexpressing DCK.  He also conducted the transfections of the TALENs 
and overexpression vectors into the cells.  He created Figure 2.3c and Figure 3.4c.  He 
wrote the “TALEN assembly and generation of KO cells” and “Inducible DCK 
overexpression vector” sections of the Methods and Materials in Appendix A. 
Christopher B. Stoltenberg assisted in the RNAi knockdown experiments and associated 
drug assays.  He assisted with the creation of Figure 3.3a.  He wrote the “RNAi 
experiments” section of the Methods and Materials in Appendix A. 
Natalie K. Aumann performed the DNA isolations of the KO cells.  She assisted in the 
design of primers and the analysis of sequencing data to verify the KOs.  She also 
assisted in drug assays.  She wrote the “Cell culture” section of the Methods and 
Materials in Appendix A.  
Eric P. Rahrmann performed the Westerns blots.  He created Figures 3.1e, 3.3d, and 
3.4d.  He wrote the “Western blot analysis” section of the Methods and Materials in 
Appendix A. 
Natashay J. Bailey performed the DNA isolations of the BXH-2 cells and assisted in the 
analysis of the sequencing data to detect the Dck mutations in the B117H and B140H 
cells. 
Ellen G. Melrose assisted in the qPCR efforts and wrote the “quantitative PCR” section 
of the Methods and Materials in Appendix A. 
59 
 
Dominic A. Beckmann designed the primers to verify the TALEN-based KOs and 
assisted in the DNA isolation and sequencing analysis of the KOs. 
Chase R. Liska assisted in the generation of single cell clones from the TALEN-based 
Dck KOs and the DCK OE cells, as well as assisted in the drugs assays to measure the 
Ara-C IC50 in the KO cells and OE cells.  He also assisted in the creation of Figures 3.4a 
& b. 
  
60 
 
  The technical evolution from gene expression microarrays to 
transcriptome deep-sequencing (RNA-seq) and from RNA interference to highly specific 
gene knockouts using Transcription Activator-Like Effector Nucleases (TALENs) has 
provided a new experimental partnership for identifying and quantifying the effects of 
gene changes on drug resistance.  In a previously published microarray analysis we 
identified the downregulation of Dck as the primary common change in two Ara-C 
resistant murine acute myeloid leukemia cell lines (B117H and B140H), when compared 
to their Ara-C sensitive parental cell lines (B117P and B140P).  In this publication we 
describe the results of deep-sequencing (RNA-seq) of the same RNA samples, and 
present a Transcription Activator-Like Effector Nuclease (TALEN) based method for 
accomplishing complete Dck gene knockout (KO) in AML cells.  Our analysis of the 
RNA-seq data led to the identification of protein modifying loss-of-function mutations in 
the Dck transcripts in both Ara-C resistant cell lines.  TALEN-based KO of Dck in the 
B117P cell lines dramatically increased the IC50 of Ara-C near those displayed by the 
Ara-C resistant B117H cells.  Introduction of a DCK overexpression vector in the Dck 
KO clones resulted in a significant, but incomplete, restoration of Ara-C sensitivity.  The 
RNA-seq analysis also identified a number of significant expression changes that did not 
appear in the microarray analysis, and identified other mutations, which may contribute 
to Ara-C resistance.  This effort demonstrates the power of using RNA-seq transcriptome 
analysis and TALEN-based KOs to identify and verify genes associated with drug 
resistance.  
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Introduction 
The 12,000+ patients diagnosed with acute myeloid leukemia (AML) in the 
United States each year face a dismal prognosis.  The induction chemotherapy, which 
will most likely result in a remission, is typically not curative.  However, induction 
chemotherapy can significantly reduce blast cells providing the clinician with additional 
time to try other therapies.  Unfortunately, the additional therapies are generally not 
effective at achieving a long-term durable remission.  At relapse, most patients will no 
longer respond to induction therapy, since the leukemic clones surviving the initial 
onslaught of induction chemotherapy have an innate resistance, and have therefore 
become the prevalent disease cells (Estey, 2012). 
Arabinoside cytarabine (Ara-C) has been the primary component of induction 
chemotherapy for over 40 years.  Ara-C, a cytidine analog, enters the cell via the dNTP 
salvage pathway, where it is metabolically activated by the addition of three phosphates 
in the same manner as cytidines.  Each phosphate is added by a different kinase.  The first 
kinase in the dNTP salvage pathway is deoxycytidine kinase (DCK), the rate limiting 
enzyme in the metabolic activation of Ara-C.  Numerous studies have shown DCK 
expression is frequently downregulated in cells that are unresponsive to Ara-C (Cai et al., 
2008; Rathe and Largaespada, 2010; Shi et al., 2004; Song et al., 2009; Veuger et al., 
2000; Veuger et al., 2002). 
We theorize there are other pathways whose regulation is altered in order to 
compensate for DCK loss.  If identified, those pathways could be potential targets for 
drugs, to be used in combination with Ara-C to treat AML.  In a previous publication, we 
reported the results of a microarray gene expression analysis, which compared gene 
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expression of two Ara-C resistant cell lines (B117H and B140H) with their respective 
Ara-C sensitive parental cells lines (B117P and B140P) (Rathe and Largaespada, 2010). 
The B117H and B140H cells tolerated concentrations of Ara-C 500-1000 times that of 
their parental lines (Yin et al., 2006a).  The most dramatic common change identified by 
the microarray study was the significant downregulation of Dck (Rathe and Largaespada, 
2010). 
Here we report the results of a subsequent RNA sequencing of the transcriptome 
of the same four murine AML cell lines (B117P, B117H, B140P, and B140H).  RNA-seq 
analysis uncovered evidence to the nature of the Dck functional impairment in both the 
B117H cells and the B140H cells: a large deletion of DNA spanning the splice acceptor 
of the last exon of Dck and a frameshift mutation in the fourth exon of Dck, respectively.  
Both mutations resulted in aberrant RNA transcripts for Dck.  RNA-seq also identified 
gene expression changes not previously detected by gene expression microarray.   
Total KO of Dck using Transcription Activator-Like Effector Nucleases 
(TALENs) in the B117P cells confirmed the loss of Dck expression was nearly sufficient 
for the high Ara-C IC50 levels found in the Ara-C resistant cell lines.  Introduction of an 
inducible DCK overexpression vector in the B117P Dck KO clones restored most of the 
original Ara-C sensitivity. 
This research demonstrates the value of using RNA-seq methods to identify 
changes in cells as they become resistant to drugs and a new method for generating 
candidate drug resistant gene KOs in difficult-to-transfect AML cells using TALENs 
with single step drug selection.  Further study of the cells containing the TALEN-based 
63 
 
knock-outs of Dck may identify upregulated genes and/or pathways compensating for the 
loss of Dck, and thus lead to the discovery of effective companion drugs to Ara-C.. 
Materials and methods 
Cell culture, transcriptome deep sequencing and analysis, DNA and RNA 
isolation and sequencing, genomic DNA PCR, quantitative PCR, RNAi experiments, 
TALEN assembly and generation of KO cells, inducible DCK overexpression vector, 
Western blot analysis, drug assays are all described in Appendix A. 
Raw data files and processed expression files are available online in the Gene 
Expression Omnibus at http://www.ncbi.nlm.nih.gov/geo/ (accession number 
GSE47454).   
Results 
RNA-sequencing identifies more gene expression changes than microarray hybridization 
Samples of RNA had previously been isolated from 2 murine BXH-2 AML cell 
lines and their Ara-C resistant derivatives, and then evaluated by microarray.(Rathe and 
Largaespada, 2010)  In order to find gene expression changes associated with Ara-C 
resistance not previously implicated by the microarray analyses, aliquots of RNA from 
the microarray experiment were submitted for RNA-sequencing (RNA-seq).  TopHat was 
used to map the data to the mouse transcriptome (NCBI37/mm9), and the quality of the 
mapping was tested using Picard-tools.  All samples had over 20 million paired reads 
with over 90% mapped and over 89% uniquely mapped (Supplementary Table C.2).  
Cuffdiff (Roberts et al., 2011a; Roberts et al., 2011b; Trapnell et al., 2010) was used to 
determine changes common to both Ara-C resistant cell lines (B117H and B140H) when 
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compared to their parental lines.  To avoid division by zero, a minimum FPKM was 
established at 0.001 based on FPKM distribution patterns (Supplementary Figure C.1).  
These patterns also showed genes expressed in just one sample, a phenomenon not seen 
when studying microarray expression data due to the presence of background noise.  
Genes where both the parental and its Ara-C resistant derivative had FPKM levels less 
than 0.5 were excluded from the analysis, since even technical replicates display a high 
degree of variability at these lower expression levels (Mortazavi et al., 2008).  Integrated 
Genomic Viewer (IGV; http://www.broadinstitute.org/igv) was then used to eliminate 
false positives, which included distortions due to reads mapping outside the normal 
transcription area, a high abundance of non-unique reads, and projected non-protein 
coding RNA sequences.   
The previous microarray analysis identified 8 genes with expression levels with 
2X or more fold changes.  In comparison the RNA-seq method identified 60 genes.  
Seven genes appeared in both lists (Figure 3.1a).  Genes identified by RNA-seq with a 
3X or more fold change in both sets of cells (B117H vs. B117P and B140H vs. B140P) 
are listed in Table 3.1, while the greater than 2-fold and less than 3-fold change genes are 
included in Supplementary Table C.3.  The only gene identified by microarray and not 
by RNA-seq was Psph, where the expression did not meet the 2-fold threshold in the 
RNA-seq analysis. The RNA-seq list includes Dck, the only gene appearing in the 
microarray data as being changed by more than 5-fold.  The expression levels of Dck 
were verified by qPCR (Figure 3.1b).  Of the 53 genes identified by RNA-seq but not by 
microarray, 3 genes did not have a probe designed on the microarray chip 
(2310007A19Rik,  2210417A02Rik, and AI427809), 1 gene had expression levels so high 
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it probably saturated the microarray chips (Mpo), 10 genes had probes lacking specificity, 
22 had expression levels too low for the microarray chips to distinguish significant 
differences (including Dab2ip), and 15 just missed the 2 fold cutoff in the microarray 
analysis, most likely due to the distortive effect of background noise.  As for the last 2 
genes, microarray was unable to distinguish between Ly6c2 and Ly6c1 expression levels 
due to sequence similarities between these two genes, or between Gng5 and its family 
members. 
We next looked at changes unique to either the B117H cells or the B140H cells 
when compared to their individual parental cell lines, B117P and B140P, respectively.  
These lists were significantly longer than those generated by microarray, so we confined 
our analysis to the gene expression changes of 100-fold or more (Supplementary Tables 
C.4 and C.5).  Again due to the distortion caused by background noise only one gene had 
a 100X change within the microarray data (Ddx3y in the B117 cells).   
RNA-sequencing identifies mutations in Dck in the B117H cells and B140H cells 
Missense Mutation and Frameshift Location Reporter (MMuFLR) (Rathe et al., 
2013), a Galaxy (Blankenberg et al., 2010; Giardine et al., 2005; Goecks et al., 2010) 
based workflow developed to look for frameshift and missense mutations, was used to 
identify mutations in the Ara-C resistant cell lines that were not present in their respective 
parental cell lines.  MMuFLR identified a single thymidine insertion in exon 4 of Dck 
following the 462nd nt from the translational start site, which would result in a severely 
truncated protein.  Sanger sequencing showed the insertion was present in all expressed 
Dck transcripts (Figure 3.2b) and homozygous in the genomic DNA (Supplementary 
Figure C.2). The nearly complete elimination of Dck protein was verified by Western 
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blot (Figure 3.1f).  The genomic insertion would result in a severely truncated protein 
(Supplementary Figure C.3). 
To confirm the expression levels of Dck identified by Cuffdiff, and to look for 
any sequence anomalies within the Dck transcript, IGV was used to visualize the TopHat 
(Langmead et al., 2009; Trapnell et al., 2009) generated mapped reads (Figure 3.1c).  
Transcripts were also assembled independently of a reference genome and then mapped 
back to the reference genome, and visualized using IGV (Figure 3.1d).  The IGV views 
of the TopHat and Cufflinks processes elucidated the changes that took place in Dck. 
In the B117H cells, IGV clearly showed run-through transcription into intron 6, a 
loss of transcription in all but a small section of the 3’-UTR and a continuation of 
transcription beyond the 3’-UTR.  The run-through transcription into intron 6 suggested a 
deletion of the splice acceptor site of exon 7.  Cufflinks (Roberts et al., 2011a; Roberts et 
al., 2011b; Trapnell et al., 2010) was used to generate transcripts by evaluating 
overlapping reads, but without the benefit of a reference genome.  When the results were 
mapped back to the mm9 reference genome, the aberrant nature of the Dck transcript in 
B117H was again apparent (Figure 3.1d).  A long template PCR of genomic DNA 
indicated there was a deletion of approximately 1 kb in the Dck locus in the B117H cells 
(Supplementary Figure C.4).  This deletion was verified by amplifying segments of 
DNA and then sequencing the amplified segments.  The actual deletion was determined 
to be 878 bases (Figure 3.2a).  The deletion started 750 bases before the start of exon 7, 
and ended 128 bases into exon 7.  The loss of the splice acceptor for exon 7 resulted in 
the splicing machinery selecting alternative splice sites.  Sequencing of the RNA 
transcript verified the mapping of Dck done by IGV.  The transcription proceeded into 
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intron 6 up to the deletion, continued beyond the deletion for 49 bases into exon 7, 
skipped 190 bases, transcribed an additional 207 bases, and then skipped another 2825 
bases, where it picked up transcription again, well beyond the 3’-UTR.  The protein 
generated from this aberrant transcript should have resulted in the translation of a protein 
with 20 amino acids generated from the start of the intron 6 region, rather than the 8 
amino acids that would have been translated from exon 7 in a normal transcript.  Dck 
proteins form homodimers, and although there are no specific functional domains within 
the C-terminus of Dck, it is highly conversed across a broad spectrum of species 
indicating its importance in Dck function (Supplementary Table C.6).  Western blots 
(WB) of Dck in the B117P and B117H cell lines showed a Dck protein was being 
generated in the B117H cells (Figure 1e), but the WB technique was not sensitive 
enough to detect a size change. 
Mutation analyses tools identify other mutations acquired in Ara-C resistant cells 
In addition to the frameshift mutation identified in Dck of B140H, another 
frameshift was identified by MMuFLR as being introduced in Ccdc88b of B140H 
(Supplementary Table C.7).  The Ccdc88b frameshift was shown to be heterozygous by 
Sanger sequencing.  No frameshifts were detected in the B117H cells that were not also 
present in the B117P cells (Supplementary Table C.8). 
MMuFLR also identified 21 mutations introduced into either the B117H cells or 
the B140H cells (Table 3.2).  The potential for functional changes to comparable proteins 
in human cells was examined using both PolyPhen-2 (Adzhubei et al., 2010) and 
PROVEAN Protein (Choi et al., 2012).  PolyPhen-2 identified the mutations in KDM5C, 
PRKACB, VPS33B, PBRM1, and ZNF668 as “probably damaging”, while PROVEAN 
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Protein identified the mutations in PRKACB, PUS7L, RASGRP2, ATPBD4, and 
SMARCA4 as “deleterious”.    
deFuse (McPherson et al., 2011) was used to look for the introduction of any 
protein modifying fusions in the Ara-C resistant cell lines, when compared to their 
respective parental lines.  No protein modifying fusions were found (data not shown).  
Partial suppression of Dck using RNAi results in an increase of the IC50 for Ara-C 
To test whether the downregulation of Dck alone can change a cell’s response to 
Ara-C, knockdowns of Dck were performed in the parental cell lines, B117P and B140P, 
using OpenBiosystems shRNA constructs.  Two TRC constructs for Dck were used, one 
targeted exon 6 (KD1) and the other targeted a sequence spanning exon 2 and 3 (KD2).  
The Dck knockdowns were verified by qPCR.  Drug assays were used to determine the 
Ara-C IC50 in the knockdown cell lines.  The Ara-C IC50’s were higher in the cell lines 
with the greater downregulation of Dck (Figure 3.3a).  As controls, knockdowns of 
Nfkb1 and p53 were also performed on the B117P cells.  No change in IC50 for Ara-C 
was observed (data not shown).   
Total KO of Dck using TALENs results in a significant increase of the IC50 for Ara-C 
TALENs were used to knock-out (KO) Dck function by performing a targeted 
deletion approximately 50 nt from the translational start site (Figure 3.2c).  Single cell 
clones were grown out and tested for Ara-C sensitivity.  Ara-C IC50’s in the Dck 
knockouts were comparable to the Ara-C IC50’s in the Ara-C resistant cell lines (Figure 
3.3a).  The location of the deletion in the DNA of each of the B117P KO clones (T2A, 
T6B, and T11A) was determined by PCR amplification of the TALEN target area and 
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Sanger sequencing (Figure 3.3b).  RT-PCR was performed on RNA-derived cDNA to 
look for transcript changes within the first 3 exons of Dck, and resulted in multiple light 
bands for the KO clones (Figure 3.3c).  The top two bands of the T6B clone were 
sequenced.  The top band revealed an alternatively spliced version of Dck 
(Supplementary Figure C.5), and the second band was an off target amplification of 
another gene.  The absence of Dck protein in the KO clones was verified by Western blot 
(Figure 3.3d). 
Rescue of Dck expression in Dck KO clones results in a decrease of the IC50 for Ara-C 
A doxycycline inducible human DCK overexpression vector (Figure 3.4c) was 
stably integrated into to the three B117P Dck KO cell lines (T2A, T6B, and T11A) using 
the piggyback transposon system.  The control of DCK expression was confirmed by 
qPCR (Figure 3.4a).  In the absence of doxycycline, the cells exhibited an Ara-C IC50 
slightly lower than the Dck KO cells (Figure 3.4b).  Inducing DCK with doxycycline 
resulted in a significant reduction in the Ara-C IC50.  Gene expression levels were 
measured by qPCR and the presence of DCK protein was confirmed by Western Blot 
(Figure 3.4d).  However, the DCK protein levels were much lower than the Dck levels 
found in the B117P cells. 
Discussion 
The B117H and B140H cells used in this study are highly resistant to Ara-C, 
tolerating concentrations of Ara-C 500-1000 times greater than the parental cell lines 
from which they were derived (Yin et al., 2006a).  We theorized this dramatic change in 
drug response would allow us to focus on the most prominent changes in the cells.  RNA 
70 
 
samples, previously analyzed using gene expression microarray technology, were 
examined using the Illumina HiSeq 2000 RNA-sequencing platform.  Numerous software 
tools were used to evaluate the resulting RNA-seq data.  TopHat was used to map the 
RNA-seq data to the mouse genome, while Cuffdiff was used to measure gene expression 
levels.  Comparing the microarray results to RNA-seq was problematic and revealed 
many advantages of RNA-seq.  Microarray results have an inherent background signal 
level, while RNA-seq does not have any technically generated background levels.  To 
avoid division by zero in the RNA-seq data, we elected to set a minimum level of 0.001 
FPKM for any genes with an FPKM less than 0.001.  Less than 0.01% of the genes had 
expression levels greater than zero and less than 0.001.  Due to the absence of 
background signal, RNA-seq was able to identify significant changes in genes expressed 
at much lower levels than could be detected by microarray.  Examples of such genes were 
Dab2ip and Hectd2, which were downregulated and upregulated, respectively, in the Ara-
C resistant cell lines.  In contrast to microarray probes, which lack the ability to 
distinguish between genes with similar sequences, RNA-seq (through the detection of 
single nucleotide differences) was able to uniquely assign reads to the genes with similar 
sequences, as with the case of Ly6c1 and Ly6c2.  Furthermore, RNA-seq’s unbiased 
approach to expression analysis has the potential to identify expression changes in genes 
not represented on microarray chips, and to detect expression levels at an mRNA isoform 
level.  
RNA-sequencing has at least one other critical advantage over microarray 
analysis.  It has the potential to identify RNA variants, such as unusual transcripts, 
fusions, frameshifts, and missense mutations.  The RNA-seq results were instrumental in 
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identifying the unusual changes to the Dck locus in both the B117H and B140H cell lines.  
In the B117H cells, microarray data had previously shown part of the 3’-UTR was 
missing, but only in the areas where the microarray probes were designed to detect.  
However, the IGV visualization of the RNA-seq data specifically showed expression in 
the first part of intron 6, and a small section of expression in the 3’-UTR, as well as a 
large transcribed section beyond the exon encoding the 3’-UTR.  The sequence of amino 
acids at the C-terminus of Dck forms an alpha-helix, which is highly conserved across 
various species.  The end of the C-terminus is in close proximity to a number of residues 
(Ile24, Ala119, and Pro122) important for Dck kinase activity (Kocabas et al., 2008).  
The replacement of 8 amino acids by 20 amino acids in the case of the aberrant Dck 
transcript in B117H may result either in instability of the resultant structure of Dck or 
interference with residues important to Dck’s function.  The frameshift mutation 
identified by MMuFLR in exon 4 of Dck in the B140H cells would result in a severely 
truncated version of the Dck protein. 
Although RNA-seq is clearly a technological advancement from microarrays, it is 
not without problems or limitations.   For example, the sequencing process has difficulty 
determining the correct number of nucleotides when reading through a poly-A or poly-T 
sequence, which can lead to the identification of small indels that do not really exist, an 
artifact referred to as “stuttering” (Fazekas et al., 2010).  MMuFLR has parameters that 
can be set to ignore this type of error.  On the analysis side, software tools to interpret the 
RNA-seq data are still in their early developmental stages, as are the tables used to 
characterize the data, such as the tables identifying SNPs and isoforms.  Normalizing 
RNA-seq data between samples is also providing a challenge, and many efforts are 
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underway to improve normalization techniques (Bullard et al., 2010; Roberts et al., 
2011b).  Using the FPKM normalization technique provided by Cuffdiff was adequate for 
comparing drug resistance derivatives to parental cell lines, as in this study, where the 
samples were all prepared at the same time using the same technique (Roberts et al., 
2011b).  Although there is no agreement on which approach is more accurate for 
measuring differential expression changes (microarray, RNA-seq, or qPCR), we did find 
RNA-seq, based on the quality measurement of the reads, perfectly and uniquely mapped 
reads to genes that could not be verified by qPCR due to the inability to create primers 
specific to the gene in question. 
It was not surprising to find Dck was the primary common change to both Ara-C 
resistant cell lines and the level of Dck expression correlated to the Ara-C IC50 level, 
since Dck is the rate limiting enzyme in the dNTP salvage pathway, which is required for 
the metabolic activation of Ara-C.  An alternatively spliced version of DCK was also 
found in a study of Ara-C resistant human acute lymphoblastic cell lines (Cai et al., 
2008), and downregulation of DCK was discovered in Ara-C resistant human acute 
myeloid cell lines (Song et al., 2009).  In the clinical setting, the presence of DCK SNPs 
and alternatively spliced versions of DCK have been correlated to patient response to 
chemotherapy (Shi et al., 2004; Veuger et al., 2000; Veuger et al., 2002).  Since Dck was 
both downregulated and mutated in the Ara-C resistant B117H and B140H cell lines, we 
suspect during the process of creating the Ara-C resistant cell lines, by adding increasing 
concentrations of Ara-C, the cells initially responded by downregulating expression of 
Dck.  Eventually the Ara-C concentrations became so high only the cells with defective 
Dck were able to survive. 
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Although changes in DCK expression have been associated with Ara-C resistance, 
the importance of DCK regulation has not been quantified.  The significance of Dck 
regulation alone to Ara-C resistance was demonstrated by the knockdown and KO of 
Dck.  The use of new and powerful TALEN-based techniques to specifically and 
completely KO Dck  in the B117P cells proved this single modification can account for 
over 85% of the Ara-C resistance present in the B117H cells.  Rescue of DCK expression 
significantly reduced Ara-C resistance.  The failure of the DCK overexpression to return 
the B117P Dck KO cells to its original Ara-C IC50 level may be due to the use of a human 
version of DCK, which may vary from mouse Dck in its kinetics or activation/repression 
methods.  As evidence to this, the DCK protein levels in the dox-induced DCK 
overexpression cell lines were significantly less than the Dck levels found in the B117P 
cells.  The ability to reintroduce DCK to the cells to restore most of the Ara-C sensitivity 
also indicated most of the changes, which took place when Dck was lost, were not 
permanent.  However, it is possible other gene alterations or gene expression changes 
partially contributed to the residual Ara-C resistance in these cell lines. 
Other potential gene regulation changes were identified, which may contribute 
directly to Ara-C drug resistance or may be compensating changes associated with the 
loss of Dck.  For example, there was significant and consistent downregulation of two 
tumor suppressor genes, Dab2 and Dab2ip, both of which are negative regulators of Ras.  
Missense mutations were also identified in 3 genes found within the Ras/MAPK 
pathway: Prkacb, Rasgrp2, and Map3k11.  One study showed introduction of a Ras 
oncogene resulted in a loss of DCK activity and Ara-C resistance in Rat-1a fibroblasts 
and human mammary HBL100 cells (Riva et al., 1995).  Their results, indicating 
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overactivation of Ras impedes Dck activity, and our results, indicating loss of Dck 
downregulates Ras repressors, suggests a balance and/or interdependency between these 
two pathways.  
This study illustrates normal Dck functionality is critical for Ara-C responsiveness 
in murine AML cell lines.  These cell lines provide a model for understanding the clinical 
response to Ara-C and the development of Ara-C resistant AML.  It demonstrates the 
many ways by which Dck function can be altered by mutation.  Further analysis of 
transcriptome changes in the Dck knockout cell lines will provide a better understanding 
of the changes taking place in the cells to compensate for the loss of Dck.  This will be 
crucial in identifying drug targets to prevent the expansion of AML cells with defective 
Dck function.  The TALEN-based KO techniques described here are especially suited to 
test each of the gene targets identified in these subsequent research efforts.  
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Table 3.1:  Gene expression changes common to both Ara-C resistant cell 
lines 
Gene expression changes common to both Ara-C resistant cell lines were identified by 
analyzing data generated from the Illumina NGS sequencing platform with the use of 
TopHat for genome mapping, and Cuffdiff for gene expression comparison.  Genes in 
bold with * were also identified by gene expression microarray with 2-fold+ changes in 
expression (Rathe & Largaespada, 2010). Expression levels are expressed in fragments 
per kilobase of transcript per million mapped reads (FPKMs).  Fold change compares the 
Ara-C resistant gene expression to the Ara-C sensitive parental lines. Negative values 
indicate a decrease in expression while positive values represent an increase in 
expression.  The table is sorted by the minimum fold change, which is the least of the two 
fold change values. 
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Gene symbol
B117P 
FPKMs
B117H 
FPKMs
B117H vs. 
B117P 
fold chg
B140P 
FPKMs
B140H 
FPKMs
B140H vs. 
B140P 
fold chg
Minimum 
fold 
change
Ly6c2 27.174 0.433 ‐62.787 2.345 0.061 ‐38.362 ‐38.362
Dab2ip 3.835 0.213 ‐17.983 0.775 0.015 ‐52.118 ‐17.983
Dck 20.102 3.312 ‐6.069 17.756 2.444 ‐7.265 ‐6.069
C230035I16Rik 1.699 0.396 ‐4.287 3.242 0.602 ‐5.382 ‐4.287
Ksr1 1.210 0.222 ‐5.447 1.326 0.347 ‐3.821 ‐3.821
Ifitm1 22.679 2.112 ‐10.736 18.128 4.779 ‐3.793 ‐3.793
2310007A19Rik(Riiad1) 0.962 0.194 ‐4.963 0.920 0.252 ‐3.651 ‐3.651
Cd14 37.783 11.521 ‐3.279 0.628 0.001 ‐628.324 ‐3.279
Mpo 1450.210 473.280 ‐3.064 10.416 0.913 ‐11.403 ‐3.064
Fbxo44 2.339 7.264 3.106 0.876 5.796 6.616 3.106
Plag1 0.154 0.887 5.751 0.168 0.547 3.263 3.263
Chst3 0.232 0.848 3.648 0.370 5.113 13.803 3.648
Myl10 0.001 1.014 1013.690 0.534 2.278 4.267 4.267
AI427809 0.617 3.427 5.557 0.106 0.541 5.097 5.097
Cib3 0.506 5.240 10.349 0.099 0.889 9.018 9.018
Hectd2 0.001 1.316 1315.930 0.098 1.022 10.446 10.446
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Table 3.2:  Protein modifying missense mutations identified by MMuFLR 
Protein modifying missense mutations identified by MMuFLR and verified in IGV as 
being found in the B117H and B140H cells, but not found in the respective parental cell 
lines, B117P and B140P.  Mutations projected by either damaging or deleterious in 
human cells by either Polyphen-2 or PROVEAN and then verified by Sanger sequencing 
are noted in bold.   
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Variant   Seq. Protein  
Cell Line Gene Position Ref. Var. Prevalence Depth Change
B117H Commd5 chr15:76730961 T G 0.37 38 L43V
Dram1 chr10:87803336 G A 0.53 17 V91I
Kdm3b chr18:34987086 T C 0.40 30 S1157P
Kdm5c chrX:148705903 G T 0.33 39 V1222L
Pigt chr2:164328088 C T 0.47 108 P386S
Prkacb chr3:146409579 G T 0.44 94 E209D
Pus7l chr15:94358455 C T 0.37 19 R499C
Pyroxd1 chr6:142303201 A G 0.43 7 N179S
Rasgrp2 chr19:6407273 G T 0.41 99 S349I
Susd1 chr4:59328600 T A 0.35 72 S748T
Vps33b chr7:87432008 G A 0.37 27 D414N
B140H Atpbd4 chr2:114470474 C G 0.45 33 L99V
Chd7 chr4:8678934 A G 0.50 6 N95D
Map3k11 chr19:5700807 G A 0.38 52 M684I
Mettl16 chr11:74609506 G A 0.34 67 R203Q
Pbrm1 chr14:31863259 A C 0.37 62 S375R
Rnf149 chr1:39609321 G A 0.49 142 C394Y
Smarca4 chr9:21445509 G A 0.49 164 E525K
Spag5 chr11:78118221 C T 0.42 73 S284L
Usp34 chr11:23321104 C G 0.50 38 L1812V
Zfp668 chr7:135009900 G A 0.43 37 R542Q
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Figure 3.1:  Dck expression patterns and protein levels  
Dck expression patterns and protein levels verified by IGV, qPCR and Western blot.  (a) 
Venn diagram depicting the overlap in the genes identified as having a greater than 2-fold 
expression change in both sets of cell lines (B117H vs. B117P and B140H vs. B140P) 
when evaluated by gene expression microarray and RNA-seq. (b) Reduced expression of 
Dck in the BXH-2 cell lines was confirmed by qPCR using primers designed to span 
exons 5 and 6 of Dck.  Error bars depict standard deviation.  (c) RNA-seq reads were 
mapped to the NCBI reference genome.  Visualization of Dck expression using IGV.  (d) 
Transcripts were assembled independently of a reference genome using Cufflinks, then 
mapped to the mm9 mouse genome using Cuffcompare, and the resulting gtf file was 
visualized by IGV.  (e) Western blot of Dck protein levels in the BXH-2 cell lines. 
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Figure 3.2:  Sequence abnormalities in Ara-C resistant cells  
Sequence abnormalities in Ara-C resistant cells verified by Sanger sequencing.  (a) 
Sanger sequencing of DNA in B117H cells identified an 878 nt deletion spanning the 
splice acceptor of intron 6 and the translated portion of exon 7.  Sanger sequencing of 
RNA verified a transcript matching the configuration identified by TopHat and IGV.  (b)  
Sanger sequencing of the RNA in B140H cells verified an insertion mutation in exon 4. 
(c) Structure of the TALENs used to knockout Dck in the B117P cell line.  
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Figure 3.3:  Reducing Dck expression in the B117P parental cell line 
Reducing Dck expression in the B117P parental cell line results in increases of the IC50 
value for Ara-C.  (a)  Reduction of Dck expression in B117P cells was accomplished 
marginally by RNA interference (KD1 and KD2) or completely using TALENs (KO).  
(b)  )  DNA modifications to Dck in the TALEN based KO cell lines confirmed a 1 nt 
deletion in the T2A cells, a 32 nt deletion in the T6B cells, and a 2 nt deletion in the 
T11A cells, and in each case the deletion occurred  just a little over 50 nt from the 
translation start site.  (c)  RT-PCR of cDNA copy of RNA of a 595 base sequence 
straddling the translational start site.  Primers are described in Supplementary Table S1. 
(d) Western blot verifying the absence of Dck proteins in the Dck KO clones. 
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Figure 3.4:  Rescue of Dck expression in the B117P KO clones 
Rescue of Dck expression in the B117P KO clones results in a decrease of the IC50 value 
for Ara-C.  (a)  qPCR of DCK expression in Dck KO clones plus DCK overexpression 
with and without DCK expression activation by doxycycline.  (b)  Ara-C IC50 levels in 
Dck KO clones plus DCK overexpression with and without DCK expression activation by 
doxycycline, as determined by MTS-Tetrazolium assay.   (c)  Structure of the 
doxycycline inducible DCK overexpression vector.  (d) Western blot of Dck/DCK 
proteins levels in the TALEN-based Dck KO clones with doxycycline induced DCK 
overexpression (OE).  Protein levels shown with and without doxycycline activation of 
DCK. 
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Chapter 4:  Screening for Ara-C Co-resistance or Hyper-sensitivity Using Ara-C 
Resistant Murine AML Cell Lines 
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Acute myeloid leukemia (AML) can display de novo or acquired resistance to 
cytosine arabinoside (Ara-C), a primary component of induction chemotherapy.  We 
hypothesized the changes required by the cells to become Ara-C resistant, might also 
make them more susceptible to elimination by other drugs.  We also hypothesized there 
may be drugs which are most effective at treating de novo AML in combination with 
Ara-C.  To test these hypotheses, we used two highly resistant murine AML cell lines, 
B117H and B140H, which were derived by introducing increasing concentrations of Ara-
C to their parental cell lines, B117P and B140P, respectively.  We previously 
demonstrated the loss of deoxycytidine kinase was one mechanism of resistance in the 
Ara-C resistant B117H and B140H cells, a mechanism which has also been documented 
in human cases of refractory disease.  A medium throughput drug screen was conducted 
to determine if an increase in Ara-C resistance would result in increased sensitivity to 
other drugs.  The screen evaluated 446 FDA approved drugs, and despite the diverse 
nature of the parental cell lines and their Ara-C resistant derivatives both Ara-C resistant 
cell lines showed an increase in sensitivity to prednisolone.  We also conducted an assay 
which combined Ara-C individually with 50 other drugs.  Ara-C proved most synergistic 
with cladribine in the parental cell lines, while the Ara-C resistant cell lines demonstrated 
a lack of synergy between Ara-C and cladribine.   
Introduction 
 The standard induction therapy used by clinicians to treat patients with acute 
myeloid leukemia (AML) contains the chemotherapy agent cytarabine (Ara-C).  Ara-C is 
a cytidine analog that interferes with DNA replication in fast growing cells.  Ara-C is 
highly effective at eliminating AML blast cells.  Unfortunately it is typically ineffective 
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in totally eradicating AML.  It appears some AML cells are capable of escaping the initial 
assault by the chemotherapy drugs.  Chapter 3 described how an in vitro model of Ara-C 
resistance was used to identify one possible explanation for Ara-C resistance, the loss of 
normal deoxycytidine kinase (Dck) function.  Dck is the rate-limiting enzyme in the 
metabolic activation of Ara-C.  Through the use of Dck knockouts, it was shown the loss 
of Dck accounted for over 85% of the Ara-C resistance found in the B117H cells. 
 As cells become resistant to Ara-C, it seemed probable the cells would become 
more sensitive to other drugs.  A standard drug screen was used to test this theory.  It 
interrogated the response of all four cell lines to 446 FDA approved drugs.  The response 
of the Ara-C resistant cells was compared to the response of their respective parental 
cells.  It was found the Ara-C resistant cells became more sensitive to 3 corticosteroids 
with the most pronounced change in the glucocorticoid prednisolone.  
 A second screen was conducted to test 50 drugs for synergy with Ara-C in the 
B117P cells.  It identified cladribine as the most synergistic drug to Ara-C in treating 
Ara-C sensitive cells.  Subsequent assays confirmed the synergy between Ara-C and 
cladribine in both Ara-C sensitive parental cell lines, and lack of synergy in the Ara-C 
resistant cell lines. 
 The results from these screens on matched sets of Ara-C sensitive and Ara-C 
resistant murine AML cell lines are consistent with trends seen in patients.  Some AML 
patients have been shown to respond well to treatments using glucocorticoids 
(Hicsonmez, 2006).  Some de novo AML patients respond better when cladribine is 
included in the chemotherapy cocktail, while there is no evidence of improved outcome 
when cladribine is given to patients with refractory disease (Holowiecki et al., 2004; 
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Rubnitz et al., 2009; Rubnitz et al., 2004).  Future work with this model will strive to 
characterize the molecular elements associated with positive drug response, for the 
purpose of creating clinical tools to assess a patient’s probable response to various 
therapies and select the most effective drugs for that patient.   
Methods and Material  
Procedures for performing cell culture, the FDA screen, the combination screen, 
and drug assays for determining IC50 and CI50 are all described in Appendix A.  
Results 
Drug screen determines Ara-C resistant cells become sensitive to prednisolone 
A drug screen was conducted on four BXH-2 derived cell lines, two Ara-C 
resistant (B117H and B140H) and the two Ara-C sensitive parental lines (B117P and 
B140P), from which the Ara-C resistant cells were derived.  446 FDA approved drugs 
were tested in each of the four cell lines at a concentration of 10 M, and the results were 
expressed in the percent of cells inhibited as compared to untreated cells.  Of the 446 
drugs tested, 165 showed less than a 30% change in the cells’ response to the drug and 
218 drugs were inconclusive, since they resulted in killing all of the cells or none of the 
cells.   47 drugs showed a greater than 30% change in only one set of the cells, and 16 
showed a greater than 30% change in drug response in both sets of cells (Table 4.1). 
Of the 13 drugs identified by the screen as being more effective at eliminating the 
Ara-C resistant cell lines than their Ara-C sensitive parental lines by greater than 30%, 3 
of the drugs fell into the category of corticosteroids: prednisolone, loteprednol etabonate, 
and corticosterone (Table 4.2). 
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Verification of prednisolone response by determining IC50 
Since prednisolone has been used to treat AML, an MTS tetrazolium assay was 
used to establish the IC50 for prednisolone (Figure 4.1).  The B117P displayed a high 
level of prednisolone resistance (IC50 = 105 mM), but its Ara-C resistant derivative, 
B117H, had a 20-fold reduction in the prednisolone IC50.  The B140P cells were even 
more sensitive to the prednisolone than the B117H cells, and the B140P’s Ara-C resistant 
derivative, B140H, demonstrated a 3-fold reduction in the prednisolone IC50.   
Dexamethasone is another glucocorticoid used in treating leukemia 
(clinicaltrials.gov).  The IC50 for dexamethasone was derived using the MTS Tetrazolium 
Assay and provided a similar trend of IC50’s in the four cell lines, but at much lower 
concentrations (Table 4.3).  
Glucocorticoid sensitivity is dependent on binding to the glucocorticoid receptor 
Cells respond to glucocorticoids in a number of ways, some of which are 
independent of glucocorticoid receptor (GR) binding (Di Santo et al., 1996).  To 
determine if the GR is an integral part of the response to prednisolone in the BXH-2 cell 
lines, a combination drug assay was performed using a constant concentration of 
prednisolone and a variable concentration of mifepristone.  Mifepristone is a steroid 
antagonist that binds to a number of steroid receptors including the GR (Agarwai, 1996).  
Mifepristone binding to the GR prevents the formation of an activated GR complex even 
in presence of a GR agonist, such as prednisolone (Cadepond et al., 1997).  The drug 
assay demonstrated mifepristone was able to totally block the toxic effects of 
prednisolone at concentrations of 2-4 M in all four BXH-2 cell lines (Figure 4.2).  
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Combination drug assays were also used to determine the combination index CI50 for the 
four cell lines.  The resulting CI’s were 5.7, 6.2, 6.0, and 6.6 for the B117P, B117H, 
B140P, and B140H cells, respectively, all reflective of a high degree of antagonism 
between prednisolone and mifepristone.   
RNA-sequencing analysis identifies genes potentially envolved in glucocorticoid 
resistance 
The high degree of variability in the four BXH-2 cell lines in their response to 
prednisolone and dexamethasone may be reflective of corresponding gene expression 
changes of similar direction and magnitude.  The microarray data described in Chapter 2 
and the RNA-seq data described in Chapter 3 were studied, looking for expression 
patterns mirroring the prednisolone and dexamethasone IC50 values.  Six candidate genes 
were identified by the microarray, which may be associated with glucocorticoid response 
(Table 4.4).  
The RNA-seq analysis, due to its unbiased approach for evaluating expression 
levels and its lack of distortions from background noise, identified 42 potential genes 
involved in prednisolone resistance (Table 4.5).  The RNA-seq list did not include any of 
the same genes on the microarray candidate list.  This was due to the more stringent 
selection criteria used in the RNA-seq analysis (30-fold vs. 10-fold between B117P and 
B140H, and the addition of a 2-fold change between B117P and B117H, between B140P 
and B140H), which was used to limit the number of potential candidates. 
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Combination drug screen identifies cladribine as synergistic to Ara-C in treating Ara-C 
sensitive AML 
Synergy can be detected at a gross level by looking for graphical trends when 
combining a constant concentration of one drug with increasing concentrations of a 
second drug.  Figure 4.3 illustrates trends seen when the combination of drugs is 
synergistic, additive or antagonistic.  The antagonistic trend was detected when 
prednisolone and mifepristone were tested together.   
To find drugs synergistic with Ara-C, a drug assay was devised to test the 
response of the B117P cells when treated with 200 ng/ml of Ara-C and 7 different 
concentrations of the second drug being tested in 2X increments.  The concentration of 
Ara-C used was selected to affect ~ 50% of the cells.  Across the 9 plates used, the actual 
effect of Ara-C treatment alone was 51% (S.D. 6.7%).  The additional effect provided by 
the second drug is present in Table 4.6.   
Cladribine was found to have the highest level of “change”.  This change level 
reflects the steepness of the curve as the concentration of the second drug is added.  To 
verify the synergy of the Ara-C and cladribine, a constant ratio of Ara-C and cladribine 
was introduced to all four cell lines using the standard MTS Tetrazolium Assay (Table 
4.7).  The constant ratio was determined by using the IC25 of Ara-C with the IC25 of 
cladrine.  The results were compared to Ara-C or cladribine alone to determine the 
combination index at 50% inhibition (CI50).  The B117P cell line demonstrated a 
synergistic response when the two drugs together (CI50 < 1.0), while the B117H cell line 
showed an antagonistic response (CI50 > 1.0).  This implies cladribine may enhance Ara-
C response in cells that are already sensitive to Ara-C. 
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Discussion 
AML is a heterogeneous disease.  There is a diverse collection of mutations 
driving AML progression in each patient, making it problematic to establish a standard 
protocol for treating the disease effectively.  The AML from patients with 
relapsed/refractory disease have additional therapy-related cellular changes.  There are 
currently over 500 clinical trials underway for treating AML and over 1000 completed or 
suspended trials (clinicaltrials.gov), with approximately half the trials specific to 
relapsed/refracatory AML.  These trials are testing a wide variety of drugs and drug 
combinations and yet there has been very little improvement in survival trends for AML.  
Most of the trials depend on the identification of the FAB subtype and a handful of 
known fusions.  Even though over 100 of the active trials include Ara-C in the regime, 
none evaluate the functional status of deoxycytidine kinase or its pathway members for 
predicting the effectiveness of Ara-C.  The same can be said for the 35 active studies 
testing decitabine and the 5 testing cladribine.  Both decitabine and cladribine depend on 
deoxycytidine kinase for activation (Lotfi et al., 2003; Momparler, 2005).  The use of 
synthetic glucocorticoids, such as prednisolone and dexamethasone, in treating AML is 
very rare.  There are only 6 active AML trials using prednisolone and only 5 using 
dexamethasone.  The use of glucocorticoids in treating ALL is more prevalent with over 
200 clinical trials using prednisolone and over 400 using dexamethasone.  
These statistics underscore the critical need for developing a better understanding 
of the molecular genetics driving drug response with the goal of providing patient-
specific drug options.  Perhaps there are some AMLs that would respond to 
glucocorticoid treatment if the drivers of the glucocorticoid response could be 
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determined.  In the case of the BXH-2 cell lines, the B117P cells are resistance to 
glucocorticoids, while the B140P cells are significantly more sensitive (Table 4.3).  
Synthetic glucocorticoids are given as anti-inflammatory and immunesuppresive 
agents in the treatment of a variety of ailments, including asthma and graft-versus-host 
disease (Martin et al., 2012; Rhen and Cidlowski, 2005; Schaaf and Cidlowski, 2002).  
Glucocorticoids affect metabolic processes and transcriptional regulation via a number of 
pathways, most of which are dependent upon binding to the GR (Schaaf and Cidlowski, 
2002).  The high number of clinical trials involving glucocorticoids to treat ALL, but not 
AML, is due to a mechanism of glucocorticoid-induced apoptosis, which is prevalent in 
ALL (Schlossmacher et al., 2011), but not in AML (1966).  The development of 
resistance to glucocorticoids is a common problem, but only a few mechanisms of 
resistance have been documented to date.  These mechanisms typically involve the 
inhibition of GR activity (Schaaf and Cidlowski, 2002).  
The drug screen, reported here, evaluating 446 FDA approved drugs indicated 
that as cells become resistant to Ara-C they become significantly more sensitive to 
glucocorticoids, such as prednisolone and dexamethasone.  Thus, the response to 
glucocorticoids in AML cells can be altered by unidentified regulatory stimulations.   
These results imply there may be some patients with de novo AML who might respond 
well to the inclusion of glucocorticoids in their treatment regimen, and perhaps 
glucocorticoids should be considered in the treatment of Ara-C resistant AML.  To 
determine when glucocorticoids should be used in the treatment of AML, the functional 
changes in the cells driving both the Ara-C and the glucocorticoid response need to be 
identified. 
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As to the nature of the glucocorticoid response, there are three distinct phases that 
have been identified in glucocorticoid-induced apoptosis (Frankfurt and Rosen, 2004).  
The first phase, the “initiation stage”, is triggered by glucocorticoid reception binding.  
The second phase, the “decision stage”, occurs within the mitochondria.  The last phase, 
the “execution stage”, involves the apoptotic caspase cascade.  Since all 4 of the BXH-2 
cell had similar response to combination of prednisolone and mifepristone, it appears the 
glucocorticoid receptor is functioning normally in all 4 cell lines, and the prednisolone 
resistance found in the B117P is not related to the “initiation stage”.  One type of 
glucocorticoid resistance found in the “decision stage”, involves the overexpression of 
anti-apoptotic proteins, such as the members of the Bcl-2 superfamily (Sionov, 2013).  
However, none of these genes were included in the list of genes which compared 
glucocorticoid response to gene expression levels (Table 4.5).  The Sionov, 2013, review 
article also provided a comprehensive description of other genes which have been shown 
to be differentially expressed in glucocorticoid resistant cells, but none of these genes 
were shown to be differentially expressed in the glucocorticoid resistant B117P cells. 
The second screen of 50 drugs used in combination with Ara-C identified 
cladribine as potentially the most synergistic of the drugs tested.  Subsequent MTS-
tetrazolium assays verified the synergy in the Ara-C sensitive B117P cell lines, and 
antagonism in the Ara-C resistant B117H cells (Table 4.7).  This same pattern has been 
seen in clinical trials.  Cladribine has been found to be an effective partner to Ara-C in 
treating de novo disease (Holowiecki et al., 2004; Rubnitz et al., 2009), but not effective 
in treating refractory disease (Rubnitz et al., 2004).  The exact nature of the synergy 
between cladribine and Ara-C is not fully understood.  Both drugs are activated by Dck, 
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and both are nucleotide analogs that interfere with DNA replication, although their 
mechanisms of action are different.  Ara-C is incorporated into DNA (Grant, 1998), while 
cladribine is a strong inhibitor of ribonucleotide reductase activity, which is required for 
de novo synthesis of nucleosides (Sigal et al., 2010).  Perhaps the synergy between Ara-C 
and cladribine is due to the combined effect of the strong interference of Ara-C to the 
dNTP salvage pathway and cladribine blocking the de novo dNTP pathway, although this 
could just be an additive effect.   It is also interesting to note the IC25 for cladribine was 
18-fold higher in the B117H as compared to the B117P, while the IC25 change in 
response to Ara-C was 1300-fold.  This reduced level of cladribine resistance to the loss 
of Dck may be explained by the fact that cladribine can also be activated by deguanosine 
kinase (Lotfi et al., 2003) or it may be indicative of a secondary mode of action for 
cladribine in the cells accounting for the synergy between Ara-C and cladribine. 
These drug screens support the premise that the BXH-2 cell lines are useful tools 
for understanding the molecular characteristics driving drug response.  For example, the 
assay combining a fixed amount of prednisolone with variable amounts of mifepristone 
confirmed a high degree of antagonism between the drugs in all four cell lines confirming 
the glucocorticoid apoptotic activity in leukemia cells is dependent on glucocorticoid 
reception binding.   
The RNA-seq analysis identified a number for genes that may be involved in 
prednisolone response.  One of the genes, Cd14, is a marker of monocytes and one study 
showed a very different expression profile induced by prednisolone in CD14+ monocytes 
as compared with CD14-CD4+ T cells (Toonen et al., 2011).  This implies cells respond 
differently to prednisolone based on the cells’ CD14 status.  Perhaps this difference also 
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affects the ability of cells to undergo glucocorticoid induced apoptosis.  There was a 
markedly different response to prednisolone in the CD14+ B117P cells, which had a 
prednisolone IC50 of 100 M, and the CD14- B140P cells, which had a prednisolone IC50 
of 1.5 M.   
For this drug study, two drug screens were performed, one to determine if AML 
cells became more sensitive to other drugs when they became resistant to Ara-C (a model 
of refractory AML), and a second to determine what drugs were synergistic with Ara-C 
in treating Ara-C sensitive cells (a model of de novo AML).  The first screen showed the 
BXH-2 cells became more sensitive to glucocorticoids as they became resistant to Ara-C, 
and the second screen identified cladribine as synergistic with Ara-C in the Ara-C 
sensitive B117P cells.  The RNA-seq analysis provided a list of genes which may be 
involved in the glucocorticoid response.  Uncovering the significant cellular 
characteristics associated with these responses, such as gene expression levels or mutated 
genes, could be instrumental in developing tests to determine the most effective drug 
combinations for treating AML patients. 
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Table 4.1:  Summary of Drug Screen of 446 FDA Approved Drugs 
446 FDA approved drugs were tested in the B117P, B117H, B140P and B140H cell lines.  
Each drug was tested at concentration of 10 M.  The percent of effect for each of the 
drugs tested were summarized and categorized. 
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Drug
Response of Cells to Drugs in Drug Screen Count
B117H and B140H cells became more sensitive than parentals by > 30% 13
B117H and B140H cells became more resistant than parentals by > 30% 3
B117H became more sensitive than B117P by > 30% 15
B117H became more resistant than B117P by > 30% 2
B140H became more sensitive than B140H by > 30% 29
B140H became more resistant than B140H by > 30% 1
Less than 30% change in both sets of cells 165
All 4 cell lines resistant to drugs (< 10% inhibition) 198
All 4 cell lines sensitive to drugs (> 90% inhibition) 20
Total 446
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Table 4.2:  13 Drugs Have a Higher Effect in Ara-C Resistant Cells 
13 of the drugs tested in the B117P, B117H, B140P and B140H cell lines had an increase 
in percent affected of >30% in the Ara-C resistant cell lines (B117H and B140H). 
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Least
Compound Description Type B117P B117H B140P B140H change
SAM001246965 AM404 Analgesic 48.3 95.5 ‐6.7 52.9 47.2
SAM001246897 Prednisolone Corticosteroid 29.2 72.3 34.7 79.1 43.1
SAM001246630 Loteprednol etabonate Corticosteroid 34.9 74.7 22.9 70.8 39.8
SAM001247051 Mesoridazine Phenothiazine 9.1 47.8 ‐1.7 58.4 38.7
SAM001247098 R(+)-SCH-23390 hydrochloride D1 receptor antagonist 2.7 38.5 23.7 87.4 35.8
SAM001247066 CGS 12066B 5‐HT1b agonist 12.4 47.8 ‐3.0 58.2 35.4
SAM001246750 Aripiprazole Antipsychotic ‐13.9 49.6 3.6 38.4 34.8
SAM001247070 Pergolide mesylate salt Dopaminergic agonist ‐2.9 49.0 ‐8.6 25.4 34.0
SAM001246879 Corticosterone Corticosteroid 24.2 57.3 6.7 53.1 33.1
SAM001246658 Naftopidil 1‐adrenergic receptor antagonist ‐25.6 48.1 ‐2.1 30.7 32.8
% affect of 10M on each cell line
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Table 4.3:  IC50’s for Prednisolone and Dexamethasone in BXH-2 Cell Lines 
The IC50 for prednisolone and dexamethasone was determined using the MTS 
Tetrazolium Assay.  Assay was repeated a minimum of 3 times.  r-values > 0.88.  
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Drug Statistic B117P B117H B140P B140H
Prednisolone Average IC50 (M) 100.198 3.450 1.547 0.338
Standard Deviation 14.348 0.980 0.952 0.072
Dexamethasone Average IC50 (M) 1.468 0.183 0.125 0.032
Standard Deviation 0.393 0.047 0.061 0.006
Cell Line
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Table 4.4:  Potential Genes Involved in Prednisolone Resistance as 
Identified by Microarray Analysis 
Gene involved in glucocorticoid resistance were identified from microarray data by 
selecting genes with  both a 10-fold change in expression between the B117P and B140H 
and an upward or downward expression level trend across the four cell lines consistant 
with the trends of the prednisolone and dexamethasone IC50 values.  
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IC50 value (M) B117P B117H B140P B140H B117H B140P B140H
     Prednisolone 100.198 3.450 1.547 0.338 29.0 64.8 296.4
     Dexamethasone 1.468 0.183 0.125 0.032 8.0 11.8 45.3
Microarray Gene Expression Levels
   Overexpressed in B117P
      BC100530, Stfa3 (1435761_at) 831.8 31.3 26.0 25.8 26.5 32.0 32.2
      Hpgd (1419905_s_at) 572.1 43.7 15.0 10.0 13.1 38.1 57.3
   Underexpressed in B117P
      Atp1b1 (1439036_at) 13.7 382.7 464.5 989.1 27.9 33.8 72.0
      Glul (1426235_a_at) 18.5 121.9 125.4 186.1 6.6 6.8 10.1
      Glul (1426236_a_at) 9.5 396.2 436.6 588.1 41.9 46.2 62.2
      Il7r (1448576_at) 22.2 121.1 232.3 393.4 5.5 10.5 17.8
      Pcgf6 (1424081_at) 28.1 288.0 1234.8 1269.5 10.3 44.0 45.3
      Pcgf6 (1454120_a_at) 8.1 95.0 407.3 410.2 11.7 50.2 50.6
Ratio of B117P to
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Table 4.5:  Potential Genes Involved in Prednisolone Resistance as 
Identified by RNA-Seq Analysis  
Gene candidates involved in glucocorticoid resistance were identified from RNA-seq data 
by identifying genes with 30-fold change in expression between the B117P and B140H, a 
continuous upward or downward expression level trend across the four cell lines, and at 
least a 2-fold change between B117P and B117H and between B140P and B140H.  The 
FPKMs for either the B117P cells or the B140H cells were > 1.0. 
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RNA-Seq Gene Expression Levels (FPKMs)
   Overexpressed in B117P B117P B117H B140P B140H B117H B140P B140H
     2010300C02Rik 1.438 0.046 0.024 0.001 31.2 60.4 1437.7
     Abca1 1.878 0.602 0.368 0.031 3.1 5.1 61.0
     Ccbl2 15.548 6.695 3.791 0.001 2.3 4.1 15548.4
     Cd14 37.783 11.521 0.628 0.001 3.3 60.1 37782.9
     Cd9 30.507 4.389 0.048 0.001 7.0 640.4 30506.7
     Cdc42ep4 2.778 1.039 0.107 0.001 2.7 25.8 2777.5
     Cldnd2 1.075 0.496 0.105 0.001 2.2 10.3 1075.3
     Csf3r 6.192 0.286 0.124 0.001 21.7 49.8 6192.2
     Elane 81.118 14.846 0.385 0.154 5.5 210.7 525.3
     Fkbp11 20.183 9.735 5.533 0.340 2.1 3.6 59.3
     Gm5643 1.239 0.518 0.493 0.001 2.4 2.5 1239.3
     Gp49a 5.403 0.289 0.043 0.001 18.7 125.6 5402.9
     Hck 6.469 0.099 0.077 0.020 65.2 83.8 320.9
     Hist2h3c2-ps 1.480 0.495 0.287 0.046 3.0 5.2 32.2
     Id1 5.069 1.117 0.065 0.001 4.5 78.1 5069.2
     Isg15 4.589 0.773 0.243 0.066 5.9 18.9 69.8
     Kcng1 4.692 2.027 0.138 0.001 2.3 33.9 4692.0
     Lgals3 79.326 34.940 0.040 0.001 2.3 1960.3 79325.6
     Lgals3bp 24.418 11.489 0.173 0.039 2.1 140.9 629.6
     Lyz1 4.368 1.712 0.446 0.106 2.6 9.8 41.2
     Mocos 2.256 1.114 0.073 0.001 2.0 30.8 2256.4
     Mpo 1450.210 473.280 10.416 0.913 3.1 139.2 1587.6
     Ms4a3 217.785 15.342 0.115 0.001 14.2 1896.4 217785.0
     Nt5e 26.361 9.577 0.029 0.011 2.8 902.3 2318.1
     Oas2 2.199 0.587 0.081 0.021 3.7 27.2 104.7
     Retnlb 9.076 3.842 0.090 0.001 2.4 101.0 9075.7
     Sell 80.764 18.619 0.073 0.019 4.3 1111.6 4258.7
     Siglecg 2.640 0.807 0.021 0.001 3.3 123.2 2640.0
     Tm4sf19 1.582 0.345 0.045 0.001 4.6 35.3 1582.0
     Tmem132a 2.393 0.537 0.015 0.001 4.5 159.5 2393.2
     Tmem180 25.612 8.967 0.070 0.018 2.9 363.9 1394.7
     Tnfsf14 1.813 0.902 0.234 0.023 2.0 7.7 78.9
     Tuba8 19.869 9.444 0.349 0.092 2.1 56.9 216.0
     Zfp516 2.029 0.180 0.020 0.005 11.2 101.7 394.0
   Underexpressed in B117P
     Bank1 0.014 0.047 0.372 1.121 3.4 26.7 80.4
     Camk2a 0.031 0.106 0.560 1.628 3.4 17.8 51.7
     Dnahc6 0.001 0.004 0.044 1.309 3.9 44.2 1309.2
     Gm5148 0.120 0.537 1.119 4.552 4.5 9.3 37.9
     Gpr25 0.214 0.878 17.899 37.890 4.1 83.7 177.3
     Hmgb1-rs17 0.033 0.185 0.384 1.273 5.6 11.6 38.6
     Serinc5 0.075 0.282 0.456 5.207 3.7 6.1 69.1
     Ublcp1 0.001 0.024 2.437 8.111 24.2 2437.3 8110.7
Ratio of B117P to
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Table 4.6:  Combination Assay Using Fixed Amount of Ara-C and Variable 
Concentrations of a Second Drug in the B117P Cell Lines 
MTS Tetrazolium assay was used to measure fraction affected when 200ng/ml of Ara-C 
was combined with 7 different concentrations of a second drug  in the B117P cell line.  
Fraction affected was the fraction relative to Ara-C alone.  Combinations were repeated 
in 2 wells.  The IC50 for the second drugs was also determined for the second drug 
without Ara-C, except for those highlight in AG490 and AZD6244, which used 
information from literature.  Although 50 drugs were tested, only those with > 0.5 
fraction affected at the highest concentration were included in the table.  Most drugs were 
tested at the high concentrations (top scale), whereas aminopterin, PD-0325901, 
triptolide, bortezomib, and 5-fluorouridine  were done at smaller concentrations (lower 
scale) due to their lower IC50’s.   Change (*) was determined adding the highest fraction 
affected at the 0.625 concentration level to the difference between the 0.625 and the 
0.15625 (top scale), or between the 0.0625 and the 0.015625 (lower scale). 
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10 5 2.5 1.25 0.625 0.3125 0.15625
Drug IC50(M) 1 0.5 0.25 0.125 0.0625 0.03125 0.015625 Change*
Mifepristone 5.500 0.771 0.441 0.240 0.066 0.000 0.072 0.195 ‐0.195
Parthenolide (PTL) 1.250 0.977 0.849 0.719 0.340 0.038 0.000 0.247 ‐0.171
AG490 20.000 0.795 0.651 0.410 0.135 0.000 0.000 0.148 ‐0.148
GSK‐3B Inhibitor 0.805 0.969 0.809 0.412 0.023 0.000 0.010 0.147 ‐0.147
Cantharidin 1.892 0.891 0.101 0.000 0.000 0.000 0.000 0.146 ‐0.146
Harki1020 3.315 0.947 0.562 0.235 0.000 0.006 0.018 0.116 ‐0.104
IKK Inhibit VII 1.000 1.000 0.000 0.000 0.000 0.000 0.229 0.074 ‐0.074
MG132 1.208 1.000 0.978 0.000 0.000 0.028 0.134 0.068 ‐0.011
Nelarabine 12.354 0.269 0.098 0.000 0.135 0.062 0.000 0.135 ‐0.011
Mevastatin 2.830 0.858 0.306 0.093 0.106 0.000 0.000 0.000 0.000
Harki1001 2.235 0.783 0.284 0.000 0.000 0.000 0.000 0.000 0.000
AM404 9.812 0.897 0.729 0.438 0.208 0.108 0.174 0.213 0.004
Harki1019 5.300 0.500 0.177 0.016 0.049 0.054 0.096 0.085 0.023
RAD001 0.149 0.957 0.923 0.867 0.627 0.206 0.307 0.253 0.160
MK‐0457 0.775 0.688 0.013 0.000 0.000 0.118 0.000 0.047 0.189
5‐Fluoro‐2'‐deoxyuridine 0.149 0.507 0.456 0.413 0.425 0.416 0.418 0.393 0.438
Sunitinib 0.200 0.872 0.964 0.967 0.651 0.297 0.116 0.081 0.514
Dexamethasone 1.500 0.939 0.839 0.747 0.605 0.467 0.345 0.390 0.543
Aminopterin 0.010 0.535 0.507 0.527 0.542 0.529 0.498 0.481 0.577
GDC0941 0.650 0.944 0.840 0.750 0.636 0.517 0.523 0.369 0.665
NFkB Inhibitor 0.098 0.683 0.624 0.597 0.604 0.399 0.000 0.000 0.798
CPEC 0.157 0.717 0.751 0.735 0.736 0.776 0.744 0.709 0.842
AZD6244 10.000 0.940 0.816 0.739 0.612 0.637 0.406 0.359 0.914
PD‐0325901 0.007 0.941 0.936 0.881 0.791 0.715 0.583 0.498 0.931
Triptolide (HSP inhibitor) 0.018 1.000 1.000 1.000 0.981 0.488 0.001 0.023 0.953
Bortezomib 0.006 1.000 1.000 1.000 1.000 1.000 1.000 0.994 1.006
5‐Fluorouridine 0.034 0.950 0.838 0.800 0.721 0.647 0.387 0.000 1.295
Cladribine 0.800 1.000 0.957 0.828 0.805 0.718 0.433 0.095 1.341
Fraction affected at different concentrations of second drug (M)
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Table 4.7:  Fixed Ratio Combination Assay Verifies Synergy between Ara-C 
and Cladrine in B117P Cells, but Antagonism in B117H Cells 
MTS Tetrazolium assay was used to determine CI50 when Ara-C was combined with 
cladribine at a fixed ratio.  Assay was repeated 3 times.  CI50 was determined using 
CalcuSyn, by comparing the combination assay with assays of Ara-C alone and 
cladribine alone, which were conducted at the same time.  Each set of experiments were 
repeated 3 times. 
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B117P B117H
Ara‐C IC25 (g/ml) 0.08 110.00
Cladribine IC25 (M) 0.70 13.00
Average CI50 0.73 1.66
CI50 standard deviation 0.16 0.38
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Figure 4.1:  Ara-C Resistant Cells Are More Sensitive to Prednisolone 
The prednisolone IC50 was determined using the MTS Tetrazolium Assay.  Assay was 
repeated 3 times with comparable results. 
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 Figure 4.2:  Mifepristone Blocks the Effects of Prednisolone in All Four 
BXH-2 Cell Lines 
MTS Tetrazolium Assay with a constant concentration of prednisolone and an increasing 
concentration of mifepristone.  Assay was repeated 3 times with similar results.  
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Figure 4.3:  Graphic Trends of Combination Assay 
Graphical depiction of synergistic, additive, and antagonistic trends in fraction affected 
when drug one of a constant concentration is tested with increasing concentrations of a 
second drug. 
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Chapter 5:  Future Research Opportunities 
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Summary of Research 
The goal of this research was to understand how AML cells become resistant to 
Ara-C and to search for more effective drug treatment combinations based on cellular 
characteristics, such as gene expression patterns and mutations.  In Chapter 2, the 
research focused on using microarray analysis of four BXH-2 murine cell lines to 
determine the gene expression changes associated Ara-C resistance.  The primary change 
found by this effort was the significant downregulation of Dck in the two Ara-C resistant 
cell lines when compare their two Ara-C sensitive parental cell lines.  It was also 
determined, by testing other chemotherapy drugs, the highly drug resistance phenotype 
was not applicable to any other drug except decitabine, which also depends on Dck for 
metabolic activation.  
Chapter 3 described further research on these same cell lines to determine the 
functional changes taking place in the cells, which account for the Ara-C resistance.  
RNA-seq was used to locate mutations in Dck in both the Ara-C resistant cell lines.  
Knockdown and knockout of Dck in the Ara-C sensitive cell lines clearly showed a direct 
correlation between Dck expression and Ara-C response with loss of Dck accounting for 
85% of the Ara-C resistance.  Most of the Ara-C sensitivity was rescued by introducing 
DCK to the Dck knockout cell lines. 
The focus of Chapter 4 was finding drugs more effective in treating Ara-C 
resistant AML, as well as drugs synergistic with Ara-C for treating de novo AML.  A 
drug screen of 446 FDA approved drugs, showed that the Ara-C resistant cells became 
more sensitive to glucocorticoids, such as prednisolone.  It was also determined the 
sensitivity of the AML cell lines to prednisolone was dependent on glucocorticoid 
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receptor binding.  A second drug screen evaluated the synergy of 50 different drugs with 
Ara-C in the Ara-C sensitive B117P cell line, and determined cladribine was the most 
synergistic.  Combination drug assays confirmed synergy between Ara-C and cladribine 
in the B117P, while there was antagonism in the B117H cell lines.  This result was 
consistent with results seen in clinical trials using the Ara-C and cladribine combination 
in treating de novo AML (Holowiecki et al., 2004; Rubnitz et al., 2009), but not 
refractory AML (Rubnitz et al., 2004). 
Additional Research Opportunities Using the BXH-2 Model 
Since the results gleaned thus far by studying the BXH-2 model of Ara-C 
resistance have proved consistent with findings from clinical trials, it seems evident these 
cells can continue to be valuable experimental tools for resolving a number of 
unanswered questions, such as:  (1)  How do Ara-C resistant cells compensate for the loss 
of Dck?  (2)  Do Ara-C resistant cells depend on a compensating up-regulation of the 
Ras/MAPK pathway?  (3)  What are the molecular processes responsible for innate 
glucocorticoid resistance in some Ara-C sensitive cells, why Ara-C resistant cells become 
more sensitive to glucocorticoids, and how can cells be induced to become glucocorticoid 
sensitive?  (4)  Are there other mechanisms of toxicity for cladribine and what accounts 
for the synergy existing between Ara-C and cladribine in Ara-C sensitive cells?  
Strategies for answering these questions are outline below. 
Compensating for the loss of Dck 
A number of changes occurred in the Ara-C resistant cells, some of which may be 
compensating for the loss of Dck.  These include the downregulation of Dab2ip, Dab2, 
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Cd14, Mpo, Ksr1, and Riiad1.  Dab2ip, Dab2, and Ksr1 are negative regulators of Ras 
(Calvisi et al., 2011; Therrien et al., 1996; Zhou and Hsieh, 2001), Cd14 is a monocyte 
marker (Griffin et al., 1981), and Mpo is involved myeloid differentiation (Koeffler et al., 
1985).  Very little is known about Riiad1.   
Clustered Regularly Interspaced Short Palindromic Repeats (CRISPRs) have been 
designed to target three distinct sites of each of these genes.  The CRISPR system was 
first identified in Escherichia coli, but has since been modified to work effectively in 
vertebrate cells (Mali et al., 2013; Qi et al., 2013).  The system requires the preparation of 
CRISPR oligos, which are 23 bases long and a direct match to a protein coding segment 
of the target gene, preferably near the translational start site.  The oligo sequence must 
begin with a ‘G’ and end with ‘GG’, and must be tested in silico for specificity to the 
target gene.  Introduction of a vector containing the Cas9 coding sequence, the enzyme 
that directs the oligo to the matching genomic sequence and executes a double strand 
DNA break at that site, results in double strand breaks which are inefficiently repaired by 
the double-strand break repair system of the cell.  This results in short deletions which 
typically disrupt gene function.  In that respect the CRISPR system is very similar to the 
TALEN system, but CRISPR is faster and less expensive to use.  It still remains to be 
determined if the CRISPR system is as specific as TALENs.  
The CRISPR oligos targeting Dab2ip, Dab2, Cd14, Mpo, Ksr1, and Riiad1 will 
be introduced individually to the Ara-C sensitive B117P and B140P cells, and selected 
for incorporation using puromycin.  A number of experiments will be conducted on the 
resulting knockout cell lines to determine:  (1) if the Ara-C IC50 has increased, (2) if the 
Dck expression levels have been reduced, (3) if there is an increase in the proliferation 
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rate in the cell lines, and (4) how receptive the cells are to becoming Ara-C resistant.  
These results will help to determine the level of participation of each of the genes in the 
Ara-C resistant phenotype.  Similar experiments will be done on the other genes 
identified by the RNA-seq analysis as being down-regulated or mutated in the Ara-C 
resistant cell lines.   
RNA-seq of the TALEN based Dck KO cells and dox-induced DCK 
overexpression cells will be used to narrow the list of candidate genes, by identifying 
genes having expression levels strongly correlating to Dck levels, either positively or 
negatively.  An initial RNA-seq was accomplished for the B117P T6B Dck KO cell line 
and its associated DCK overexpression cell line (induced by doxycycline).  Table 5.1 
outlines the most prominent and reversible changes to the cells as compared to each other 
and the B117P starting cells.   
The top 8 genes are all located in close proximity to one another on chromosome 
16 of the mouse genome.  They are all members of the stefin family of genes, which are 
only found in murine cells.  They are immediately downstream from cystatin A (Csta), 
and are all protein coding genes.  Their protein sequences are very similar and each most 
closely match cystatin A, both in murine and human cells according to Ensembl’s 
PBLAST utility (www.ensembl.org), indicating they are Csta replicates in the mouse 
genome, which have independently evolved over time.  They all have a highly conserved 
promoter region of 221 bp located approximately 1000 bp upstream.  In the Stfa1 gene, it 
is located at -1028bp from the transcriptional start site.  This promoter region is not found 
upstream of Csta, and there was no significant change in Csta expression levels in the 
Dck KO and Dck KO/DCK OE cells, suggesting there is no relevance to this change in 
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human cells.  As for function, Stfa1 and Stfa2 were shown to be strong inhibitors of 
papain-like endopeptidases, while human CSTA was not (Mihelic et al., 2006).   Even 
though Csta did not undergo significant expression changes in the Dck KO and Dck 
KO/DCK overexpression cells, the stefins may be performing some other cystatin A type 
functions.  Cystatin A has been shown to be an inhibitor of cysteine proteases (Anastasi 
et al., 1983; Brzin et al., 1984), a blocker of apoptosis by inhibiting cathepsin B 
(Takahashi et al., 2007), a modulator of migration and invasion (Chang et al., 2010), and 
a risk factor for breast cancer (Kuopio et al., 1998).  There is nothing in the literature 
describing a relationship between Dck and any cystatin/stefin.   
Another interesting pair of genes, S100a8 and S100a9, appeared on the list as 
being highly upregulated in the Dck KO cells and then downregulated in the Dck KO/Dck 
OE cells.  The S100a8 and S100a9 genes generate proteins which form a heterodimer 
called calprotectin (Hessian and Fisher, 2001).  S100a8 and S100a9 have both been 
shown to be activators of the Ras/MAPK pathway (Kwon et al., 2013; Wu et al., 2013).   
Ingenuity Pathway Analysis (Ingenuity® Systems, www.ingenuity.com) of all the genes 
on the list indicated a close relationship of these genes to the Ras/MAPK pathway in the 
top 2 networks (Table 5.2).  There is nothing in the literature describing a relationship 
between Dck and any of the genes listed in Table 5.1.    
The expression of the genes identified in Table 5.1 will need to be verified by 
qPCR, and evaluated in the other Dck KO B117P cell lines (T2A and T11A), as well as 
Dck KOs in the B140P cell lines.  If confirmed, generation of a DCK knockout human 
AML cell line will be needed to confirm the relationship of DCK to these same genes in 
human cells.  Evaluation of several human AML cell lines is underway to find cells with 
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moderate DCK expression levels, and DCK is also being sequenced to confirm there are 
no DCK mutations present.  
Importance of Ras regulation in Ara-C resistance 
There are several indicators in the research implicating the Ras/MAPK pathway 
in Ara-C resistance, including:  (1) downregulation of the Ras inhibitors Dab2ip and 
Dab2 in the Ara-C resistant cell lines (Table 3.1 and Supplementary Table C.3, 
respectively), (2) the introduction of missense mutations into three members of the 
Ras/MAPK pathway (Prkacb and Rasgrp2 in B117H and Map3k11 in B140H), (3) a 
possible synergy between Ara-C and the MEK inhibitor PD035901 (Table 4.6), (4) 
S100a8 and S100a9, activators of MAPK, are upregulated in the Dck KO cells and 
downregulated in the Dck KO/DCK OE cells (Table 5.1), and (5) the identification of the 
Ras/MAPK pathway as the primary network associated with genes whose regulation 
changed when Dck was knocked out (Table 5.2).   Furthermore, a research study showed 
Dck can be downregulated by MAP kinase signaling in human tonsillar lymphocytes 
(Keszler et al., 2005).  These data implicate a bidirectional relationship between Dck and 
the Ras/MAPK pathway.  To study the role of the Ras/MAPK pathway in Ara-C 
resistance and its ability to compensate for the loss of Dck, Raf1 will be knocked out, 
using either TALENs or CRISPR in the all four BXH-2 cell lines, and the Raf1 KO cells 
will be evaluated for changes in response to Ara-C, changes in Dck expression, and 
changes in proliferation rates.  In addition, flow cytometry of the cells will be conducted 
using antibodies to phospho-c-Raf, phospho-MEK1/2, and phospho-ERK1/2, to 
determine the activation status of the various members of the Ras/MAPK pathway. If the 
results are compelling, drugs targeting the Ras/MAPK pathway will be tested in 
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combination with Ara-C to determine their combined effectiveness in a variety of human 
and murine AML cell lines.  The challenge of these experiments will be to find the 
optimal doses and the timing of the doses for the most effective outcome.   
Mechanisms of glucocorticoid resistance in the B117P cell lines 
A number of genes, which may be associated with innate resistance to 
glucocorticoids in some AML cells, have been identified in Tables 4.4 and 4.5.   They 
need to be evaluated for their specific role in a cell’s response to glucocorticoids.  Similar 
techniques can be used as those defined for finding synergistic partners for Ara-C.  
Interestingly, Mpo and Cd14 appear on both lists as being associated with Ara-C 
resistance and glucocorticoid resistance.    
Another interesting relationship, which needs to be studied in more depth, is the 
one between Dck and calprotectin.  Calprotectin is a tetramer, composed of two S100a8 
and two S100a9 molecules, and found in high levels in neutrophils, from which it is 
released into the blood stream.  This response is typically associated with 
infections/inflammation (Hessian and Fisher, 2001).  Calprotectin has also been shown to 
have an active role in apoptosis (Zali et al., 2007).  Its role in cancer has not been 
elucidated, although it has been shown to be elevated in colorectal carcinoma (Stulik et 
al., 1999), and the up-regulation of calprotectin was shown to be associated with 
glucocorticoid resistance in the treatment of acute lymphoid leukemia (Spijkers-
Hagelstein et al., 2012).  In our study the calprotectin genes, S100a8 and S100a9, were 
highly up-regulated in the B117P T6B Dck KO cells when compared to the B117P cells.  
The expression levels or the calprotectin genes were subsequently reduced when DCK 
was introduced into the B117P T6B Dck KO cells.  This trend implicates a direct 
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relationship between Dck and calprotectin.  And yet, there are no significant differences 
in the expression levels of the calprotectin genes in the four BXH-2 cell lines, two of 
which had defective Dck function.  Furthermore, if the role of calprotectin in AML is 
similar to its role in ALL, i.e. higher levels of calprotectin result in glucocorticoid 
resistance, the B117P cells, which are highly resistance to glucocorticoids, should have a 
much higher level of calprotectin than the more glucocorticoid sensitive B117H cells.  It 
will be interesting to see if there is a change in glucocorticoid sensitivity in direct 
response to the loss of Dck, by testing the Dck KO and Dck KO/DCK OE cells for 
changes in response to prednisolone and dexamethasone.    
Determining the compensating role of calprotectin in the Dck KO cells will be 
quite complicated, especially since S100a8 and S100a9 can function independently or in 
the form the tetramer calprotectin.   Fluorescent microscopy of the B117P cells, Dck KO 
cells, and the Dck KO/DCK OE cells, using different fluorescently labeled antibodies for 
the S100a8 and S100a9 proteins, can be used to determine the location of the proteins in 
the cell, and whether the proteins are co-localized.  Immunoprecipitation of the S100a8 
and S100a9 proteins from the B117P cells, Dck KO cells and the Dck KO/DCK OE cells, 
followed by mass spectrometry of the protein complexes can identify the binding partners 
for each protein.  This will help to determine the primary function of the S100a8 and 
S100a9 in the Dck KO cells.  For example, S100A8 or S100A9 may bind to TLR4 or 
RAGE to activate the MAPK pathway (Ichikawa et al., 2011).  In addition, the 
relationship between DCK and calprotectin needs to be evaluated in human cell lines, as 
well primary AML and ALL cells.  If a compensating relationship between Dck and 
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calprotectin is confirmed in AML cells, drug treatments can be devised to exploit this 
relationship. 
Cladribine’s role in AML toxicity 
Based on the data showing cladribine is synergistic with Ara-C in Ara-C sensitive 
cells and yet experiences only a 10-fold increase in IC50 when Dck is knocked out, it 
appears cladribine has a second method of toxicity in AML.  A second mode of toxicity 
for cladribine in hairy cell leukemia was suggested, involving the triggering of apoptosis 
by changing the transmembrane potential of the mitochondria (Marzo et al., 2001).  
To identify a second mode of toxicity in the AML cells, cladribine resistance cell lines 
will need to be developed which have a cladribine IC50 at least 100 times normal.  Due to 
presence of a mutagenic retrovirus, the B117P and B140P cell lines will be ideal for this 
project.  RNA-seq will be used to evaluate the changes required for the cells to become 
cladribine resistant, just as was done in defining the mechanisms of resistance in the Ara-
C cell lines.    
An In Vivo Model of Ara-C Resistance 
Finding drug targets and drug combinations to test in vitro is only the first step in 
finding effective drug treatments for AML.  These drugs need to be tested in an in vivo 
animal model of AML, which includes an Ara-C resistant derivative.  To this end, a bank 
of mouse AML cells was established from genetically engineered mice having a Class I 
dox-inducible Tet-off Nras oncogene, and a Class II Mll-AF9 fusion (TNM model) (Kim 
et al., 2009).  RNA-sequencing of the TNM cells showed expression levels of Dck of ~20 
FPKMs, consistent with the Dck expression levels found in the B117P and B140P cells.  
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IGV visualization of Dck found normal splicing patterns and no mutations in the TNM 
primary AML cells.  The cells can transplanted via tail vein injection into SCID/beige 
mice and within 14-16 days white blood cell (WBC) counts will start to elevate.  Without 
treatment the mice will become moribund by day 17-18 with WBC counts > 200K 
cells/l.  Treatment with 50 mg/kg/day of Ara-C daily over 5 days starting at day 16 after 
AML transplantation with reduce the WBC count significantly, usually below 50K 
cells/l, but the mice will expire by day 22 due to anemia, resulting from loss of red 
blood cells. 
To determine if Ara-C resistant cells could be developed by repeated exposure of 
the cells to Ara-C via passages through multiple SCID/beige mice, two strategies were 
implemented.  In the first strategy, the mice were started with Ara-C treatment once their 
WBC count reached > 150K cells/l and they received 4 injections of 60 mg/kg at 12 
hour intervals.  When they became moribund, their WBC count was tested and the spleen 
cells from the mouse with the highest WBC counts were implanted into the next set of 
SCID/beige mice.  After 4 passages the cells were evaluated for drug resistance.  20 mice 
were transplanted with AML, 10 receiving cells that had never been exposed to Ara-C, 
and 10 receiving cells that had been passaged and exposed to Ara-C 4 times.  The only 
difference in the two groups was the time of the initial onset of the disease. (Table 5.3)       
Since this approach only succeeded in selecting for slower growing AML cells, 
rather than Ara-C resistant cells, a second approach was tried.  Starting at 3 days 
following transplantation, the mice were given lower doses of Ara-C of 50 mg/kg every 
other day.  These lower doses could be given indefinitely without causing anemia in the 
mice.  Once the mice became moribund, the spleen cells from the mouse with the highest 
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WBC count were transplanted into the next set of mice.  In each subsequent passage, the 
mice became moribund 3-4 days earlier than the previous passage (Table 5.4)       
After four passages the cells were compared to cells which had never been 
exposed to Ara-C (Table 5.5).  Although there was some drop in the WBC count in the 
mice with AML cells previously exposed to Ara-C, the mice were moribund within 24 
hours of starting treatment with Ara-C, indicating the mice were indeed more resistant to 
Ara-C.  In addition, during the necropsy of the mice, the Ara-C resistant mice presented 
with a dark discoloration in the bowels.  Pathological examination of the tissues, as well 
as RNA-sequencing would be the next steps in understanding the changes that took place 
in the cells to make them more Ara-C resistant.  It would also be interesting to compare 
the response of the cells to cladribine and glucocorticoids in vivo. 
Conclusions 
The BXH-2 derived cell lines (B117P and B140P) and their Ara-C resistant 
derivatives (B117H and B140H) have been valuable tools in understanding the molecular 
changes taking place in cells in response to Ara-C exposure, such as the loss of Dck 
function, which has also been documented in human Ara-C resistant AML.  The use of 
RNA-seq was instrumental in describing the mutations found in Dck in the Ara-C 
resistant cell lines.  Ironically, the focus of research during the past 15 years on the use of 
gene expression microarray analysis has actually resulted in a delay in the determination 
of the importance of loss of Dck function in Ara-C resistance, since mutations in Dck, 
which radically alter Dck function leading to Ara-C resistance, may not result in changes 
in Dck expression.    
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The drug screens and drug assays conducted on these cell lines are consistent with 
results seen in clinical setting, such as leukemias being responsive to Ara-C or 
glucocorticoids, but typically not both, and a synergy between Ara-C and cladribine in de 
novo disease, but not refractory disease.  The continued interrogation of these cell lines, 
as well as the study of human AML cell lines and primary AML samples, may provide a 
better understanding of why leukemias respond differently to these drugs.  This 
knowledge will assist clinicians in selecting the most appropriate drugs to treat patients 
based on the molecular profile of each individual’s AML.  The establishment of a 
molecular profile for each patient will depend on in silico analysis of the patient’s AML 
using tools such as MMuFLR. 
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Table 5.1:  Changes in the B117P T6B Dck KO Cells, Which Were Reverted 
by the Introduction of DCK 
RNA-seq gene expression analysis using Cuffdiff and comparing the B117P sample to 
the B117P T6B Dck KO and the T6B DCK OE (induced with dox).  Includes genes with 
2-fold changes or better and total FPKM shift of greater than 5 FPKMs.  Genes are sorted 
by decreasing fold change of the KO cells compared to parental cells.  List was verified 
in IGV and only protein coding genes are shown.  Stefin family genes include Stfa3, 
Stfa2l1, Stfa2, Gm5416, BC100530, GM5483, Stfa1, and 2010005H15Rik, and 
calprotectin genes include S100a8 and S100a9. 
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B117P B117P Dck_KO vs. DCK_OE vs.
gene_id locus B117P Dck_KO DCK_OE B117P Dck_KO
Stfa3 chr16:36450622‐36455478 0.001 20.696 0.176 20695.800 ‐117.398
Stfa2l1 chr16:36156896‐36162034 0.001 18.518 0.786 18517.700 ‐23.555
Stfa2 chr16:36404031‐36408449 0.001 3.605 0.001 3604.850 ‐3604.850
Gm5416 chr16:36210488‐36217874 0.001 1.268 0.001 1268.020 ‐1268.020
BC100530 chr16:36359467‐36367656 0.140 25.611 0.935 182.634 ‐27.405
Gm5483 chr16:36184297‐36188196 0.154 26.489 1.667 171.817 ‐15.889
Stfa1 chr16:36277233‐36285457 0.606 56.992 4.290 94.057 ‐13.284
2010005H15Rik chr16:36221647‐36257513 0.109 5.505 0.115 50.281 ‐47.689
5830411N06Rik chr7:147433199‐147485690 1.612 14.898 6.195 9.243 ‐2.405
Scd1 chr19:44468939‐44482199 0.203 1.871 0.751 9.216 ‐2.491
S100a9 chr3:90496554‐90499613 10.106 87.544 9.172 8.663 ‐9.544
Lcn2 chr2:32240156‐32243259 1.023 8.522 0.675 8.330 ‐12.630
S100a8 chr3:90472992‐90473956 13.494 102.208 14.349 7.575 ‐7.123
Hsd11b1 chr1:195047834‐195090239 0.322 2.123 0.621 6.604 ‐3.418
Slc22a4 chr11:53796627‐53841592 0.571 2.789 0.910 4.882 ‐3.067
Dnmt3l chr10:77492775‐77526360 0.621 3.004 1.378 4.833 ‐2.179
Trat1 chr16:48734802‐48772069 0.393 1.590 0.749 4.046 ‐2.123
Ltf chr9:110921795‐110945270 0.532 2.088 0.015 3.922 ‐137.298
Il7r chr15:9435913‐9459631 0.917 3.096 1.112 3.376 ‐2.786
Thbs1 chr2:117937657‐117952869 2.053 6.170 1.842 3.006 ‐3.349
Ngp chr9:110322311‐110325516 1.772 4.927 0.620 2.781 ‐7.942
Lyz2 chr10:116714596‐116719328 68.691 183.206 84.245 2.667 ‐2.175
Vegfa chr17:46153942‐46169326 14.748 7.021 18.350 ‐2.100 2.613
Ddit4 chr10:59412422‐59414518 7.464 3.531 8.065 ‐2.114 2.284
Aldoc chr11:78137699‐78140262 2.268 0.985 10.068 ‐2.302 10.220
Gp9 chr6:87728129‐87729756 1.534 0.632 1.786 ‐2.427 2.826
Asns chr6:7625170‐7643182 25.881 10.409 22.732 ‐2.487 2.184
Cth chr3:157557211‐157588027 3.954 1.557 4.580 ‐2.539 2.941
Gfi1b chr2:28464969‐28477502 16.831 6.023 12.907 ‐2.795 2.143
Gcet2 chr16:45610552‐45622980 1.539 0.519 1.935 ‐2.962 3.725
Ckb chr12:112907565‐112910549 3.225 1.015 3.574 ‐3.179 3.522
Trib3 chr2:152163160‐152169796 5.362 1.446 6.373 ‐3.708 4.407
Cd244 chr1:173489323‐173515447 13.019 3.338 7.509 ‐3.900 2.250
Nupr1 chr7:133766759‐133768984 11.413 2.883 18.901 ‐3.959 6.557
Slc6a9 chr4:117507862‐117545075 9.404 2.119 8.021 ‐4.439 3.786
Clec11a chr7:51559135‐51562329 37.443 8.418 27.679 ‐4.448 3.288
Ccl3 chr11:83461344‐83462880 165.965 34.841 83.274 ‐4.763 2.390
Cyp4f18 chr8:74512380‐74533525 2.489 0.449 0.950 ‐5.539 2.115
Slc1a4 chr11:20202182‐20232716 2.770 0.489 1.745 ‐5.661 3.566
Chac1 chr2:119176977‐119180062 3.746 0.625 5.098 ‐5.991 8.152
Malat1 chr19:5795689‐5802671 31.467 4.852 20.938 ‐6.485 4.315
FPKMs Fold change
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Table 5.2:  Ras/MAPK Pathway Associated with Genes Differentially 
Expressed in Dck KO cells  
Networks identified by Ingenuity Pathway Analysis (Ingenuity® Systems, 
www.ingenuity.com) from the list of genes differentially expressed in the B117P T6B 
Dck KO cells when compared to the B117P cells.   Genes from Table 5.1 are in bold. 
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ID Molecules in Network Score
Focus 
Molecules Top Functions
1 Alp, Alpha catenin, Ap1, ASNS, CCL3L1/CCL3L3, CD244, CKB, 
CLEC11A, CTH, DDIT4, elastase, ERK1/2 ,F Actin, Fcer1, 
Fibrinogen, HSD11B1, IL1 ,IL12 (complex),Immunoglobulin, 
LCN2, LTF, Lyz1/Lyz2 ,MAP2K1/2, Mek, P38 MAPK, p70 S6k 
,PDGF BB, S100A8, S100A9, Stfa1 (includes others), Tgf beta, 
THBS1, TRAT1, TRIB3, VEGFA
45 18 Hematological System Development and 
Function, Inflammatory Response, Tissue 
Morphology
2 ABLIM, ADRB, Akt, ALDOC, AMPK, ANGEL1 ,caspase, CD3, 
chemokine, Cpe, Cyp2j9, CYP4F2, EPGN, ERK, estrogen 
receptor, FSH, GP9, IgG, IL7R, Insulin, Lh, LOC81691, Mapk, 
NFkB (complex), NUPR1, PI3K (complex), Pkc(s), Rac, Ras, SCD, 
SLC22A4, SLC6A9, Stfa3, Utp14b, Vegf
19 9 Hematological Disease, Hereditary 
Disorder, Lipid Metabolism
3 ADIRF, AGPAT6, ANKRD6, ASRGL1, BEX1, CHAC1, CSTA, CTSB, 
DHX34, DNMT3L, ENTPD6, FAM193B, GALT, GFI1B, GON4L, 
GSK3B, HDAC1, IFFO1, LPHN3, MON1A, MT1F, NFE4, Ngp, 
NTSR1, OSR1, Peg12, PHPT1, RPL36AL, RSL24D1, SLC1A4, 
SPICE1, UBC, UHRF1BP1, ZNF135, ZNF160
11 6 Gene Expression, Embryonic 
Development, Organismal Development
4 5830411N06Rik, IL17A 3 1 Cell Death and Survival, Cell‐To‐Cell 
Signaling and Interaction, Cellular 
Development
5 mir‐223, Stfa2/Stfa2l1, TLR3, TLR9 2 1 Cell‐To‐Cell Signaling and Interaction, 
Inflammatory Response, Cancer
6 CDH1, IGFBP2, MALAT1, mir‐182, miR‐182‐5p (and other 
miRNAs w/seed UUGGCAA), NCAM1, SNAI2, SRSF1
2 1 Cancer, Reproductive System Disease, 
Endocrine System Disorders
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Table 5.3:  AML Cells Exposed to High Doses of Ara-C for 4 Passages Grew 
Slower, but Had the Same Response the Ara-C as Cells Not Previously 
Exposed to Ara-C   
Two cohorts of mice received AML transplants.  The first 10 mice received AML cells 
from the spleen of a mouse which had never been exposed to Ara-C, and the second 10 
mice received AML spleen cells which had been previously passaged through 4 mice and 
during each passage received high dose exposure to Ara-C (4 doses of 60 mg/kg) at 12 
hour intervals once the mice had WBC counts > 150K/l.  WBC counts of the mice were 
taken every 3 days and the mice were started on Ara-C when any of the mice in the 
cohort exceeded a WBC of 150K/l.  Mice received injections of Ara-C (50 mg/kg) 
every 24 hours for 4 days.  Tissues were harvested when the mice became moribund. 
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Previous
Ara‐C
Mouse ID Exposure Day 16 Day 17 Day 18 Day 19 Day 20 Day 21 Day 22 Day 23 Day 24 Day 25 Day 26 Day 27
SC389 00 None 122.56 27.56 22.14
SC390 01 None 132.96 22.50 20.80
SC391 03 None 178.10 56.48
SC392 10 None 126.92 21.30
SC393 30 None 115.18 14.12
SC394 00 None 122.16 19.96
SC395 01 None 84.98 18.54
SC396 03 None 85.62 24.70
SC397 10 None 85.06 87.44
SC398 30 None 83.24 8.22
SC399 00 4 sets 5.66 46.32 78.14 63.52
SC400 01 4 sets 8.10 50.24 10.12 3.06
SC401 03 4 sets 5.50 63.68 16.84 5.44
SC402 10 4 sets 12.05 117.42 3.36
SC403 30 4 sets 22.36 125.88 5.40 1.50
SC404 00 4 sets 2.46 5.34 1.32 14.32
SC405 01 4 sets 4.74 6.12 1.64 2.08
SC406 03 4 sets 23.16 25.22 2.20 2.58
SC407 10 4 sets 4.72 5.70 1.50 19.22
SC408 30 4 sets 61.28
Received Ara‐C injections
Moribund
WBC counts
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Table 5.4:  AML Cells Exposed to Low Continuous Doses of Ara-C for 4 
Passages Resulted in Earlier Onset of Disease and Earlier Morbidity 
TNM AML cells were passaged 4 times through SCID beige mice.  The mice were 
treated with 50 mg/kg of Ara-C every other day starting on the 3rd day after 
transplantation and continuing until the mice were moribund. 
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Mouse Passage Day 15 Day 17 Day 18 Day 19 Day 21 Day 22 Day 23 Day 25 Day 26 Day 29
SC422 1 3.22 13.72 78.46 378.8
SC453 2 6.52   1.54   40.24 60.92
SC474 3 35.86 93.58 100.56
SC529 4 3.06 9.06 38.3
Moribund
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Table 5.5:  AML Cells Exposed to Low Continuous Doses of Ara-C for 4 
Passages Became Less Responsive to Ara-C 
Response of TNM AML cells passaged 4 times through SCID beige mice and exposed to 
low doses of Ara-C were compared to cells which had never been exposed to Ara-C.  On 
day 15 following transplantation the mice were treated with 50 mg/kg of Ara-C daily for 
5 day or until moribund. 
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Previous
Ara‐C
Mouse ID Exposure Day 15 Day 16 Day 17 Day 18 Day 19 Day 20 Day 21 Day 22
SC519 00 None 67.70 12.04
SC520 01 None 103.13 78.46
SC521 03 None 2.92 1.68
SC522 10 None 80.40 14.64
SC523 30 None 76.46 14.32
SC524 00 4 sets 119.16 49.41
SC525 01 4 sets 51.34 46.82
SC526 03 4 sets 129.92 78
SC527 10 4 sets 208.40 107.28
SC528 30 4 sets 136.50
Transplantion failed
Moribund
WBC Count
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Appendix A:  Methods and Materials 
Cell Culture 
The B117P, B117H, B140P, and B140H (murine BXH-2) cell lines were 
maintained by incubating at 37°C in 10% CO2 in ASM (Largaespada et al., 1995) in the 
absence of Ara-C.  Cells were passaged three times each week.  Cells were replaced from 
frozen stocks every 3-4 months, to minimize genetic drift.  Knockdown cells (KDs) were 
maintained in the same manner, but in the presence of selective doses of puromycin (1.5 
g/ml for the B117P KDs and 0.6 g/ml for the B140P KDs).  Ara-C was acquired from 
Bedford Laboratories (Bedford, OH).   
Proliferation Assay 
Each BXH-2 cell line was plated at an initial cell concentration 2.5 x 105 cells/ml.  
Cells were incubated at 37°, 10% CO2 in ASM with 10% FBS. After 24 hours the cell 
concentrations were determined using Countess® Automated Cell Counter (Life 
Technologies Corporation, Carlsbad, CA). Each cell line was then split to 2.5 x 105 cells 
/ml.  Cell counts were calculated for 7 days and the doubling times and standard 
deviations determined. 
Gene Expression Microarray and Analysis 
RNA was isolated from 3 separate passages of the BXH-2 cell lines (B117P, 
B117H, B140P and B140H).  The RNA was amplified and labeled using the Ambion® 
MessageAmpTM III RNA Amplification Kit (Life Technologies Corporation, Carlsbad, 
CA) and gene expression process was conducted using the GeneChip Mouse Genome 
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430 2.0 Array (Affymetrix, Santa Clara, CA).  The resulting data was normalized using 
the RMA algorithm of Genedata Expressionist software (Genedata AG, Basel, 
Switzerland). 
Transcriptome Deep Sequencing and Analysis 
Aliquots of RNA derived from the cells designated “passage B” of B117P, 
B117H, B140P, and B140H (GSM457359, GSM457362, GSM457365, and GSM457368, 
respectively) for the previously published microarray experiment(Rathe and Largaespada, 
2010) were submitted for transcriptome sequencing.  The RNA was quality tested using a 
Bioanalyzer 2100 (Agilent Technologies, Santa Clara, CA) and all four samples had 
RNA integrity numbers (RINs) of 10.0.  cDNA was created by reverse transcription of 
oligo-dT purified polyadenylated RNA.  The cDNA was fragmented, blunt-ended, and 
then ligated to barcoded adaptors.  Lastly, the library was size selected, and the selection 
process was validated and quantified by capillary electrophoresis and qPCR, respectively.  
Sequencing was accomplished on the HiSeq 2000 (Illumina Inc., San Diego, CA), with 
the goal of generating a minimum of 20 million paired-end 76 bp reads.  The resulting 
data was loaded into Galaxy.(Blankenberg et al., 2010; Giardine et al., 2005; Goecks et 
al., 2010)  TopHat 2.0.5(Langmead et al., 2009; Trapnell et al., 2009) was used to map 
the paired reads to the NCBI37/mm9 assembly of the mouse genome.  The mean inner 
distance was established using the insertion size metrics feature of Picard-tools 
(http://picard.sourceforge.net).  Other than stipulating the use of NCBI mouse genes for 
the gene model annotation, the default parameters (as defined by the University of 
Minnesota’s Galaxy implementation) were used.  The resulting TopHat data served as 
input to other analytical tools, which compared data from B117H to B117P, and B140H 
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to B140P.  Visualization of the mapped reads was accomplished using the Integrative 
Genomic Viewer (http://www.broadinstitute.org/igv).  Gene expression analysis of the 
RNA-seq data was conducted using Cufflinks tools.(Roberts et al., 2011a; Roberts et al., 
2011b; Trapnell et al., 2010)  Cuffdiff mapped reads to the NCBI37/mm9 mouse genome 
assembly and presented the data in terms of fragments per kilobase of transcript per 
million mapped reads (FPKMs).  Cuffdiff was executed from Galaxy using default 
parameters.  Transcripts were also assembled using Cufflinks, but without stipulating a 
reference transcriptome.  The resulting transcripts were then mapped back to the 
NCBI37/mm9 reference genome using Cuffcompare.  Cufflinks and Cuffcompare were 
executed from Galaxy using default parameters.  Fusion analysis was conducted using 
deFuse(McPherson et al., 2011) from the Galaxy platform using default parameters.  
Frameshift and missense mutations were identified by MMuFLR: Missense Mutation and 
Frameshift Location Reporter. (Rathe, Johnson et al., submitted to Bioinformatics).  The 
potential effects of the missense mutations on protein function were evaluated using 
PolyPhen-2(Adzhubei et al., 2010) and PROVEAN Protein.(Choi et al., 2012)   
DNA and RNA Isolation and Sequencing 
RNA isolations were performed using the RNeasy® Midi Kit (QIAGEN, Venlo, 
Netherlands), following the protocol for isolating cytoplasmic RNA.  For each sample, 
107 cells were processed and the centrifugation steps were performed at 2850 g.  DNA 
was eliminated using the RNase-Free DNase Set (QIAGEN) at the recommended step in 
the RNeasy® protocol.  RNA concentration was determined using a NanoDropTM 1000 
Spectrometer (Thermo Fisher Scientific Inc., Waltham, MA).  The RNA samples were 
then stored at -80°C. 
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Genomic DNA isolations from the BXH-2 cell lines (B117P, B117H, B140P, 
B140H) were performed using a DNeasy Blood & Tissue Kit (QIAGEN).  The resulting 
samples were quantified using a NanoDropTM 1000 Spectrometer (Thermo Fisher 
Scientific Inc.).  DNA samples were stored at -20°C. 
cDNA was prepared from RNA using the InvitrogenTM Superscript® III First-
Strand Synthesis System (Life Technologies).  DNA (or cDNA) was amplified using Taq 
DNA Polymerase (QIAGEN), and separated by gel electrophoresis on a 2% agarose gel.  
The DNA was extracted from the resulting bands using the UltraClean® GelSpin® DNA 
Extraction Kit (MO BIO Laboratories, Inc., Carlsbad, CA).  Classic Sanger sequencing 
was done using the ABI PRISM® 3730xl DNA Analyzer (Life Technologies 
Corporation).    
Genomic DNA PCR and Quantitative PCR (qPCR) 
The DNA samples from the B117P and B117H cell lines were amplified using the 
Expand Long Template PCR System (Roche Applied Systems, Indianapolis, IN).  
Primers are described in Supplementary Table C.1.   
Quantitative PCR (qPCR) was performed using SYBR® Green PCR Master Mix 
(Life Technologies Corporation) on a Mastercycler® ep realplex device (Eppendorf, 
Hamburg, Germany).  Primers are described in Supplementary Table C.1.  
RNAi Experiments 
The Open Biosystems’ shRNA TRC constructs for Dck, 25382 (KD1) and 25383 
(KD2) (Thermo Fisher Scientific Inc.), were provided in E. coli and plated on 
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carbenicillin media to isolate single clones.  Next, the plasmids containing the shRNA 
constructs were isolated from the E. coli using the InvitrogenTM PureLink® Quick 
Plasmid Miniprep Kit (Life Technologies Corporation).  The plasmids were then 
transfected into Open Biosystems’ packaging cells, TLA-HEK293T, using the Open 
Biosystems’ Trans-Lentiviral™ Packaging System (Thermo Fisher Scientific Inc.).   The 
TLA-HEK239T cells were maintained in the recommended growth media.  Viral 
particles were then collected and concentrated using PEG-itTM Virus Precipitation 
Solution (System Biosciences, Mountain View, CA).  The viral particles were transduced 
into the B117P and B140P cell lines by adding virus (MOI of 100) and 8 g/ml of 
polybrene to the cells and incubating for 2 hours at 37°C followed by spinoculation (30 
min, 300 g). 
TALEN Assembly and Generation of KO Cells  
Candidate Dck TALENs were designed using TALE-NT 
(https://boglab.plp.iastate. edu/node/ add/talen).  From the list of candidate TALENs 
generated using TALE-NT, three were chosen and constructed based on optimal RVD 
content, spacer length, and binding site length based on previous TALEN publications 
and our own experiences with TALENs.  TALENs were assembled using Golden Gate 
cloning as previously described.(Cermak et al., 2011)  The truncated GoldyTALEN 
backbone used has also been previously described.(Carlson et al., 2012)  Assembled 
TALENs were validated by transient transfection into NIH 3T3 cells using the NEON® 
Transfection System (Life Technologies Corporation, Carlsbad, CA), following 
manufacturer’s instructions.  Three days after TALEN transfection DNA was collected 
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using standard Phenol:Chloroform extraction and CEL-I assays were performed as 
previously described.(Guschin et al., 2010) 
Validated Dck TALENs were then electroporated into B117P cells using the 
NEON® Transfection System (Life Technologies Corporation), following 
manufacturer’s instructions.  Three days after transfection cells were selected for Dck 
Knockout (KO) using 50 g/ml of Ara-C for 5 days.  From this pool of TALEN modified 
cells single cell clones were isolated by limiting dilution cloning.  Clones were analyzed 
for Dck KO by direct PCR and sequencing of the TALEN targeted region of Dck, using 
primers described in Supplementary Table C.1. 
Inducible DCK Overexpression Vector 
Full-length human DCK cDNA was purchased from GeneCopoeia (Rockville, 
MD) in a ready entry ORFEXPRESSTM Gateway® Plus Shuttle (Cat#GC-C0081).  The 
DCK cDNA was then transferred to PB-TRE-DEST-EF1A-rtTA-IRES-Puro(Moriarity et 
al., 2013) via the InvitrogenTM Gateway® LR Clonase® reaction (Life Technologies 
Corporation), following manufacturer’s instructions.  Two micrograms of PB-TRE-Dck-
EF1A-rtTA-Puro was electroporated with 2 g of Super piggyBac transposase (System 
Biosciences, Mountain View, CA) into B117P using the NEON® Transfection System 
(Life Technologies Corporation), following manufacturer’s instructions.  Two days after 
transfection cells were selected with 1.5 g/ml puromycin for 5 days to generate stable 
cell lines.  Overexpression was activated by adding 1.0 g/ml of doxycycline.   
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Western Blot Analysis 
Protein lysate was isolated from cells using RIPA lite buffer (50nM Tris-HCL 
pH7.6, 150mM NaCl, 1% NP40, 5mM NaF, 1mM EDTA) supplemented with protease 
inhibitors (Roche Applied Systems) and phosphatase inhibitors (Sigma-Aldrich, St. 
Louis, MO).  200g of protein lysate was separated on a NuPAGE® Novex® 10% Bis-
Tris Gel (Life Technologies Corporation) and transferred to PVDF membrane.  The 
membrane was blocked with 5% milk in 1XTBST (4hrs RT) and incubated overnight at 
4°C with the primary antibodies anti-DCK (1:500, Proteintech, Chicago, IL) and anti-
Gapdh (1:10,000, Cell Signaling Technology, Danvers, MA).  Goat anti-Rabbit HRP 
conjugated secondary antibodies were utilized at 1:5000 dilution (Santa Cruz 
Biotechnologies, Dallas, TX).  Membranes were developed with WesternBright Ecl kit 
(BioExpress, Kaysville, UT). 
Drug Assays   
Drug assays were performed using the CellTiter 96® Aqueous Non-Radioactive 
Cell Proliferation Assay (Promega, Madison, WI), as described previously.(Rathe and 
Largaespada, 2010)  For each cell line the drug was tested using 10 different 
concentrations, and each drug concentration was tested in quadruplicate.  The drug 
concentrations were selected to maximize the number of data points between IC5 and 
IC95.  For the results to be acceptable there needed to be data points on both sides of the 
IC50 and the r-value needed to be greater than 0.85.  Inhibitory concentrations (IC) values 
and r-values were calculated using CalcuSyn 2.0 (Biosoft, Cambridge, UK). 
167 
 
Screen of 446 FDA Approved Drugs  
A screen using a NIH Clinical Collection of 446 FDA approved drugs 
(http://www.nihclinicalcollection.com/) at 10M was conducted for each of the four 
BXH-2 cell lines (B117P, B117H, B140P and B140H).  Cell viability was measured using 
Alamar Blue and fluorescence readout on a Molecular Devices Spectromax 2e microplate 
reader.   
Combination Screen of Ara-C with 50 Individual Drugs  
A drug screen was conducted to test 50 different drugs in combination with Ara-C 
in the B117P cell line using the MTS-tetrazolium assay.  The drugs tested are listed in 
Supplementary Table C.9.  The concentration of Ara-C used was 200ng/ml.  It was 
combined with 7 different concentrations at 2X increments of each of the 50 drugs.  Each 
drug concentration was conducted in duplicate.    
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Appendix B:  MMuFLR:  Missense Mutation and Frameshift Location Reporter 
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Motivation: Cancer researchers seeking immunotherapy targets in cancer cells 
need tools to locate highly expressed proteins unique to cancer cells.  Missense Mutation 
and Frameshift Location Reporter (MMuFLR), a Galaxy-based workflow, analyzes Next 
Generation Sequencing (NGS) paired read RNA-seq output to reliably identify small 
frameshift mutations, as well as missense mutations, in highly expressed protein-coding 
genes.  MMuFLR ignores known SNPs, low quality reads, and poly-A/T sequences.  For 
each frameshift and missense mutation identified MMuFLR provides the location and 
sequence of the amino acid substitutions in the novel protein candidates for direct input 
into epitope evaluation tools. 
 Availability:  http://toolshed.g2.bx.psu.edu/ 
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Introduction  
Next Generation Sequencing (NGS) holds promise for individualized targeted 
treatment, particularly in the realm of cancer immunotherapy (Meinke et al., 2005).  
Identifying aberrant transcripts from a patient’s tumor cells may provide candidate target 
epitopes which can be used to generate patient specific vaccines.  Given the quantity of 
data generated by NGS, it is important to have an efficient and repeatable process to 
deconstruct the data and present the most relevant vaccine targets, which includes 
missense and small frameshift mutations located in protein coding regions of highly 
expressed genes. We offer Missense Mutation and Frameshift Location Reporter 
(MMuFLR) as a process to analyze NGS RNA-seq paired read output to identify a 
limited set of peptides which may be targets for immunotherapy.   MMuFLR is 
implemented as a workflow in Galaxy (Blankenberg et al., 2010).  Galaxy is a server 
based workflow system designed to run a series of applications, presented to the user as 
tools, in an easy to use, repeatable manner.  MMuFLR uses a few custom developed 
Galaxy tools as well as those in the standard distribution of Galaxy.  In this pilot project 
MMuFLR’s ability to identify potential vaccine targets was tested in RNA-seq data sets 
derived from two benign human meningiomas.  However, the use of MMuFLR is not 
limited to cancer immunotherapy.  It can also be used to locate prominent mutations 
responsible for cancer development and for other maladies, such as genetic diseases, 
developmental defects, and drug resistance. 
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Workflow 
2.1     Map read sequences to reference genome     MMuFLR starts with the NGS 
RNA-seq paired read output in the form of two fastq-formatted files.   Each read pair is 
individually mapped to the reference genome using TopHat (Langmead et al., 2009) 
resulting in a bam formatted file.  The standard galaxy distribution includes TopHat in its 
toolset.  The custom galaxy tool “Filter SAM or BAM"  invokes the SAMtools (Li et al., 
2009) view command to filter TopHat bam output by the MAPQ score. 
2.2     Refine the mapping     TopHat, as is typical with short read mappers, may 
find multiple mappings for individual read pairs which are equally valid.   The mapped 
reads can be analyzed in aggregate to improve upon the initial mapping of individual 
reads.  The MMuFLR workflow uses software from the Genome Analysis Toolkit 
(GATK) (DePristo et al., 2011; McKenna et al., 2010) along with Picard-tools 
(http://picard.sourceforge.net) to perform this collective analysis and realign the 
individual reads.  GATK requires bam input to be labeled with read group information 
and be sorted in reference order.  Several Picard-tools (“Add or Replace Groups”, “Paired 
Read Mate Fixer”, “Mark Duplicate Reads”, and “Reorder SAM/BAM”) add the read 
groups, filter out unmapped pairs, remove exact duplicate reads, and sort the resulting 
bam output into reference order.   Two GATK tools, “Realigner Target Creator” and 
“Indel Realigner”, realign the reads based on aggregate information from all reads.  
Duplicate reads are again identified and removed with “Mark Duplicate Reads.” 
2.3    Multiple alignment    The realigned reads are then assembled into a multiple 
alignment using the Galaxy tool “MPileup” which invokes SAMtools mpileup.  The 
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custom galaxy tool, "Pileup to VCF", filters the pileup results and converts them to the 
standard Variant Call Format (VCF). Filter parameters to the "Pileup to VCF" tool 
include Minimum Base Quality, Minimum Coverage Depth, and Minimum Frequency of 
a Specific Allele. 
2.4    Eliminate common variants   The resulting VCF file will likely contain 
many commonly known variants which would not be useful in determining candidate 
targets.  MMuFLR uses the “annotate” command of SnpSift (Cingolani et al., 2012) to 
merge variants from the samples being evaluated with known variants from the dbSNP 
database (Sherry et al., 2001), as well as a user provided list.  Then the “filter” command 
of SnpSift is used to eliminate those annotated variant entries.   
2.5    Determine variant effects     MMuFLR next categorizes the effect of each 
variant using SnpEff (Cingolani et al., 2012).  The “filter” command of SnpSift is used to 
separate the missense and frameshift variants into individual files for reporting. 
2.6    Report variants     Finally, a new Galaxy tool, "SnpEff Ensembl CDS", 
inserts the variants into transcripts retrieved from Ensembl (Flicek et al., 2013) and 
reports the amino acid sequence of the abnormal peptides.  Included in the report are the 
sequencing depth of reads at the mutation site and the prevalence of the mutation.  A 
parameter can be set to ignore poly-A/T sequences of specified lengths.  
Frameshift and missense mutations identified by MMuFLR and verified using 
Sanger sequencing.  Included in the table are the location of the variant, the reference 
sequence being replaced, the fraction of reads with the mutation (prevalence) and the 
number of reads (depth). 
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MMuFLR was executed for two human meningioma RNA-seq data sets, MG1 
and MG2.  MMuFLR settings restricted the selection of candidate genes with minimum 
coverage of 5 reads, with a prevalence greater than 0.32, and a Phred quality score of 20 
or more.  MMuFLR also ignored poly A/T mononucleotide sequences of 5 or more.  
MMuFLR identified 16 frameshifts and 576 missense mutations in the MG1 sample, and 
10 frameshifts and 509 missense mutations in the MG2 sample.  The candidates were 
evaluated for their presence in other samples.  Sanger sequencing of 9 prominent 
candidates, not found in other cancer samples, verified the existence of the mutations 
within the tumor samples, with the MMuFLR prevalence accurately reflecting the relative 
abundance of the mutation within the total transcripts present (Table 1).  Since there were 
no normal samples available for comparison, these mutations may represent rare germline 
variants. 
Conclusions 
One challenge for developing patient specific cancer vaccines is identifying novel 
peptides specific to the tumor cells.  MMuFLR is an innovative Galaxy-based software 
tool designed to locate highly abundant transcripts with frameshift or missense mutations 
within protein coding sequences.  MMuFLR ignores potentially false candidates such as 
frameshifts located within poly A/T sequences of mononucleotides, which is believed to 
result from a loss of fidelity during replication due to dissociation within the reverse 
transcriptase binding site in a phenomenon referred to as “stuttering” (Fazekas, Steeves, 
and Newmaster, 2010).  Because there is always a lag between the identification of SNPs 
and their incorporation into the dbSNP database, MMuFLR provides the ability to 
establish a supplementary SNP table in which the researcher can record and thereby 
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ignore SNPs identified during their research efforts.  MMuFLR has been successfully 
tested with both human and mouse samples, but should be easily adaptable to other 
organisms. 
Supplementary information 
Processing of biological samples 
Two meningioma samples (MG1 and MG2) were provided by the Biological 
Materials Procurement Network at the University of Minnesota.  Samples were flash 
frozen.  RNA was isolated from the cells using RNeasy® Midi Kit (QIAGEN, Venlo, 
Netherlands), and DNA was eliminated using RNase-Free DNase Set (QIAGEN, Venlo, 
Netherlands).   RNA integrity numbers (RINs) were determined using a Bioanalyzer 
2100 (Agilent Technologies, Santa Clara, CA).  The RIN for the MG1 and MG2 samples 
were 8.6 and 7.2, respectively.  RNA-seq was performed on a HiSeq 2000 (Illumina Inc., 
San Diego, CA) and generated 24 million paired reads of 100 cycles for each sample.  
cDNA was prepared from RNA using the First Strand Transcriptor cDNA Synthesis Kit 
(Roche Applied Systems, Indianapolis, IN).  cDNA was amplified using GoTaq Green 
PCR Master Mix (Promega, Madison, WI), and separated by gel electrophoresis on a 1% 
agarose gel.  The DNA was extracted from the resulting bands using QIAquick Gel 
Extraction Kit (QIAGEN, Venlo, Netherlands).   Classic Sanger sequencing was 
performed on an ABI PRISM® 3730xl DNA Analyzer (Life Technologies Corporation, 
Carlsbad, CA).   
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MMuFLR features and use 
MMuFLR is a biologist friendly Galaxy workflow designed to assist researchers 
in the identification of legitimate frameshift and missense mutations, while minimizing 
the number of “false positives”.  The generation of hundreds of “false positives” by 
existing bioinformatics tools frequently deters researchers from taking advantage of the 
wealth of valuable information provided by next generation sequencing.  MMuFLR uses 
a series of filters to eliminate “false positives”, as well as known SNPs.  These filters 
include:  1) the mutation must occur within a coding region, 2) a setting for the minimum 
number of reads spanning a mutation location, 3) a setting for a minimum number of 
reads containing the mutation, 4) a setting for a minimum ratio of reads with the mutation 
relative to the total number of reads, 5) the ability to ignore poly A/T sequences which 
result from polymerase “stuttering”, 6) the ability to ignore reads with low phred scores, 
7) the elimination of PCR duplicates, 8) the ability to ignore known SNPs, and 9) the 
ability to ignore a list of SNPs provided by the researcher. 
The minimum phred and poly A/T logic were introduced into two new algorithms 
created specifically for the MMuFLR workflow, “Pileup to VCF” and “SnpEff Ensembl 
CDS”, respectively.  The combination of just these two features reduced the number of 
mutation candidates in the MG1 and MG2 samples by more than 60%.  The “SnpEff 
Ensembl CDS” algorithm also provides other labor saving features to the researcher.  It 
automatically identifies the protein sequence changes resulting from the mutation, 
thereby eliminating the need to do this very necessary next step using another software 
tool.  It provides the novel protein sequences in a form which can be cut and pasted 
directly into an epitope finder, such as the Immune Epitope Database and Analysis 
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Resource (www.iedb.org) (Vita et al., 2010).  It describes missense mutations in a 
standard format which can be input directly into tools to predict the effect of the 
mutation, such as Polyphen-2 (Adzhubei et al., 2010) and PROVEAN Protein (Choi et 
al., 2012), or into tools which describe known somatic mutations, such as COSMIC 
(Forbes et al., 2011).  Further, it identifies the sequence of the stop codon, including the 
nucleotide preceding and the nucleotide following the stop codon.  The configuration of 
the stop codon and surrounding bases affects the likelihood of translation beyond the stop 
codon (Floquet et al., 2012), a feature which can be quite valuable to some researchers.   
Ideally, researchers using MMuFLR should have paired samples, such as a cancer 
sample paired with a normal tissue sample, or a metastatic cancer sample paired with a 
primary cancer sample, or a drug resistant sample paired with its original drug sensitive 
sample.  There are two approaches which can be used to compare samples, such as in the 
case where a researcher would like to eliminate germline mutations (those found in the 
normal tissue sample) from cancer samples, to leave only the somatic mutations.  In the 
first method MMuFLR can be run individually for both of the paired samples and the 
resulting TSV files can be interrogated by the “Compare two datasets” utility of Galaxy 
to eliminate the mutations found in one sample from those found in the other.  In the 
second method, MMuFLR can be run first for the normal sample, and the resulting VCF 
file from the first SnpSift Filter step can be used as the exception file (VCF file of 
additional known variants) in the second run of MMuFLR for the cancer sample.  The 
FASTq file being input to MMuFLR for the normal sample could have been generated 
from exome or genome sequencing, not just RNA-sequencing.  
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It is still necessary to review visually all the candidate mutations presented by 
MMuFLR.  This will insure there is no other explanation for the presence of the 
candidate, such as the absence of expression in the paired sample or the prominence of 
the mutation appearing at the end of reads.  We utilized the Integrative Genomic Viewer 
(http://www.broadinstitute.org/igv) to verify the candidate mutations.  Following this in 
silico verification step, all of candidates selected for verification by RT-PCR and Sanger 
sequencing were confirmed as true mutations.  The MMuFLR Supplementary Tables 
contain the MMuFLR reports prior to in silico verification.      
In the MMuFLR runs to analyze the MG1 and MG2 samples, we set the minimum 
number of reads covering the mutation location to 5, the minimum number of reads with 
the mutation to 2, the minimum prevalence to 0.32, the minimum phred level to 20, and 
the poly A/T threshold to 5.  Another research group recently published their analysis of 
RNA-seq data to locate frameshift and missense mutations in prostate cancer samples as 
compared to benign matching tissue samples (Xu et al., 2013).  They used some of the 
same filtering strategies available in MMuFLR.  They looked for mutations in coding 
regions, a minimum of 5 reads containing the variant, a phred quality of more than 20, 
and they ignored known SNPs.  From the description of their process, it appears they 
utilized a number of Unix based tools, and wrote custom programs for some of the 
filtering steps.  MMuFLR makes a similar, but more robust, analytic process available to 
any biologist with access to Galaxy.  
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Accessing and executing MMuFLR  
The MMuFLR workflow,” MMuFLR_Human_v1.2”, and the two new Galaxy 
tools, “Pileup to VCF” and “SnpEff Ensembl CDS”, can be acquired from the Galaxy 
toolshed at Penn State University:  
http://toolshed.g2.bx.psu.edu/view/jjohnson/mmuflr  
http://toolshed.g2.bx.psu.edu/view/jjohnson/pileup_to_vcf  
http://toolshed.g2.bx.psu.edu/view/jjohnson/snpeff_cds_report 
Instructions for deploying a workflow from the Galaxy toolshed are documented 
in the Galaxy wiki: http://wiki.galaxyproject.org/ToolShedWorkflowSharing along with a 
screencast tutorial demonstrating how to run a workflow: 
http://screencast.g2.bx.psu.edu/mt-workflowImport. 
MMuFLR uses a variety of preexisting Galaxy tools and for the MMuFLR 
workflow to execute properly most of the parameters should not be changed.  The 
parameters which can be safely adjusted are described here. 
The first 4 steps of the MMuFLR workflow request the identification of 4 input 
files. 
1.  the “Forward reads fastq” file for the sample being analyzed 
2.  the “Reverse reads fastq” file for the sample being analyzed 
3.  a “VCF file of known variants (dbSNP)” 
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4.  a “VCF file additional known variants” as provided by the researcher 
The last input file contains known variants which will be excluded from the 
MMuFLR analysis.  This can be a VCF file generated by a previous run MMuFLR.  For 
example, MMuFLR can be run first on a normal tissue sample, using workflow: 
“MMuFLR_Human_germline_v1.2”, and the resulting VCF file can be used as input to a 
run of MMuFLR to identify mutations in a matching tumor sample which are not found 
in the normal tissue.   
The “Mean Inner Distance between Mate Pairs” and the “Std. Dev for Distance 
between Mate Pairs” can be set in the TopHat for Illumina step. 
Pileup to VCF allows the selections of “Minimum Base Quality”, “Minimum 
Coverage Depth”, and “Minimum Frequency of a Specific Allele”.  (Note: the Minimum 
base quality in the MPileup step should not be changed) 
SnpEff Ensemble CDS allows the selection of the type of report (Filter SnpEffect) 
which can be FRAME_SHIFT or NON_SYNONYMOUS_CODING.  It also provides 
the ability to “Ignore variants that are part of a Poly-A of at least this length”.   
   
181 
 
Table C.1.  Frameshift and missense mutations identified by MMuFLR 
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Frameshift Mutations
Sample Gene Variant Position Ref Var Prev Depth
MG1 ZNF812 chr19:9800968 CT T 0.50 20
MG2 CPNE1 chr20:34215234 G TG 0.45 98
MRPL16 chr11:59577372 C GC 0.37 27
ZP3 chr7:76071183 T TG 0.50 14
DNAJB7 chr22:41257834 A TA 1.00 6
Missense Mutations
Sample Gene Variant Position Ref Var Prev Depth
MG1 COL6A2 chr21:47545737 A G 0.50 899
MG2 APP chr21:27484329 T A 0.46 432
FRMPD2 chr10:49389016 A G 0.48 227
CCDC74A chr2:132288362 T C 0.97 29
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Appendix C:  Supplementary Tables and Figures  
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Supplementary Table C.1:  Primers 
Primers designed to find mutations and to verify expression levels. 
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Experiment Target Forward Reverse
qPCR Dck  (Exon 5‐
6)
CTGGCTCCTTCATCGGACT CCAGGCTTTCGTGTTTGTCT
qPCR Dck  (3'‐UTR) TGAGGATAGAACATGCCAAGG CGCCTAGGCTTCTCAGTGTC
qPCR ‐ 
Reference gene
Rps9  (Exon 2‐
3)
TCTATTCACCATGCCCGTGT GGCGAACAATGAAGGATGG
RNA sequencing Dck    
Quartile 1
GCAGGTCAGGATCTGGCTTAG CTATGTAAGCATGTCTCTGGAGTGG
RNA sequencing Dck    
Quartile 2
TGAACGATCTGTGTATAGTGACAGG CAACCTGCTGAGGAAGACAAA
RNA sequencing Dck    
Quartile 3
GCAGGAAATGTAGAGGTAGATGG CACTGCACACCTTAACTAAACAAAC
RNA sequencing Dck    
Quartile 4
AAATTAATGAAGACAGAGGCTAGAA
AG
TTATTAGCGTCTTTTCAATTCTACAA
A
qPCR ‐ 
Reference gene
Rap2c  (Exon 
2‐3)
CCCGAGAAGCAAGATCAGTG GTGCAAATTTCCTCTGAGTTTGTAA
Expand Long 
Template PCR
Dck  deletion 
in B117H
GACAAACACGAAAGCCTGGT CAACCAGCTGCATGAGAGAA
RNA sequencing Dck  deletion 
in B117H
ATCCTGGACTCTAGAGGAGCATT GGGTGTGGAGGAAACTGTGT
DNA sequencing Dck  deletion 
in B117H
CTGTCTGGCTGTTTGCTATAAAGA TTAACCCACTCAGGATGACAAGT
RNA sequencing Ccdc88b 
deletion in 
B140H
TCATGGACCAGTACCGTGTG GGACTAAATGACGCAGAGCTTC
RNA sequencing Dck  insertion 
in B140H
TTTGAAAGATCTGTGTATAGTGACA
GG
TTTCTCGGGAGTAGCTCGAA
DNA sequencing Dck  insertion 
in B140H
GATTGAGAAGCGCATTTACCC ACCTCGGGAGTAGCTCGAAG
RNA sequencing Dck  start site 
(KO's)
AGGAACCACAGACATGC CTCTCTCAATGGCAAGCTCA
DNA sequencing Dck  start site 
(KO's)
GAGGCGTATAGGGTGGGAGT GGGGACACCTTACCGATGT
Primers
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Supplementary Table C.2:  RNA-seq stats 
The number of paired-end 76 bp reads generated by Illumina NGS sequencing for the 
murine cell lines B117P, B117H, B140P, and B140H, and the ability of the reads to be 
mapped uniquely by TopHat. 
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Total Mapped    % Unique % 
Cell line Read pairs Read pairs Mapped Read pair Unique
B117P 24,914,387 22,998,275 92.3 22,640,193 90.9
B117H 21,620,354 19,656,507 90.9 19,321,761 89.4
B140P 20,570,801 19,114,959 92.9 18,838,702 91.6
B140H 27,977,177 25,952,317 92.8 25,585,528 91.5
TopHat Stats PE
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Supplementary Table C.3:  Common expression changes 
Gene expression changes common to both Ara-C resistant cell lines when compared to 
their parental cell lines were identified by analyzing data generated from the Illumina 
NGS sequencing platform with the use of TopHat for genome mapping, and Cuffdiff for 
gene expression comparison.  Included in this table are genes with a minimum fold 
change between 2 and 3.  Genes with a greater than 3 fold change are included in Table 
3.1. Genes in bold with * were also identified by gene expression microarray with 2-
fold+ changes in expression (Rathe & Largaespada, 2010). (1) Expression levels are 
expressed in fragments per kilobase of transcript per million mapped reads (FPKMs).  (2)  
Fold change compares the Ara-C resistant gene expression to the Ara-C sensitive parental 
lines. Negative values indicate a decrease in expression while positive values represent an 
increase in expression.  (3)  The table is sorted by the minimum fold change, which is the 
least of the two fold change values.  
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Gene symbol 
B117P 
FPKMs1 
B117H 
FPKMs1 
B117H 
vs. 
B117P 
fold chg2 
B140P 
FPKMs1 
B140H 
FPKMs1 
B140H vs. 
B140P 
fold chg2 
Minimum 
fold 
change3 
Sh3tc1  2.773  0.872  ‐3.181 2.337 0.788 ‐2.964  ‐2.964
Mex3a  2.270  0.639  ‐3.552 4.567 1.716 ‐2.661  ‐2.661
Osgin1  0.593  0.213  ‐2.791 1.185 0.476 ‐2.491  ‐2.491
Dab2*  68.710  12.284  ‐5.594 13.793 5.717 ‐2.413  ‐2.413
Satb2  3.286  0.946  ‐3.475 2.237 0.933 ‐2.398  ‐2.398
Cxcl10  2.890  0.884  ‐3.270 1.140 0.476 ‐2.394  ‐2.394
Ier3  8.200  0.505  ‐16.223 1.582 0.672 ‐2.353  ‐2.353
2810410L24Rik  1.654  0.709  ‐2.332 1.089 0.151 ‐7.203  ‐2.332
Ccbl2*  15.548  6.695  ‐2.322 3.791 0.001 ‐3790.700  ‐2.322
Igfbp4  101.925  13.223  ‐7.708 105.091 45.829 ‐2.293  ‐2.293
Smpdl3b  7.676  1.762  ‐4.356 0.703 0.309 ‐2.275  ‐2.275
Fam160a2  0.834  0.371  ‐2.247 1.920 0.790 ‐2.432  ‐2.247
1700109H08Rik  7.218  3.223  ‐2.240 2.172 0.919 ‐2.363  ‐2.240
Serpinb6b  5.757  2.589  ‐2.224 8.700 1.926 ‐4.517  ‐2.224
Gpr183  8.932  4.158  ‐2.148 1.829 0.783 ‐2.335  ‐2.148
Sash1  4.016  1.902  ‐2.112 2.270 0.116 ‐19.538  ‐2.112
Plp1  0.540  0.242  ‐2.231 0.543 0.261 ‐2.079  ‐2.079
Fkbp11  20.183  9.735  ‐2.073 5.533 0.340 ‐16.252  ‐2.073
Klhl23  5.132  2.108  ‐2.435 0.629 0.305 ‐2.059  ‐2.059
Cds1  5.988  2.947  ‐2.032 3.019 0.900 ‐3.354  ‐2.032
Gjb3  0.686  0.001  ‐685.977 0.832 0.410 ‐2.030  ‐2.030
2210417A02Rik  2.075  1.032  ‐2.010 2.551 0.909 ‐2.805  ‐2.010
Gng5  71.113  142.262  2.001 78.906 184.445 2.338  2.001
Acadm  12.394  24.907  2.010 16.925 36.069 2.131  2.010
Chpf  0.059  1.118  19.060 1.098 2.229 2.030  2.030
Fpgt  1.267  3.218  2.541 1.454 2.976 2.047  2.047
Kmo  4.019  8.514  2.118 2.236 4.611 2.062  2.062
Bcl10  10.187  21.039  2.065 8.611 20.871 2.424  2.065
Ssx2ip  5.298  11.077  2.091 4.246 9.297 2.189  2.091
Traf5  1.411  3.134  2.222 0.598 1.263 2.113  2.113
Gpr25  0.214  0.878  4.105 17.899 37.890 2.117  2.117
Depdc1a  0.001  3.868  3868.250 3.159 6.693 2.119  2.119
Znhit6  4.859  10.512  2.163 6.821 14.549 2.133  2.133
Ankrd13c*  6.405  13.990  2.184 8.611 19.645 2.282  2.184
Dact3  0.515  1.192  2.312 0.635 1.400 2.204  2.204
2410004B18Rik  3.861  8.836  2.289 5.156 13.242 2.568  2.289
Trpa1  4.909  13.575  2.765 2.901 6.775 2.335  2.335
Ccdc112  0.879  2.097  2.387 0.151 0.781 5.171  2.387
2610524H06Rik  12.971  31.344  2.417 7.959 31.839 4.001  2.417
Pigk  3.112  7.577  2.435 3.750 9.630 2.568  2.435
Rtn4rl1  2.940  7.237  2.462 1.586 4.844 3.054  2.462
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Slc14a1*  0.267  1.766  6.604 0.289 0.745 2.579  2.579
Aff3*  13.743  37.371  2.719 0.120 0.870 7.259  2.719
Il1r2  0.179  0.521  2.905 0.625 2.572 4.115  2.905
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Supplementary Table C.4:  B117H expression changes  
Gene expression changes between the Ara-C resistant B117H cells compared to its 
parental cell line, B117P, were identified by analyzing data generated from the Illumina 
NGS sequencing platform with the use of TopHat for genome mapping, and Cuffdiff for 
gene expression comparison.  Genes in bold with * were also identified by gene 
expression microarray with 100-fold+ changes in expression.  . (1) Expression levels are 
expressed in fragments per kilobase of transcript per million mapped reads (FPKMs).  (2)  
Fold change compares the Ara-C resistant gene expression to the Ara-C sensitive parental 
lines. Negative values indicate a decrease in expression while positive values represent an 
increase in expression. 
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Gene symbol  Description 
B117P 
FPKMs1 
B117H 
FPKMs1 
B117H vs. 
B117P 
fold chg2 
5730528L13Rik  RIKEN cDNA 5730528L13 gene  4.437  0.001  ‐4437.220
Uty  ubiquitously transcribed tetratricopeptide 
repeat gene, Y chromosome 
1.986  0.001  ‐1985.690
Ccl5  chemokine (C‐C motif) ligand 5  1.630  0.001  ‐1629.900
Klk8  kallikrein related‐peptidase 8  1.167  0.001  ‐1167.290
Zfyve9  zinc finger, FYVE domain containing 9  0.831  0.001  ‐830.902
Zfp157  zinc finger protein 157  0.798  0.001  ‐797.719
Gjb3  gap junction protein, beta 3  0.686  0.001  ‐685.977
Upk1b  uroplakin 1B  0.637  0.001  ‐636.522
Stfa1  stefin A1  0.606  0.001  ‐605.925
8430408G22Rik  RIKEN cDNA 8430408G22 gene  0.550  0.001  ‐549.757
Ddx3y*  DEAD (Asp‐Glu‐Ala‐Asp) box polypeptide 3, Y‐
linked 
7.466  0.043  ‐172.670
Tnxb  tenascin XB  0.011  2.441  222.762
Glul  glutamate‐ammonia ligase (glutamine 
synthetase) 
0.033  15.557  474.688
2610109H07Rik  RIKEN cDNA 2610109H07 gene  0.001  0.510  509.710
Kcnmb4  potassium large conductance calcium‐
activated channel, subfamily M, beta member 
4 
0.001  0.610  609.674
Blk  B lymphoid kinase  0.001  0.623  622.966
Nxf3  nuclear RNA export factor 3  0.001  0.701  701.321
1700019E19Rik 
(Ift43) 
intraflagellar transport 43 homolog  0.001  0.713  712.901
Thsd4  thrombospondin, type I, domain containing 4  0.001  0.731  730.994
Tspan12  tetraspanin 12  0.001  0.743  742.820
Il17rb  interleukin 17 receptor B  0.001  0.756  756.133
Myl10  myosin, light chain 10, regulatory  0.001  1.014  1013.690
Hectd2  HECT domain containing 2  0.001  1.316  1315.930
Prr5  proline rich 5 (renal)  0.001  1.826  1826.190
Lrrc49  Leucine rich repeat containing 49  0.001  1.962  1962.050
Ggt7  gamma‐glutamyltransferase 7  0.001  3.278  3278.190
Depdc1a  DEP domain containing 1a  0.001  3.868  3868.250
Zfp13  zinc finger protein 13  0.001  7.147  7147.450
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Supplementary Table C.5:  B140H expression changes 
Gene expression changes between the Ara-C resistant B140H cell compared to its 
parental cell line, B140P, were identified by analyzing data generated from the Illumina 
NGS sequencing platform with the use of TopHat for genome mapping, and Cuffdiff for 
gene expression comparison.  (1) Expression levels are expressed in fragments per 
kilobase of transcript per million mapped reads (FPKMs).  (2)  Fold change compares the 
Ara-C resistant gene expression to the Ara-C sensitive parental lines. Negative values 
indicate a decrease in expression while positive values represent an increase in 
expression. 
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Gene symbol  Description 
B140P 
FPKMs1 
B140H 
FPKMs1 
B140H vs. 
B140P 
fold chg2 
Cenpb  centromere protein B  11.488  0.001  ‐
11487.700
Pepd  peptidase D  5.479  0.001  ‐5478.620
Ccbl2  cysteine conjugate‐beta lyase 2  3.791  0.001  ‐3790.700
Ephb2  Eph receptor B2  2.352  0.001  ‐2351.650
Pou2af1  POU domain, class 2, associating factor 1  2.215  0.001  ‐2215.060
Lmo1  LIM domain only 1  2.152  0.001  ‐2151.920
Hgsnat  heparan‐alpha‐glucosaminide N‐
acetyltransferase 
2.057  0.001  ‐2057.290
Tarsl2  threonyl‐tRNA synthetase‐like 2  1.925  0.001  ‐1924.690
Cdh17  cadherin 17  1.770  0.001  ‐1769.610
Zbtb10  zinc finger and BTB domain containing 10  1.225  0.001  ‐1224.630
Csf2  colony stimulating factor 2 (granulocyte‐
macrophage) 
0.841  0.001  ‐841.152
Col11a1  collagen, type XI, alpha 1  0.817  0.001  ‐817.413
Rab39  RAB39, member RAS oncogene family  0.798  0.001  ‐798.492
Psd3  pleckstrin and Sec7 domain containing 3  0.796  0.001  ‐796.090
Lipg  lipase, endothelial  0.772  0.001  ‐771.597
Faah  fatty acid amide hydrolase  0.738  0.001  ‐738.177
Nkain1  Na+/K+ transporting ATPase interacting 1  0.729  0.001  ‐728.751
Batf  basic leucine zipper transcription factor, 
ATF‐like 
0.720  0.001  ‐720.441
Cacnb2  calcium channel, voltage‐dependent, beta 2 
subunit 
0.657  0.001  ‐656.769
Spef1  sperm flagellar 1  0.638  0.001  ‐638.260
Cd14  CD14 antigen  0.628  0.001  ‐628.324
Rabl2  RAB, member of RAS oncogene family‐like 2  0.566  0.001  ‐566.329
Ppfibp1  PTPRF interacting protein, binding protein 1 
(liprin beta 1) 
4.666  0.008  ‐562.055
Apcdd1  adenomatosis polyposis coli down‐
regulated 1 
0.510  0.001  ‐510.038
Fbxl5  F‐box and leucine‐rich repeat protein 5  5.110  0.017  ‐296.832
S100a10  S100 calcium binding protein A10 
(calpactin) 
105.583  0.401  ‐263.358
Tbc1d16  TBC1 domain family, member 16  1.454  0.006  ‐255.435
Spint2  serine protease inhibitor, Kunitz type 2  27.160  0.173  ‐157.145
Elovl6  ELOVL family member 6, elongation of long 
chain fatty acids (yeast) 
2.432  0.020  ‐120.742
Cd2  CD2 antigen  0.001  0.595  595.349
Gm1631  predicted gene 1631  0.001  0.735  735.306
2200002J24Rik  RIKEN cDNA 2200002J24 gene  0.001  0.787  786.621
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Supplementary Table C.6:  Dck C-terminus protein sequence 
The C-terminus of Dck is highly conserved across a number of species.  (Source:  
Ensembl) 
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Organism  Amino acid sequence at end of Dck protein 
B117H  ESLVEKVGLKKDKYVSCLVQDNPIDL 
Mouse  ESLVEKVKEFLSTL 
Human  ESLVEKVKEFLSTL 
Dog  DGLIEKVKEFLSTL 
Wallaby  ENLVEKVKEFLSTL 
Platypus  ANLIEKVKEFLSTL 
Dolphin  HDSLEKVKEFLSTL 
Chicken  DHMTEKVKEFLSTL 
Anole lizard  ENMIEKVKEFLSTL 
Zebrafish  ADMIEKVKEFLSTL 
Coelacanth  ADMVEKVREFLSSL 
MALEK (highly conserved aa in alpha 
helices) 
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Supplementary Table C.7:  B140H missense mutations 
MMuFLR identified potential frameshift mutations in the B140P and B140H cell lines.  
The mutations were screened in silico using IGV.  The two mutations confirmed by IGV 
as being newly introduced to the B140H cells, Ccdc88b and Dck, were confirmed as 
heterozygous and homozygous, respectively, by Sanger sequencing. 
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B140P  B140H 
Gene  Variant Position  Ref.  Var. Gene  Variant Position  Ref.  Var. 
Purb  chr11:6368602  CT  T  Purb  chr11:6368602  CT  T 
C2cd3  chr7:107603881  A  AG  C2cd3  chr7:107603881  A  AG 
Cyhr1  chr15:76477929  A  GA  Cyhr1  chr15:76477929  A  GA 
Sap25  chr5:138082875  GT  G  Sap25  chr5:138082875  GT  G 
Ptpmt1  chr2:90757866  C  TC  Ptpmt1  chr2:90757866  C  TC 
Ip6k2  chr9:108700131  A  AC  Ip6k2  chr9:108700131  A  AC 
Fam116b  chr15:89017849  CT  T  Fam116b chr15:89017849  CT  T 
Lst1  chr17:35325324  GA  A  not expressed in B140H     
expressed at lower levels in B140P  Baiap2  chr11:119860508  TC  T 
mutation not found in B140P    Ccdc88b  chr19:6921808  CT  T 
mutation not found in B140P    Dck  chr5:89203167  A  AT 
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Supplementary Table C.8:  B117H missense mutations 
MMuFLR identified potential frameshift mutations in the B117P and B117H cell lines.  
The mutations were screened in silico using IGV.  None were found to be newly 
introduced to the B117H cells. 
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B117P  B117H 
Gene  Variant Position  Ref.  Var. Gene  Variant Position  Ref.  Var. 
Sap25  chr5:138082875  GT  G  Sap25  chr5:138082875  GT  G 
Cyhr1  chr15:76477929  A  GA  Cyhr1  chr15:76477929  A  GA 
C2cd3  chr7:107603881  A  AG  C2cd3  chr7:107603881  A  AG 
Trerf1  chr17:47490865  AC  A  Trerf1  chr17:47490865  AC  A 
Ptpmt1  chr2:90757866  C  TC  Ptpmt1 chr2:90757866  C  TC 
Purb  chr11:6368602  CT  T  Purb  chr11:6368602  CT  T 
Fam116b  chr15:89017849  CT  T  found in B117H at lower levels 
found in B117P at lower levels  Ip6k2  chr9:108700131  A  AC 
found in B117P at lower levels  Zfp319  chr8:97847627  CAG  G 
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Supplementary Table C.9:  Drugs used in combination screen 
Source of the drugs used in the Ara-C combination screen. 
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Drug Source Catalog # 
5-Azacytidine VWR International 
TCA2033-
100MG 
5-Fluoro-2'-
deoxyuridine Sigma-Aldrich F0503 
5-Fluorouridine Sigma-Aldrich F5130 
AG490 (JAK2 inh) Sigma-Aldrich T3434-5MG 
AM 404 Tocris Bioscience 1116 
Aminopterin VWR International 10062310 
AZD6244 Selleck Chemicals S1008 
Bay 11-7082 VWR International 80016-546 
Bifemelane Tocris Bioscience 0767 
Bortezomib LC Laboratories B-1408 
Cantharidin Sigma-Aldrich   
Cladribine Sigma-Aldrich C4438 
CPEC NCI NSC 375575 
Dexamethasone Fisher Scientific ICN19456125 
Dideoxycytidine Sigma-Aldrich D5782 
Didox Cayman Chemical 10009081 
Erlotinib ChemiTek CT-EL002 
etoposide Sigma-Aldrich E1383 
GDC0941 Dr. Kevin Shannon (UCSF) 
GSK-3B Inh. Calbiochem 361540 
Harki1001 Dr. Dan Harki (UMN)   
Harki1002 Dr. Dan Harki (UMN)   
Harki1003 Dr. Dan Harki (UMN)   
Harki1004 Dr. Dan Harki (UMN)   
Harki1019 Dr. Dan Harki (UMN)   
Harki1020 Dr. Dan Harki (UMN)   
IKK Inhibit VII Calbiochem 401486 
Indomethacin Fisher Scientific ICN19021701 
LC-1 Dr. Dan Harki (UMN)   
M1 Potter lab 
Mevastatin Fisher Scientific 15997105 
MG-132 Calbiochem 474790 
Mifepristone Sigma-Aldrich M8046-100MG 
MK-0457 Merck & Co. new 
Nelarabine Selleck Chemicals S1213 
NFkB Inhibitor Calbiochem 481406 
Oxythiamine HCl MP Biomedicals 100426 
Parthenolide Dr. Dan Harki (UMN)   
PD-0325901 Dr. Kevin Shannon (UCSF) 
PI-103 Dr. Kevin Shannon (UCSF) 
Prazosin Fisher Scientific ICN15378225 
Prednisolone Sigma-Aldrich P4153-1G 
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RAD001 Selleck Chemicals S1120 
Rimcazole Tocris Bioscience 1497 
Ritonavir Dr. David Potter (UMN) 
SCH23390 Sigma-Aldrich D054-5MG 
Sunitinib 
Dr. Wendy Stock (Univ. of 
Chicago)   
Tetrahydrouridine EMD Chemicals 584222-10MG 
Trimidox Cayman Chemical 10009083 
Triptolide (HSP Inh) A.G. Scientific PG490 
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Supplementary Figure C.1:  RNA-seq and microarray expression patterns  
Distribution of expression comparing Ara-C resistant samples to parental samples using 
both microarray and RNA-seq data.  a) Dot-blot of microarray gene expression 
comparing B117H to B117P.  b) Dot-blot of RNA-seq gene expression comparing 
B117H to B117P.  c) Dot-blot of microarray gene expression comparing B140H to 
B140P.  d) Dot-blot of RNA-seq gene expression comparing B140H to B140P. 
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Supplementary Figure C.2:  Dck insertion mutation in B140H  
Insertion mutation in exon 4 of Dck in B140H is also present in the genomic DNA. (a) 
Sanger sequencing was used to interrogate the DNA sequence using primers provided in 
Supplementary Table 1. Intensity of the signal for the insertion indicates the mutation is 
homozygous.  (b) Projected change in protein sequence for Dck in the B140H cells.    
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Supplementary Figure C.3:  Extended PCR of 3’ end of B117H 
Extended PCR of a C-terminus transcript segment of Dck in B117P and B117H DNA 
shows an approximate deletion of 1000 bp in B117H cells.    
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Supplementary Figure C.4:  RNA sequence of B117P T6B Dck KO clone  
KO of Dck in the B117P T6B clone deleted a 32 bp segment toward the end of exon 1 
which resulted in an abnormally spliced transcript containing 34 nucleotides from intron 
1, starting at the 872nd nt of intron 1.  The predicted result would be a protein consisting 
of 34 amino acids.  The novel segment of protein is GGATLCMSFCKLLGSQRL. 
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Appendix D:  Analysis of RNA-Sequencing Data 
RNA-sequencing (RNA-seq) is a powerful technology for interrogating the 
transcriptome of cells.  In addition to providing an unbiased approach for determining 
gene expression levels, RNA-seq provides detailed sequencing information which, with 
the power of super computers, can be evaluated to locate mutations, fusions, and 
unusually spliced genes.  Since the advent of RNA-seq, dozens of software tools have 
been developed by various organizations.  The Minnesota Supercomputing Institute 
(MSI) is committed to providing a state-of-the-art collection of tools for the biologists at 
the University of Minnesota to take advantage of the power of RNA-seq.  To assist the 
MSI with their goals, I confined my analysis to the use of the tools acquired by MSI and 
developed by MSI, and provided practical testing of the MSI tools and detailed feedback. 
MSI provides the tools within an umbrella software tool called “Galaxy”.  Galaxy 
was originally developed at Penn State University.  Its goal was to provide a biologist-
friendly interface to various bioinformatics tools, with RNA-seq tools being just a subset 
of what is available.   
The first step for acquiring RNA-seq data is the preparation of the biological 
samples.  To generate high-quality RNA, the RNA should be isolated immediately from 
the tissue samples, or the tissues should be stored in a manner to preserve the RNA 
quality.  RNAlater® (Life Technologies) works well for this.  To perform the RNA 
isolation, it is important to use a method to produce high-quality RNA while eliminating 
DNA from the finished product.   
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Before submitting the RNA for sequencing, the biologist needs to decide on 
single or paired reads, the number of reads, and the length of the reads (cycles).  When 
asked, I recommend paired reads, 80 million reads (40 million paired reads), and 50 
cycles.  At the University of Minnesota, the RNA is submitted to the BMGC where the 
quality of the RNA is tested.  If the RIN value is greater than 7, the RNA is prepared for 
sequencing.  This process involves amplification, fragmentation, selection of fragments 
of a similar length, and attachment of adaptors.   
The output from the actual sequencing is a fastq file.  The fastq file contains the 
actually sequences, a quality code for each of the bases read, and header information 
which is needed to uniquely identify each read and match paired reads.  Prior to using the 
data, it is recommended the data be checked for quality using a tool called FastQC.  If the 
“per base sequence quality” is poor at either end of the reads, the reads can be trimmed 
by a tool called FASTQ Trimmer.  The final step of the quality control process is 
execution of the tool FASTQ Groomer, which formats the data for use by Galaxy. 
To evaluate fusions and mutations, the FASTQ groomer files can be input directly 
into deFuse (to find fusions), or MMuFLR (to find missense and frameshift mutations).  
To evaluate expression data, the data must first be mapped to a reference transcriptome.  
Galaxy uses a tool called TopHat to do the mapping.  TopHat does the mapping in two 
steps in order to make the most efficient use of computer processing.  First, it executes 
the tool Bowtie to map the reads to a reference genome.  Most of the reads can be 
mapped in this manner.  However, there will be reads that actually span two exons.  
TopHat uses a more sophisticated algorithm to compare these reads to a reference 
transcriptome.  One of the parameters to TopHat is the mean inner distance.  This is the 
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fragment length minus the length of the paired reads.  If this information is not known, it 
can be determined by running TopHat with defaults and then running NGS: Picard.  Then 
TopHat can be run again with the actual mean inner distance supplied.  The quality of the 
mapping can be determined by running the TopHat Stats PE tool. 
The output from TopHat is a bam file and its associated index file.  These files 
can be used as input to the Integrative Genome Viewer (IGV).  IGV is a powerful 
visualization tool, which allows the user the ability to see all the reads mapped to an 
individual gene.  It uses different color codes to identify reads mapped to multiple places 
and reads mapped outside the normal mean inner distance (which happens in the case of 
fusions).  It also shows how reads span introns, which is helpful for evaluating alternative 
splicing events. 
The output from TopHat can also be used as input to Cuffdiff, a tool that 
compares expression levels between multiple samples, or multiple groups of samples.  It 
measures expression levels using the FPKM calculation.  Because the RNA-seq process 
does not result in any technically-generated background noise, the user needs to decide 
on a minimum FPKM value for doing fold change comparisons.  Low FPKMs (less than 
1) can also be highly unreliable when evaluating fold changes.  It is recommended IGV 
be used to evaluate the genes on a list of differentially expressed genes, to determine the 
validity of the gene expression values.  For example, some of the reads may be mapped to 
multiple locations, or may be mapped outside the normal transcript area. 
The tools currently available to locate undocumented or aberrantly spliced genes 
are totally inadequate.  However, proving the existence of an abnormally spliced gene 
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can be verified by running a tool called Cufflinks, which can be run on a sample without 
the selection of a reference genome.  Cufflinks will build transcripts from scratch by 
overlapping the reads.  The output from Cufflinks can then be compared to a reference 
genome using CuffCompare. 
The tool selected for Galaxy to locate fusions is called deFuse.  DeFuse provides 
a sequence which includes a 100+ bases before and after the fusion point, with the fusion 
point identified by a bar (|).  It identifies the two genes involved and whether the 
sequence occurred in a coding region, an intron, a UTR, upstream or downstream.  It also 
provides a probability factor.  A probability factor of greater than 0.5 indicates the fusion 
is most likely real.  So far, deFuse has proven to be quite accurate in locating valid 
fusions, however it does not always accurately predict the location of the fusion point or 
the direction of the transcript.  It also does not describe which exons are being transcribed 
from each gene, or the projected protein sequence resulting from the fusion.  I’m 
currently working with MSI to develop a tool to provide this type of analysis of the 
deFuse output. 
   
 
